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ABSTRACT 
 
HEIDI MARIE SOETERS: The effect of tuberculosis treatment at the time of combination 
antiretroviral therapy (cART) initiation on response to cART among HIV-infected individuals  
(Under the direction of Annelies Van Rie)
 
 
Given the World Health Organization’s 2010 recommendation that all HIV-infected 
persons with tuberculosis (TB) be initiated on combination antiretroviral therapy (cART), 
regardless of CD4 count, many individuals will be initiating cART while concurrently on TB 
treatment. Co-treated individuals may experience a differential response to cART due to drug-
drug interactions, increased risk of drug toxicity, immune reconstitution inflammatory syndrome, 
and potentially lower adherence due to the high pill burden. The effect of TB treatment on a 
patient’s response to cART is not yet clear and requires careful evaluation. 
 Systematic reviews and meta-analytic methods examined the effect of TB treatment at the 
time of cART initiation on mortality and virologic and CD4 count response to cART among 
adults. A secondary analysis of South African study data assessed the effect of TB treatment on 
virologic and immunologic response to cART among children. 
Adults receiving vs. not receiving TB treatment at cART initiation had a mortality 
relative risk of 1.10 (95% confidence interval 0.87-1.40) at 1-3 months, 1.15 (0.94-1.41) at 6-12 
months, and 1.33 (1.02-1.75) at 18-98 months following cART initiation. TB treatment did not 
influence the risk of virologic suppression at any time point from 1-48 months following cART 
initiation. Differences in median CD4 count gain between those receiving vs. not receiving TB 
 iv
treatment ranged from -10 to 60 cells/µL (median 27) by 6 months and -10 to 29 (median 6) by 
11-12 months. 
Among 199 children initiating cART (median age 2.1 years), TB treatment was not 
associated with time to virologic suppression (adjusted hazard ratio [aHR] 1.36 [0.94-1.96]) or 
virologic rebound (23% vs. 24%, aHR 1.53 [0.71-3.30]). Those receiving TB treatment had 
lower median CD4 cell percentage (CD4%) until 12 months, but similar median increases in 
CD4% as children not receiving TB treatment over 24 months of follow-up. 
TB treatment may be associated with increased adult mortality after a year of cART, but 
was not associated with virologic or immunologic response to cART in adults or children, 
suggesting that patients receiving concurrent TB treatment at cART initiation may not have an 
inferior response to cART.
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 CHAPTER I 
SPECIFIC AIMS
 
Introduction 
 
Active tuberculosis (TB) threatens the health of people living with human 
immunodeficiency virus (HIV). Globally in 2011, 13% of incident TB cases were co-infected 
with HIV and an estimated 0.4 million TB deaths occurred among people living with HIV 
(PLWH) [1]. Given the World Health Organization (WHO) 2010 recommendation that all 
PLWH with TB be initiated on combination antiretroviral therapy (cART), regardless of CD4 
count [2], and the goal of 100% cART coverage of co-infected patients by 2015 [3], many 
individuals are initiating cART while concurrently on TB therapy. PLWH who are also being 
treated for TB may experience a differential response to cART due to drug-drug interactions [4, 
5], an increased risk of drug toxicity [4, 5], immune reconstitution inflammatory syndrome 
(IRIS) [6], and the potential for lower adherence due to the high pill burden [5]. The effect of TB 
treatment and its associated potential challenges and complications regarding a patient’s 
response to cART require careful evaluation. 
Therefore, this research aimed to assess the effect of receiving TB treatment at the time 
of cART initiation on virologic and immunologic response to cART along with subsequent 
mortality. This was accomplished by performing systematic reviews and meta-analyses of the 
published literature examining virologic and immunologic response and mortality in adults. 
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Additionally, data from the TB HIV IRIS and Nutrition in Kids (THINK) cohort study was used 
to examine the impact of TB treatment on virologic and immunologic response to cART among 
200 HIV-infected children aged 0 to 8 years in Soweto, South Africa. These investigations have 
a direct and important relevance to the care and management of HIV-infected individuals 
receiving TB treatment at cART initiation. The following aims were addressed: 
 
Specific Aim 1 
 
To conduct a systematic review and meta-analysis of the effect of receiving TB treatment at 
cART initiation on short- and long-term mortality among HIV-infected adults. 
Hypothesis: HIV-infected adults receiving TB treatment at cART initiation will have increased 
mortality in the first 3 months of therapy as compared to individuals not receiving TB treatment. 
However, they will experience similar long-term survival, once their TB treatment has 
concluded. 
 
Specific Aim 2 
 
To conduct a systematic review and meta-analysis of the effect of receiving TB treatment at 
cART initiation on virologic and CD4 count response to cART among HIV-infected adults. 
Hypothesis: HIV-infected adults receiving TB treatment will have decreased virologic 
suppression, increased virologic failure, and decreased CD4 count response as compared to 
individuals not receiving TB treatment, due to drug-drug interactions, lower adherence due to 
pill burden, and immune reconstitution inflammatory syndrome. 
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Specific Aim 3 
 
To evaluate the effect of TB treatment on virologic and immunologic response to cART 
among antiretroviral therapy (ART)-naïve children ages 0 to 8 years. 
Hypothesis: HIV-infected children receiving TB treatment at cART initiation will have 
decreased virologic suppression, increased virologic rebound, and decreased immunologic 
response as compared to children not receiving TB treatment. 
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CHAPTER II 
BACKGROUND AND SIGNIFICANCE
 
HIV Infection and Combination Antiretroviral Therapy 
 In 2011, a total of 34 million people were living with human immunodeficiency virus 
(HIV) worldwide, of which 3.3 million were children under the age of 15 years. Included in this 
total were 2.5 million new HIV infections, 330,000 occurring in children [7].  
 Dramatic reductions in morbidity and mortality have been observed since the 
introduction of combination antiretroviral therapy (cART) in 1996. At the end of 2012, 9.7 
million individuals in low- and middle-income countries were receiving cART, of which 630,000 
were children [8]. Most antiretrovirals (ARVs) are grouped into 3 main classes according to their 
targeted phase of the retrovirus life cycle: nucleos(t)ide reverse transcriptase inhibitors (NRTIs), 
non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). 
Additionally, a number of other ARVs with novel mechanisms of actions have been approved or 
are under development. Currently, most first-line cART regimens consist of either a NNRTI 
(efavirenz or nevirapine) or a PI, plus two NRTIs. There is much emphasis on fixed-dose 
combinations and once-daily dosing for antiretroviral regimens, which help to improve 
adherence and limit the development of drug resistance, along with simplifying storage and drug 
distribution [9]. Though each nation develops its own guidelines as to when an HIV-infected 
person should be initiated on cART and the ultimate decision is up to the patient and their doctor, 
the World Health Organization (WHO) currently recommends that all adults and adolescents 
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start cART once their CD4 cell count drops below 500 cells/µL, with priority given to those with 
severe or advanced clinical disease (WHO stage 3 or 4) and those with a CD4 count ≤350 
cells/µL [10]. 
 An individual’s first six months on cART are critical. Most patients experience a rise in 
CD4 counts as their immune system recovers and HIV ribonucleic acid (RNA) viral load 
decreases as the ARVs inhibit viral replication. Though cART dramatically decreases overall 
mortality, death rates are highest in the first three months after cART initiation [11-13], 
particularly among those with severe immunosuppression, wasting or malnutrition, or very low 
hemoglobin levels [12, 14-16]. 
 Some individuals, particularly those with severe immunodeficiency at cART initiation, 
do not initially improve on cART or may actually exhibit clinical deterioration at first. One 
complication that can occur is immune reconstitution inflammatory syndrome (IRIS), which is 
the exacerbation of a previously subclinical coexisting infection (such as tuberculosis) that 
occurs as a patient with advanced disease recovers immune function. Similarly, a latent or 
subclinical infection may become unmasked after cART initiation as the immune system 
recovers. In either case, patients first get worse before they begin a positive response to cART 
after a few months. In South Africa, IRIS occurs in around one quarter of patients initiating 
cART and accounts for one quarter of deaths in the first six months of therapy [17]. Another 
potential complication during early cART is drug toxicity. Occasionally it may be difficult to 
distinguish between hypersensitivity reactions to drugs and manifestations of IRIS. 
 Because each individual experiences a unique response to cART, it is important to 
monitor clinical, virologic and immunologic response to cART, as these measures offer an 
indication as to whether the current first-line regimen is working appropriately, or whether 
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treatment failure has occurred, requiring a switch to a second-line regimen. Treatment failure can 
occur for a variety of reasons, including poor adherence, inadequate drug levels, or antiretroviral 
resistance. 
 
HIV Infection and cART in Children 
As the clinical manifestations of HIV infection in children resemble those for a variety of 
other childhood illnesses, definitive diagnosis of HIV in children in resource-limited settings can 
be a challenge. In children older than 18 months, rapid tests or antibody-based tests can be used 
for diagnosis. However, in younger infants, tests that directly detect HIV RNA are required, 
preferably in the first 4-6 weeks of life for HIV-exposed infants [9, 10].  
In sub-Saharan Africa, without access to treatment, a third of HIV-infected children die 
by one year of age and 53% die by the age of 2 years [18]. In infants and young children, 
immune system immaturity and high viral loads produce a high risk of rapid disease progression 
[19-21]. In children less than 6 years old, CD4 percentage (CD4%) is often preferred to absolute 
CD4 count because CD4% is more consistent and does not vary according to age [4, 9]. In young 
children, neither absolute CD4 count nor CD4% is a reliable predictor of mortality, as all young 
HIV-infected children are at a high risk of mortality [9]. Additionally, failure to thrive and 
growth retardation are important indicators both of HIV infection and of HIV disease 
progression in children. Stunting often occurs during early stages of HIV infection, with wasting 
being associated with advanced disease [4].  
Fortunately, as observed in adults, increased access to cART has greatly decreased 
morbidity and mortality for HIV-infected children in high prevalence, resource-limited settings 
[22, 23]. Mortality is highest in the first six months after cART initiation [24], and children with 
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the most severe immunodeficiency at cART initiation experience the slowest but greatest 
immunologic recovery [25].  
In 2010, WHO guidelines recommended that all HIV-infected children under the age of 
two be immediately initiated on life-long cART [9]. In 2013, the WHO updated the guidelines to 
recommend that all children under the age of five initiate cART, regardless of WHO clinical 
stage of CD4 count [10]. Children ages ≥5 years of age should initiate cART if they have a CD4 
count of ≤500 cells/µL or WHO clinical stage 3 or 4 disease [10]. Since a definitive HIV 
diagnosis and virologic testing is not always available or affordable in some settings, 
measurements of decreased CD4 counts or percentages are often used to decide if antiretroviral 
treatment should be initiated. Recommended first-line cART regimens for use in pediatric 
patients are lopinavir/ritonavir (LPV/r)-based cART for children <3 years and efavirenz-based 
cART for children ≥3 years [10]. 
There are significant challenges in meeting cART guidelines in developing countries, 
including limited HIV screening, difficulties in HIV diagnosis in young children, limited 
availability of pediatric formulations, infrastructure issues related to antiretroviral delivery, and 
deficits in capacity for laboratory monitoring to ensure successful results on therapy. Partially 
due to these factors, in 2011, only 28% of cART-eligible children aged 0-14 years had initiated 
therapy [7]. As with adults, cART treatment failure in children is often due to poor adherence. 
Administration of medications to children requires a responsible, knowledgeable and convincing 
caregiver, who can limit a child’s medication refusal and encourage ingestion of each dose. 
As of 2010, South Africa had slightly different guidelines for initiating cART in children 
[26]. Only children less than 1 year were recommended to receive immediate cART upon HIV 
diagnosis, as opposed to all children <2 years old as recommended by WHO. For children aged 
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≥2 years, the recommendations were similar, and all children with symptomatic HIV infection 
(stage III or IV) were eligible for cART. The South African guidelines also include additional 
specifications to ensure cART adherence: 1) At least one caregiver is able to supervise all 
medication administrations for the child, and 2) disclosing HIV status to another adult household 
member is encouraged in order to assist cART administration. In South Africa, the recommended 
first-line cART regimen for children ≤3 years old or ≤10 kilograms is PI-based (abacavir + 
lamivudine + LPV/r), with efavirenz-based regimens recommended as first-line treatment among 
children over 3 years and >10 kilograms (abacavir + lamivudine + efavirenz). Once a child is 
initiated on cART, it is recommended that HIV RNA, CD4 count and CD4 percentage are 
performed at initiation, after six months, after one year, and then annually. 
 
TB Disease 
Due to much effort and dedication, the global community has managed to halt and begin 
to reverse the TB epidemic by decreasing TB incidence, TB prevalence and TB mortality. 
However, the worldwide burden of TB remains enormous. In 2011, an estimated 8.7 million 
incident cases of active TB occurred, and 1.4 million people died from TB. Approximately 24% 
of incident cases are from the African region, an area that has the highest rates of both TB cases 
and TB deaths per capita [1]. 
TB infection consists of two stages: latent tuberculosis infection (LTBI) and active TB 
disease. In total, approximately one third of the global population is infected with M. 
tuberculosis. In nearly 90% of people, the infection will remain latent and non-infectious and 
will not produce symptoms. In the other 10%, the immune system will not be able to hold the 
bacteria in check and the infection will eventually become active TB disease. Active TB disease 
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can take two forms – pulmonary or extrapulmonary. Some symptoms of TB disease are: 
weakness or fatigue, weight loss, lack of appetite, chills, fever or night sweats. Cases of 
pulmonary TB may experience a bad cough lasting at least three weeks, chest pain, and coughing 
up blood or sputum. Additional symptoms of extrapulmonary TB disease depend upon the body 
area affected, such as the kidney, spine or brain [27]. 
Currently, the only vaccine available to prevent TB is the Bacille-Calmette-Guérin 
(BCG) vaccine. It is almost 100 years old and mainly protects children against severe forms of 
TB, but its efficacy in adults is highly variable. BCG is not regularly used in the United States, 
but is given to infants and young children in countries that experience high TB incidence. 
Though efforts are underway to develop either an improved BCG vaccine or a new attenuated 
live M. tuberculosis vaccine, no effective options for adults are currently available [1]. 
The most common method for diagnosing TB worldwide is sputum smear microscopy. 
Also a century old, this technology uses a microscope to examine sputum samples for bacteria. 
While rather sensitive for detecting pulmonary TB, microscopy cannot be used to identify 
paucibacillary or extrapulmonary TB. Bacterial culture is the current reference standard for TB 
diagnosis. However, this tool is only available in more developed laboratories and can take up to 
two months to return a result to the patient. The newest diagnostic tool, Xpert MTB/RIF, is a 
rapid molecular test that can diagnose TB and rifampicin resistance within 100 minutes. 
Endorsed by the World Health Organization in 2010, Xpert MTB/RIF is a much-needed 
improvement over lengthy traditional culture-based diagnostics and is quite simple to use. 
Additionally, its sensitivity for detecting TB is superior to that of microscopy, particularly in 
HIV-infected patients [1]. South Africa has been a leading adopter of this technology, choosing 
to use it as a replacement for microscopy, and as the price continues to decrease, its global 
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uptake should accelerate. However, much work remains in improving TB diagnostics –in 
efficiency, available technology and laboratory infrastructure. In 2011, a third of estimated 
incident TB cases were not laboratory-confirmed at all, and a third of laboratory-diagnosed 
pulmonary TB cases were not culture-confirmed [1]. These deficits are in addition to the 
significant delay that many patients experience in receiving a TB diagnosis. 
Without proper diagnosis and treatment, active TB disease can be fatal. Once diagnosed 
with active TB, either empirically or definitively, a patient with drug-susceptible TB receives a 
standard treatment regimen of the four first-line drugs: rifampicin, isoniazid, pyrazinamide and 
ethambutol for two months, followed by four months of rifampicin and isoniazid. Fortunately, 
treatment success rates have been quite high in recent years. In 2010, 85% of all newly-
diagnosed TB cases were successfully treated [1]. These high treatment cure rates make the large 
numbers of TB deaths further inexcusable. If all TB cases are promptly diagnosed and 
adequately treated, the majority of TB deaths could be averted. 
Approximately 19% of all TB cases occurring in 2011 were multidrug-resistant (MDR), 
i.e. resistant to both rifampicin and isoniazid [1].  Most MDR cases occur among people being 
retreated for TB. On average, 9% of MDR-TB cases are categorized as extensively drug-resistant 
(XDR), meaning they are resistant to rifampicin, isoniazid, any of the fluoroquinolones and at 
least one of the three second-line injectable drugs (amikacin, capreomycin or kanamycin). Both 
MDR-TB and XDR-TB take substantially longer to treat than drug-susceptible TB and they 
require second-line drugs that are more expensive, harder to obtain, and have more side effects 
than first-line options. 
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Active TB Disease in Children 
Though it is difficult to estimate the burden of TB in children and this sub-population has 
traditionally been neglected in global TB efforts, it is thought that approximately 0.5 million TB 
cases and 64,000 TB deaths occurred in children under the age of 15 years in 2011 [1]. In high-
prevalence countries, children exposed to adults with active TB have a 30-50% risk of becoming 
infected themselves [28]. Unlike in adults, where active TB disease is generally preceded by 
latent tuberculosis infection, TB disease in young children is often a primary infection [4]. Up to 
40% of infants infected with TB develop active TB, and if untreated, they progress more rapidly 
than adults [28].  
Definitively diagnosing TB in children can be challenging, for a variety of reasons. First 
of all, there is no easy-to-use and accurate diagnostic test for TB in children. Second, children 
with active TB disease can present with a broad range of pulmonary and non-pulmonary disease 
manifestations, which may be non-specific and resemble other pathogens and conditions. Third, 
most children have paucibacillary TB. The low quantity of bacilli makes sputum smear 
microscopy and culture difficult or impossible. A recent study found that 56% of pediatric TB 
cases were pulmonary, and only 6.4% were smear-positive [29]. Additionally, children are often 
unable to expectorate sputum. Due to these challenges, diagnosis is often presumptive, especially 
in younger children. Clinicians often empirically treat TB in children after considering factors 
such as clinical signs and symptoms, a household member with known TB disease, a positive 
tuberculin skin test or interferon-gamma release assay (IGRA) and abnormal chest x-ray. The 
difficulty in culturing M. tuberculosis from infected children also limits the ability to detect drug 
resistance [30]. 
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It is recommended that children with active TB be treated using directly observed therapy 
(DOT), to ensure compliance and correct dosing. Children under the age of five years should be 
treated with only three drugs (isoniazid, rifampicin, and pyrazinamide) in the initial phase. 
Ethambutol is not recommended unless isoniazid resistance is likely or the child was diagnosed 
with adult-like TB (upper-lobe infiltration and cavitation associated with sputum production). 
Children should also have a 6 month course of TB therapy, as in adults [31].  
 
HIV/TB Epidemiology 
HIV and TB are the two leading infectious causes of death worldwide. Unfortunately, 
these pathogens have many synergistic interactions causing their co-epidemic to be even more 
devastating. With the advent of the HIV epidemic, TB reinforced its role as a serious threat to 
human health. In 2011, an estimated 1.1 million incident cases of TB occurred among persons 
with HIV infection, 23% of people with TB who were tested for HIV tested positive, and TB 
accounted for 26% of acquired immunodeficiency syndrome (AIDS)-related deaths worldwide 
[1, 7, 32, 33]. Almost 80% of TB cases among HIV-infected individuals reside in Africa [1], 
with sub-Saharan Africa experiencing the greatest density of HIV/TB co-infection. 
 
HIV/TB Interactions 
The dynamics between HIV and TB co-infection are complex and multi-faceted. The 
effect of HIV on the progression of TB has been fairly well documented. HIV infection increases 
a person’s susceptibility to infection with M. tuberculosis. Among people already infected with 
latent M. tuberculosis (i.e., LTBI), HIV infection is the strongest known risk factor for 
progressing to active TB disease. HIV-uninfected individuals with LTBI have a 10% lifetime 
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risk of their latent infection progressing to active TB disease, while in HIV-infected individuals 
this becomes a 10% annual risk of active TB [27]. In co-infected individuals, 
immunosuppression due to HIV infection and lower CD4 counts is associated with a more rapid 
progression of TB and a greater risk of disseminated tubercular disease and extrapulmonary 
infection [34]. Advanced HIV immunosuppression also makes a definitive diagnosis of TB more 
challenging [35], as individuals may present with an atypical immune response and 
extrapulmonary TB is more difficult to diagnose than pulmonary TB. 
In addition to the effect of HIV on TB disease development, without antiretrovirals, 
having TB disease is known to accelerate HIV disease progression. TB disease quickens the 
depletion of CD4 cells, increases the rate of opportunistic infections [36, 37], increases the risk 
of AIDS [37], decreases survival time [36, 37], and increases overall mortality [36, 37] in HIV-
infected individuals. In vitro studies have found that TB increases HIV replication by activating 
CD4+ T-lymphocytes and macrophages harboring latent HIV [38].  
 
Challenges with HIV/TB Co-treatment 
Even with cART, TB disease remains detrimental to HIV-infected patients. Though the 
advent of combination antiretroviral therapy helped decrease the 12-month mortality rate of 
HIV-infected tuberculosis patients from 20% in the pre-cART era to 4.9% [39], both prevalent 
and incident TB disease continue to cause treatment complications. Using cART in HIV-infected 
patients who are also being treated for TB disease is made more challenging by the potential for 
drug-drug interactions, IRIS, increased drug toxicity, and lower adherence due to the large 
amount of medications.  
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Anti-tuberculosis medications and some antiretrovirals, particularly rifampicin and the 
NNRTI and PI classes of ARVs, have similar routes of metabolism, thereby causing drug-drug 
interactions and complicating co-administration. These drug-drug interactions may result in 
subtherapeutic plasma concentrations of both types of medications and possible undertreatment 
of HIV and/or TB disease. Specifically, co-administration of nevirapine with rifampicin has been 
show to decrease levels of nevirapine by 20-58% [4]. Rifampicin also decreases exposure to 
atazanavir [40], and to lopinavir among children [41]. However, some observational studies 
found that good virologic, immunologic and clinical outcomes may still be achieved when 
efavirenz [42, 43] and nevirapine [44, 45] are used in combination with rifampicin. 
In addition, nevirapine, rifampicin, isoniazid and pyrazinamide all have potential 
hepatotoxicity. As these are first-line medications, their use is recommended, even when 
coadministered with other potentially hepatotoxic drugs or in patients with liver disease. Co-
treated patients should be monitored frequently for hepatotoxicity. Another potential symptom of 
drug toxicity is peripheral neuropathy, which can occur with administration of isoniazid or a 
number of NRTIs, or may be a manifestation of HIV disease. In adults, rifabutin is potentially 
substituted for rifampicin in an effort to avoid compounded toxicity and drug-drug interactions. 
As new ARV options become available, there will be more flexibility in choosing appropriate 
regimens for HIV/TB co-infected patients. 
As mentioned previously, patients beginning cART may experience IRIS during their 
first few months on therapy. This spectrum of clinical signs and symptoms is brought on as the 
immune system begins to recover and respond to a known, coexisting infection, and can cause a 
patient’s clinical condition to deteriorate before it begins to improve. The most common 
pathogen associated with IRIS is TB, causing TB-IRIS. A proposed clinical case definition of 
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TB-IRIS includes requirements that 1) the TB diagnosis is made prior to starting cART, 2) a 
good initial response to TB therapy is observed prior to cART start, and 3) onset of TB-IRIS is 
within three months of initiating cART [9]. It is also possible to experience similar symptoms in 
response to an unknown latent or subclinical tuberculosis infection, known as “unmasked TB”. 
Most cases of TB-IRIS resolve spontaneously or with the help of anti-inflammatory drugs [6], 
though some cases can be severe or even fatal. It is recommended that both TB treatment and 
cART continue throughout the IRIS episode [46]. 
Patients concurrently undergoing treatment for TB disease and HIV infection are often 
subject to a large daily burden of medications for a long period of time. Understanding the 
purpose and dosing schedule of each medication can be difficult, and co-treated patients may 
display lower adherence due to confusion or intolerance of so many pills. For these reasons, 
treatment support, possibly including DOT, is recommended for co-treated patients [46]. As 
cART regimens move toward single-pill once daily administration, this will alleviate some of the 
pill burden experienced by co-treated patients. 
 
Timing of HIV/TB Co-treatment 
The ideal treatment timing for individuals requiring antiretroviral and antituberculosis 
therapy has been debated, as researchers were unsure if the benefits of early cART initiation 
outweighed the previously described complications of co-treatment. Therefore, the question of 
when to start cART in HIV-infected patients with active TB has been the subject of much recent 
research, including three randomized controlled trials: SAPiT, CAMELIA and STRIDE [47-50]. 
Though the trials had varying populations and comparison groups, all results indicated that 
cART should be given concurrently with TB treatment.  
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The South African Starting Antiretroviral Therapy at Three Points in Tuberculosis 
(SAPiT) study included ambulatory HIV-infected patients with smear-positive TB and CD4 
counts <500 cells/µL, who were randomized to receive cART either during the first 4 weeks of 
TB therapy, after the first 8 weeks of TB treatment, or after the completion of TB therapy 
(sequential therapy). The sequential treatment arm was stopped mid-trial, as the mortality rate of 
integrated therapy was 56% lower than with sequential therapy [47]. In less immunosuppressed 
patients, there was no significant difference in the rate of AIDS or death between the two 
integrated therapy arms, though patients with baseline CD4 counts of <50 cells/µL experienced 
less AIDS or death with earlier initiation of cART (8.5 vs. 26.3 cases per 100 person-years) [48]. 
The Cambodian Early versus Late Introduction of Antiretrovirals (CAMELIA) study 
randomized patients with CD4 counts of <200 cells/µL to initiate cART at either 2 or 8 weeks 
after TB treatment initiation. After a median of 25 months of follow-up, patients who initiated 
cART at 2 weeks experienced 38% less mortality than those starting cART at 8 weeks. This 
significant overall reduction in mortality was experienced by all patients, regardless of baseline 
CD4 count [49]. 
Finally, the STRIDE study (ACTG 5221) was a multinational study conducted at 28 sites. 
ART-naïve patients with confirmed or probable TB and CD4 counts <250 cells/µL were 
randomized to either earlier (<2 weeks) or later (8-12 weeks) cART. Though overall rates of 
death and AIDS did not differ by treatment arm, patients with CD4 counts <50 cells/µL who 
received earlier cART did benefit from a significant reduction in AIDS or death [50]. 
Based on these results, it is now recommended that cART should be given concurrently 
with TB treatment, regardless of CD4 count, and should be initiated as soon as possible within 
the first 8 weeks of TB treatment [10]. Though in all 3 studies IRIS was more common in those 
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initiating cART earlier, IRIS was infrequently associated with mortality. Therefore, the benefits 
of earlier cART initiation appear to outweigh the risks in co-infected patients. The only 
exception to this recommendation is TB meningitis, which often has severe complications and 
high mortality. One randomized controlled trial indicated that early cART was associated with a 
higher rate of severe adverse events in patients with TB meningitis [51], and further research is 
needed in this area. 
 
HIV/TB Services Integration 
To combat these substantially overlapping epidemics, there has been much emphasis on 
integrating TB and HIV activities in recent years. For example, while only 3% of African TB 
patients were tested for HIV in 2004, 69% were tested in 2011. Integration is part of the current 
World Health Organization Stop TB strategy and has saved an estimated 1.3 million lives 
between 2005 and 2011 [1, 7].  
Integration of HIV/TB care comprises a number of elements, including screening HIV 
patients for TB, testing TB patients for HIV, co-locating HIV and TB treatment facilities, 
preventing TB among persons with HIV, and combining HIV and TB surveillance systems. As 
an intervention to prevent HIV-infected individuals from becoming infected with latent TB or 
developing active TB, preventive therapy with isoniazid is combined with cART in certain 
circumstances. Isoniazid preventive therapy (IPT), along with intensified TB case finding among 
those with HIV and increased infection control, make up the “Three Is” strategy for preventing 
TB among HIV-infected individuals [1]. 
There is much room for improvement of HIV/TB services integration. In 2011, only 40% 
of people with TB were tested for HIV and less than half (48%) of co-infected patients had 
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initiated cART [7]. A recent study in South Africa looked at the concordance of variables 
captured in separate HIV and TB surveillance systems for co-infected patients [52]. They found 
varying levels of completeness and concordance, and recommended a standardized minimum 
dataset for national reporting. Despite the fact that HIV and TB services are integrating more 
slowly then is ideal, research continues to suggest that complete integration is feasible and is 
beneficial to patients. Another recent South African study found that HIV/TB service integration 
led to a 60% increase in the number of TB patients starting cART and reduced the time to cART 
initiation by 72 days [53]. 
 
HIV and TB in Children 
The HIV/TB co-epidemic is even more challenging in children, due to the diagnostic and 
treatment challenges and high mortality rates. In resource-limited countries, the prevalence of 
HIV among children with active TB ranges from 10% to 62% [4, 29]. In infants and young 
children, immune system immaturity results in a high risk of rapid disease progression of HIV 
[19, 20] and TB [54]. 
In practice, all HIV-infected infants and children should undergo TB screening and be 
evaluated for contact with a TB case at each health visit. Common manifestations of tuberculosis 
in HIV-infected children are persistent cough, fever, and failure to thrive, though these signs and 
symptoms often are non-specific and mimic those of other common illnesses. TB disease in 
HIV-infected children does tend to be more severe and rapidly progressing than in adults, and 
often involves extrapulmonary or disseminated TB.  
As with adults, HIV infection complicates TB diagnosis in children. During the early 
stage of HIV infection, tuberculin skin tests may be positive in exposed children. However, 
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during later stages of HIV infection, tuberculin skin testing is often negative, particularly if a 
child is malnourished [55]. TB is often more common among HIV-infected children than is 
initially apparent. With systematic TB screening prior to cART initiation in Uganda, a 70% 
relative risk reduction in unmasked TB was observed [56]. An autopsy study found that 70% of 
TB disease found in deceased HIV-infected children was undiagnosed prior to autopsy [57].  
Research indicates that starting cART during TB treatment significantly improves 
survival [58-60], and perhaps virologic response [60]. However, the optimal treatment strategy 
for children with both TB and HIV is still being explored. As of 2010, WHO guidelines 
recommend to start TB treatment immediately, and then initiate cART as soon as tolerated in the 
first 8 weeks of TB therapy, regardless of clinical stage and level of immunosuppression [9]. 
When to start cART within those 8 weeks is determined by a number of factors, including age, 
level of immune suppression, pill burden, potential drug interactions, overlapping toxicities, and 
risk of IRIS. Efavirenz-based cART is not recommended for children under the age of 3, as 
information on appropriate dosing is lacking. Therefore, the preferred first-line antiretroviral 
regimen for children <3 years old and on TB treatment is nevirapine + 2 NRTIs or a triple NRTI 
regimen. Children with TB aged ≥3 years are recommended to take efavirenz + 2 NRTIs or a 
triple NRTI regimen as first-line cART [10]. A triple NRTI regimen is recommended only for 
the duration of TB treatment.  
South African guidelines do not give specific recommendations for initiating cART in a 
child already on TB treatment, but they do state that if a child is already on an efavirenz- or 
nevirapine-based regimen when they begin concurrent TB treatment, they do not require a 
change of regimen. Younger children on a LPV/r regimen should receive added ritonavir for a 
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1:1 lopinavir:ritonavir ratio, and older children on LPV/r should receive a double dose of LPV/r 
[26].  
The choice of cART regimen in children is often limited by the options available in 
pediatric drug formulations and a lack of dosing information. Older children can often be treated 
with adult formulations, but their use in younger children creates the risk of suboptimal treatment 
or overdosing. Though rifabutin can be considered as a substitution for rifampicin in adults, it 
cannot be used in children due to insufficient data and no pediatric formulation [9]. Much more 
research is needed to determine optimal co-treatment for HIV-infected children with TB. 
Though not as common as in adults, children can also experience TB-IRIS or unmasked 
TB after cART initiation. There is limited data on TB-IRIS in infants and children and the direct 
mechanism and causes are not clearly understood. Children initiating cART may experience a 
10% to 20% cumulative incidence of IRIS [61, 62], and IRIS is seen most often in younger 
children, children who initiate cART with CD4 percentages of <15%, and those with low-
weight-for-age [9, 62]. In areas with routine TB vaccination of infants with the BCG vaccine, 
BCG-associated IRIS may also be observed. 
With regards to isoniazid preventive therapy, all HIV-infected children and infants 
exposed to TB through household contacts, but with no evidence of active TB disease, are 
recommended to begin IPT. HIV-infected children, with the exception of infants, without active 
TB or any known TB contacts should receive six months of IPT as part of comprehensive HIV 
care [9]. Though uptake and adherence to IPT among children is quite poor [63], IPT has been 
shown to substantially reduce the risk of incident TB disease and TB mortality [64] and long-
term IPT appears to be acceptably safe in children [65]. 
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The Effect of TB Treatment on Response to cART 
Given WHO’s 2010 recommendation that all HIV-positive patients with TB be initiated 
on cART, regardless of CD4 count [2], and the goal of 100% cART coverage of co-infected 
patients by 2015 [3], many individuals will be initiating cART while concurrently on TB 
therapy. However, the effect of receiving TB treatment at cART initiation on response to cART 
is not yet well determined. In particular, knowing the effect of TB treatment on mortality, 
virologic response and immunologic response to cART will help describe the prognosis of TB 
patients on cART, quantify what impairment to cART response, if any, is experienced by co-
infected patients, and afford more confidence in clinical decision-making for those caring 
HIV/TB co-treated patients. As TB treatment lasts at least 6 months, it is important to 
differentiate between short- and long-term effects of TB treatment on cART response. 
 
Effect of TB Treatment at cART Initiation on Subsequent Mortality in Adults 
Worldwide, a substantial proportion of patients initiating cART die during the first year, 
and the majority of deaths occur within the first 3 months. The prevalence of undiagnosed TB 
among patients initiating cART and the risk of incident TB while on cART are high, which 
contributes to the marked mortality. Still, the extent to which receiving TB treatment at cART 
initiation contributes to mortality is not entirely understood. 
In 2010, Straetemans et al. published a meta-analysis on the effect of tuberculosis on 
mortality in HIV-positive people [66]. They found people living with HIV also suffering from 
tuberculosis had a greater risk of mortality than TB-free individuals, with a hazard ratio (HR) of 
1.8 (95% confidence interval [CI] 1.4, 2.3). However, this estimate included both prevalent and 
incident TB and the studies did not share a common time origin (e.g., HIV diagnosis, cART 
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initiation). They did report an estimate of the effect of tuberculosis on mortality in studies where 
at least 50% of persons were exposed to cART (HR 1.1, 95% CI 0.9, 1.3). Separately, they 
calculated a pooled hazard ratio for three studies that reported the effect of prevalent TB on 
mortality (HR 1.5, 95% CI 0.9, 2.2), though one of these studies was not limited to patients on 
cART [67]. Because of the paucity of data, the authors also concluded that the effect of 
tuberculosis on mortality in persons exposed to cART needs to be further evaluated once the 
results of more cohort studies become available. 
A number of recent studies have reported the effect of receiving TB at cART initiation on 
subsequent mortality. They display substantial heterogeneity in their approach, results, cART 
regimens used, patient population and study characteristics, making it difficult to discern a good 
estimate of the effect of TB treatment on mortality.  With results ranging from a mortality 
relative risk for those receiving vs. not receiving TB treatment of 0.7 (95% CI 0.5, 1.0) [14] to 
5.8 (95% CI 1.2, 28.2) [68], these studies estimated a range of protective, neutral, and harmful 
effects of TB treatment. Though some authors set out to quantify the effect of TB treatment on 
mortality, more commonly TB treatment was included in mortality regression models along with 
a variety of other predictors or simple crude proportions of mortality in those receiving vs. not 
receiving TB treatment were reported. This variation in study design results in a collection of 
crude estimates and estimates adjusted for a range of covariates that may or may not be 
appropriate for the estimation of the effect of TB treatment on mortality. Additionally, studies 
estimated mortality at a wide range of time points after cART initiation, ranging from one month 
[69] to 96 months [70]. Due to this heterogeneity, a systematic examination of these results is 
required in order to determine whether HIV-infected patients receiving TB treatment at cART 
initiation experience increased mortality, looking at both short- and long-term effects. 
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Effect of TB Treatment on Virologic Response to cART in Adults 
Though it appears that individual viral load values do not directly correlate with disease 
progression or mortality risk, monitoring virologic response to cART is useful for quantifying 
the effect of antiretroviral drugs on viral replication and for identifying treatment failure. 
Virologic response can be measured in a variety of ways, including: virologic 
suppression, virologic failure, virologic rebound, or a simple description of changes in HIV RNA 
levels over time since cART initiation. Additionally, a variety of effect measures can be used to 
estimate these outcomes, including comparing proportions, odds ratios, risk ratios, hazard ratios, 
or a comparison of median viral loads at a specific time point. All of these methods have been 
used by studies attempting to estimate the impact of TB treatment on virologic response to 
cART. As with mortality, studies also used a variety of follow-up times when describing 
virologic response and the potential effect of TB treatment, ranging from 4 weeks [71] to 48 
months [72, 73], and found a range of positive, neutral, and negative effects of TB treatment on 
virologic response. 
As an example of some of studies examining short-term virologic response, Almeida et 
al. (2011) found that 82% of PLWH receiving TB treatment experienced HIV RNA <400 
copies/mL by 4 months following cART initiation, as compared to 61% among PLWH not 
receiving TB treatment, for a crude risk ratio (RR) of 1.3 (95% CI 1.0, 1.7) for virologic 
suppression [74]. Hung et al. (2003) found the opposite trend, that PLWH receiving TB 
treatment at cART initiation experienced a worse virologic response, being 1.5 (95% CI: 0.9, 
2.4) times as likely to have HIV RNA >400 (virologic failure) by 4 months following cART 
initiation [71]. 
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As for longer-term estimates, Manosuthi et al. (2010) found no effect of TB treatment on 
virologic suppression <50 copies/mL among patients on nevirapine-based regimens at 4 years, 
with an odds ratio (OR) of 1.1 (95% CI 0.6, 2.2) [72]. Similarly, Bastard et al. (2012) found 
those receiving vs. not receiving TB treatment experienced similar virologic response at 4 years, 
with ORs of 1.1 (95% CI 0.7, 1.6) for virologic suppression <400 copies/mL and 0.9 (95% CI 
0.6, 2.0) for virologic failure >5000 copies/mL [73]. 
As illustrated, there is much variation among studies quantifying the effect of TB 
treatment on virologic response to cART, and it is difficult to ascertain the true effect without a 
systematic review and possible meta-analysis of the published effect estimates. 
 
Effect of TB Treatment on Immunologic Response to cART in Adults 
Immunologic response to cART can be assessed in a number of ways. First of all, one can 
focus on either immune reconstitution or immunologic failure. Within these categories, the 
outcome can be defined using measures such as CD4 count threshold values, absolute changes in 
CD4 count from baseline, or percent change in CD4 count from baseline. As with virologic 
response, a wide range of study designs and estimates seeking to quantify the effect of TB 
treatment on immunologic response to cART have been published, with follow-up times ranging 
from 4 weeks [71] to 53 months [75] following cART initiation. 
A handful of studies reported the mean or median increase in CD4 count from baseline in 
patients receiving vs. not receiving TB treatment at cART initiation. Most found a similar 
immune response in the two groups, regardless of length of follow-up time [71, 76-80]. 
However, three studies found a greater increase in CD4 count from baseline in those receiving 
TB treatment [81-83]. 
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Six studies measured median absolute CD4 count in the two groups at various time 
points, and found a range of results. Three studies found a similar median absolute CD4 count 
[44, 76, 84], two found those receiving TB treatment to have slightly higher CD4 counts [85, 
86], and two found those on TB treatment to have lower CD4 counts during follow-up [72, 78]. 
As examples of some other types of immunologic response measures, Dronda et al. 
(2011) found that, in patients receiving vs. not receiving TB treatment, 60% vs. 69% experienced 
an increase of ≥50 CD4 cells/µL by 6 months and 56% vs. 62% had an increase of ≥100 CD4 
cells/µL by 12 months [79]. Julg et al. (2012) found that 64% vs. 61% achieved an absolute CD4 
count >200 by 12 months and 20% vs. 15% had a CD4 count >500 by 30 months following 
cART initiation [87]. 
Again, with the variation in outcome measures and follow-up times, a systematic review 
is needed to summarize the diverse literature regarding the effect of TB treatment on 
immunologic response to cART. 
 
Effect of TB Treatment on Response to cART in Children 
To date, only a handful of studies have investigated the role of TB treatment in pediatric 
response to cART and there is a need for more data [88]. In terms of mortality on cART, limited 
research indicates that TB treatment does not significantly increase mortality in children [89-91]. 
Bong et al. (2007) found that children ≤14 years on nevirapine-based cART and TB treatment 
had 6-month and 12-month survival probabilities of 0.86 and 0.86, as compared to 0.89 and 0.88 
in TB-free children [89]. Van Dijk et al. (2013) found no difference in mortality between 
children <3 years old on efavirenz-based cART and TB treatment and those on nevirapine-based 
cART and no TB treatment (aHR1.0, 95% CI 0.3, 3.3), though 7 children on TB treatment were 
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included in the latter group [90]. Frohoff et al. (2011) also found no significant effect of TB 
treatment on mortality among children ≤2 on LPV/r-based cART (9% vs. 7%) [91]. 
In total, six pediatric studies with follow-up CD4% and/or HIV RNA measurements have 
been published, all from South Africa except for one from Zambia [90]. Three of these studies 
examine the effect of TB treatment at cART initiation on virologic response [91-93], four report 
CD4% reconstitution [90, 91, 93, 94], and one looks at the probability of severe 
immunodeficiency following cART initiation [95]. 
In terms of virologic suppression, Zanoni et al. (2011) found that TB treatment had a 
negative effect on virologic suppression overall in children ≤18 years at 6 months post cART 
initiation, but that effect disappears by 12 months [92]. However, when stratifying on cART 
regimen type, it appears that TB treatment only had a negative effect among those on PI-based 
cART. Frohoff et al. (2011) also observed that TB treatment decreased suppression among 
young children (aged 6-24 months) on double-dose LPV/r and ritonavir-based cART [91]. Reitz 
et al. (2010) found decreased suppression by 39 weeks among children <2 years on ritonavir or 
unboosted LPV/r-based cART being co-treated for TB [93]. Reitz et al. also found a lower 
incidence of virologic rebound among those on TB treatment (2.8% vs. 12%) [93]. 
In terms of CD4% reconstitution, Zanoni et al. (2012) found that children ≤10 years 
receiving TB treatment did not have an impaired CD4 response at 6 or 12 months after cART 
initiation [94]. Reitz et al. (2010) also did not find a significant effect of TB treatment on 
changes in CD4% at 39 weeks following cART initiation [93]. Frohoff et al. (2011) found that 
children receiving TB treatment had lower CD4% in the first 6 months, but TB treatment did not 
affect the change in CD4% during follow-up [91]. Van Dijk et al. (2013) had a similar finding 
[90]. The only study to examine the effect of TB treatment on the proportion of children with 
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severe immunodeficiency at 6-24 months following cART initiation was Fatti et al. (2011), who 
found no effect with an adjusted odds ratio (aOR) of 1.1 (95% CI 0.7, 1.6) [95]. 
These studies possess some limitations. Nearly all reported effect measures were crude, 
without accounting for important factors such as baseline CD4% or HIV RNA, age, or cART 
regimen. All studies except Reitz et al. were retrospectively conducted using medical records, 
which is not optimal for data quality and completeness. All studies except Van Dijk et al. and 
Fatti et al. had a year or less of follow-up time. This limits the ability to distinguish short- and 
long-term effects of TB treatment and measure longer-term outcomes such as virologic rebound. 
In Reitz et al. and Zanoni et al. (2011), those with incident TB were excluded from the 
denominator. Additionally, even though a couple of the studies adjusted for cART regimen, it is 
most helpful to stratify by cART regimen, in an effort to determine which regimens are better 
suited for use with concurrent TB treatment. 
 
Summary and Rationale 
 There is a general knowledge gap regarding the effect of TB treatment at cART initiation 
on response to cART, both in adults and children. Although numerous studies on this subject 
have been published in adults, the heterogeneity in terms of study population, outcome 
measurement, analytic methods, cART regimens, and follow-up times make it difficult to make 
sense of the literature without a formal systematic review and meta-analysis. As HIV infection, 
TB disease, and response to cART differ substantially between adults and children, additions to 
the sparse pediatric literature are needed to further understand cART response and optimize co-
treatment in children. Particularly, a pediatric study with regular prospective measurements of 
HIV RNA and CD4% and outcomes stratified according to cART regimen is needed.
  
CHAPTER III 
RESEARCH METHODS
 
Study Design and Manuscripts 
 The study’s aims were pursued via systematic reviews and meta-analytic methods, and a 
secondary analysis of data from the THINK cohort study of pediatric patients in South Africa. 
This study produced three manuscripts. The first, entitled “The Effect of Tuberculosis Treatment 
at Combination Antiretroviral Therapy Initiation on Subsequent Mortality: A Systematic Review 
and Meta-Analysis” addresses Specific Aim 1. The second, entitled “The Effect of Tuberculosis 
Treatment on Virologic and CD4 Count Response to Combination Antiretroviral Therapy: A 
Systematic Review” addresses Specific Aim 2. The third, entitled “The Effect of Tuberculosis 
Treatment on Virologic and Immunologic Response to Combination Antiretroviral Therapy 
among South African Children” addresses Specific Aim 3. 
 
Methods for Specific Aims 1 and 2 
 Specific Aims 1 and 2 consisted of systematic reviews and meta-analyses of the effect of 
receiving TB treatment at cART initiation on short- and long-term mortality (Specific Aim 1) 
and virologic and immunologic response (Specific Aim 2) among HIV-infected adults. 
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Literature Review Protocol 
To investigate the effect of TB treatment at cART initiation on mortality, virologic 
response, and immunologic response to cART, we carried out a systematic and sensitive search 
using an a priori protocol developed according to PRISMA guidelines [96]. We searched 
PubMed and EMBASE, as well as abstract databases from the 2009 to 2012 Conferences on 
Retroviruses and Opportunistic Infections (CROI), International Union Against Tuberculosis and 
Lung Disease (IUATLD) World Conferences on Lung Health, and International AIDS Society 
(IAS) Conferences. The search terms “HIV AND Tuberculosis AND (Viral Load OR CD4 
lymphocyte count OR mortality) AND Antiretroviral therapy” were used to identify relevant 
articles in PubMed and EMBASE. The terms “TB” or “tuberculosis” were used to search 
conference abstracts from CROI and IAS. The terms “HIV” or “antiretroviral therapy” were used 
to search conference abstracts from IUATLD. Searches were performed on March 1, 2013 
(Specific Aim 1) and January 29, 2013 (Specific Aim 2) and included original studies on human 
subjects research published between 1997 (the start of the cART era) and the search dates. 
Additional articles were identified from reference lists, reviews and Web of Science citation 
searches. 
 
Study selection 
Two authors (Heidi Soeters, Annelies Van Rie) independently reviewed all titles and 
abstracts of original studies retrieved by the search. One author (Heidi Soeters) reviewed full-text 
and references of all selected articles. Two reviewers (Heidi Soeters and Monita Patel) 
independently abstracted study data from full reports to ensure accuracy; discrepancies were 
resolved by consensus or by consultation with other authors. 
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Studies were included in the analysis if they included both antiretroviral-naïve HIV-
infected individuals receiving and not receiving TB treatment at cART initiation, and reported 
mortality (Specific Aim 1) or virologic and/or CD4 count response (Specific Aim 2) after cART 
initiation, stratified by TB treatment status at cART initiation. Though we sought reports of 
cART-naïve patients, studies with ≤10% antiretroviral-experienced patients or patients only 
previously exposed to a single intrapartum dose of nevirapine were also included. Studies of 
children <14 years of age were excluded. No additional exclusion criteria or language restrictions 
were imposed. 
 
Data extraction 
The following information, if available, was abstracted from each article: first author 
surname; year of publication; study design; dates of study; length of follow-up period; 
geographic location; clinical setting; sample size; number receiving and not receiving TB 
treatment; if TB treatment was the main exposure of interest; types of TB included; culture 
confirmation of TB cases; site of TB; timing of TB treatment in relation to cART initiation; 
percentage male; mean or median participant age; proportion antiretroviral-naïve; criteria for 
cART initiation; type of cART regimen; baseline median CD4 count and HIV RNA; measure of 
effect or event counts; covariate adjustment; and proportion lost-to-follow-up. Additional 
information for Specific Aim 1: if mortality was confirmed using a national death registry. 
Additional information for Specific Aim 2: HIV RNA outcome measure(s); CD4 count outcomes 
measure(s); exclusion criteria; and how each study handled loss-to-follow-up, mortality, and 
regimen switching. For this purposes of these reviews, we abstracted results as presented in the 
specific studies according to their individual methods and assumptions. 
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Meta-analysis Methods for Specific Aim 1  
Any reported mortality effect estimates (HR, RR, OR) for any time frame were 
abstracted. If only survival proportions among those receiving or not receiving TB treatment 
were reported, Episheet was used to convert the counts into a RR with a 95% CI, as the RR 
approximates the HR for an uncommon outcome. If an effect-measure estimate was reported for 
those not receiving vs. receiving TB treatment (as opposed to receiving vs. not receiving TB 
treatment), the inverse of the reported effect-measure estimate and CI were included. If only a p-
value from a univariate logistic regression model was presented, the 2x2 table was reconstructed 
and Episheet was used to calculate a RR. Standard error estimates were inferred from reported 
CIs by [ln(upper limit) – ln(lower limit)]/3.92 [97]. 
As tuberculosis is successfully treated in most patients after six months of treatment, and 
the hazard of mortality following cART initiation is not constant, we grouped the available 
cumulative effect estimates according to the length of follow-up: 1-3 months, 6-12 months, and 
18-98 months. None of the eligible studies reported estimates at 4-5 months or 13-17 months 
following cART initiation. If a study reported multiple estimates within a time category, the time 
frame closest to the category midpoint was included in the primary analysis and other time 
estimates were examined in sensitivity analyses. 
The method of moments estimate of the among-populations variance (τ2) and random-
effects summarization using unconditional variances were used to combine relative risks in the 
three groups [98]. The p-values for a standard chi-square homogeneity test statistic were used to 
assess overall consistency among the effect estimates. τ2
 
was used to calculate 95% population 
effects intervals [99] (where 95% of populations are estimated to have their relative risks), 
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opposite effects proportions [100] (proportion of populations estimated to experience a relative 
risk on the opposite side of the estimated mean, in this case below unity), and 95% prediction 
intervals [100] (95% of these intervals will cover the true value estimated by a future study). 
Stratified and random-effects meta-regression analyses were used to calculate stratum-specific 
summary measures and 95% CIs, along with ratios of the average RRs as described by 
Thompson and Sharp [101]. Study characteristics with at least two studies per stratum were 
eligible for inclusion in the meta-regression. 
Funnel plots of the log relative risk of mortality vs. the inverse-variance weight of studies 
for each time category were visually examined for asymmetry and statistically assessed using 
methods proposed by Begg [102] and Egger [103]. The trim and fill method was used to assess 
publication bias [104]. STATA (version 12, Stata corporation, College Station, TX, USA) was 
used for these analyses. 
 As Makombe et al. (2007) [105] contained multiple estimates of mortality in the 6-12 
month time frame, only the six-month estimate was included in primary analyses. The analysis 
was then repeated, substituting in the 12-month estimate. As this alternative estimate was similar 
in point estimate and precision to the 6-month estimate, the substitution did not affect the results 
or our conclusions. Likewise, Westreich et al. (2012) [106] reported estimates at 36 months and 
54 months. Regardless of which was included, the analysis results did not substantially differ. 
Additionally, as some studies reported asymmetrical confidence intervals, a sensitivity analyses 
assessed their impact on the summary measures. 
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Meta-analysis Methods for Specific Aim 2 
Reported effect estimates over any length of time were abstracted. If only count data of 
those who experienced an outcome, stratified by TB treatment status, were reported, a RR and 
95% CI were calculated.  If a study reported an outcome only graphically, outcome values were 
visually estimated [98]. Standard error estimates were inferred from reported CIs by [ln(upper 
limit) – ln(lower limit)]/3.92 [97]. As we aimed to quantify virologic suppression, if a study 
reported on patients who failed to suppress, this information was converted to obtain data on 
suppression. For CD4 counts, if 2 of 3 of the following measures were reported, we calculated 
the third measure: mean baseline CD4 count, mean change in CD4 count from baseline, mean 
absolute CD4 count. We were unable to calculate the missing measures if only median CD4 
counts were reported. 
For virologic suppression, summarized relative risks were calculated using random-
effects summarization with unconditional variances and the method of moments estimated 
between-study variance (τ2) [98]. As several studies reported estimates at multiple of time points, 
we used the estimate closest to the midpoint of each study’s follow-up time to get an overall 
relative risk for virologic suppression. In addition, to examine short- and long-term virologic 
suppression, summary relative risks at 1-4 months, 6 months, 11-12 months and 18-48 months 
were calculated. The p-values for a standard chi-square homogeneity test statistic were used to 
assess overall consistency among the effect estimates across studies. τ2
 
was used to calculate 
95% population effects intervals [99] (where 95% of populations are estimated to have their 
means), opposite effects proportions [100] (proportion of populations likely to experience a 
relative risk below unity), and 95% prediction intervals [100] (95% of these intervals will cover 
the true value estimated by a future study). Stratified and random-effects meta-regression 
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analyses were used to calculate stratum-specific summary measures and 95% CIs, along with 
ratios of the stratum-specific RRs as described by Bassler [107]. 
Funnel plots of ln(virologic suppression relative risk) vs. the inverse-variance weight of 
studies were visually examined for asymmetry and statistically assessed using methods proposed 
by Begg [102] and Egger [103] and the trim-and-fill method [104]. STATA (version 12, Stata 
corporation, College Station, TX) was used for these analyses. 
 
Methods for Specific Aim 3 
 
Study Population 
We performed a secondary analysis of data from the TB HIV IRIS and Nutrition in Kids 
(THINK) study. This South Africa-based study prospectively followed 1) children diagnosed and 
treated for TB who become eligible for cART, and 2) children who are TB-free at the time of 
cART initiation. The primary objectives were to determine the incidence, timing, and clinical 
manifestations of TB- and BCG- IRIS among children initiating cART, along with the 
association between malnutrition and the risk of developing TB- and BCG-IRIS. 
cART-naive children aged 0 to 8 years presenting at the Harriet Shezi outpatient pediatric 
HIV clinic or the Paediatric Wards of Chris Hani Baragwanath Hospital in Soweto, South Africa, 
who were eligible for cART according to South African national treatment guidelines were 
offered participation in the THINK study. The study enrolled children between September 2009 
and March 2012 and followed children for 24 months or until August 2013, when study follow-
up ended. In order to be included in this secondary analysis, children had to initiate cART and 
have ≥1 HIV RNA and/or CD4% following cART initiation. 
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TB and HIV Diagnosis 
Children were diagnosed with TB [108] and HIV [26, 109] according to South African 
guidelines. TB diagnosis was made based on a combination of clinical signs, contact with an 
adult with active TB, positive tuberculin skin test, suggestive chest X-ray, or positive sputum 
smear microscopy or culture [108]. The National Health Laboratory Service processed all 
sputum samples. Starting in July 2011, a sputum sample was also evaluated by the Xpert 
MTB/RIF assay. HIV diagnosis was confirmed according to national guidelines. 
 
Clinical Care 
 Children were treated according to national guidelines for TB and HIV [26, 108, 
110]. All children diagnosed with active TB were treated and generally received isoniazid, 
rifampicin, pyrazinamide, and ethambutol for two months followed by isoniazid and 
rifampicin for four months. 
Prior to April 2010 in South Africa, children were eligible for cART if they had recurrent 
or prolonged HIV-related hospitalizations, WHO stage II/III disease [111], CD4% <20% (if ≤18 
months), or CD4% <15% (if >18 months) [109]. Children ≤3 years or ≤10 kilograms initiated 
LPV/r-based cART (stavudine + lamivudine + LPV/r), children >3 years and >10 kilograms 
initiated efavirenz-based cART (stavudine + lamivudine + efavirenz). Initiation of cART was 
delayed for at least two months in children receiving TB treatment and they received ritonavir at 
a 1:1 dosage with lopinavir (super-boosted LVP/r).  
In April 2010, the national guidelines changed. All children ≤1 year were eligible for 
cART upon HIV diagnosis [26]. Children 1-5 years were eligible for cART if WHO stage III/IV, 
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CD4% ≤25% or CD4 count <750 cells/µL. Children >5 years were eligible if WHO stage III/IV 
or CD4 count <350 cells/µL. Children ≥3 years and ≥10 kilograms initiate efavirenz-based cART 
(abacavir + lamivudine + efavirenz), and LPV/r-based cART (abacavir + lamivudine + LPV/r) is 
used for children <3 years old or <10 kilograms. Initiation of cART was recommended to be 
delayed for 2-4 weeks after starting TB treatment, and children concurrently on TB treatment 
and LPV/r-based cART received added ritonavir: super-boosted LVP/r for younger children, and 
a double LPV/r dose for older children [26].  
The updated guidelines also recommended decentralization of pediatric cART initiation 
and follow-up care to primary care clinics. For this reason, many patients chose to receive their 
ART care closer to home and no longer returned to the hospital regularly, essentially making 
them lost-to-follow-up. However, every effort was made to encourage the children to return to 
the study for the final 24-month visit, even if they transferred to an ART service closer to home.  
 
Patient Follow-up 
The THINK study included a pre-cART visit, cART initiation visit, and visits every three 
months thereafter until 24 months post cART initiation. As part of routine care, caregivers of 
children who missed a scheduled visit were contacted ≤2 times via telephone to remind them of 
their missed appointment and encourage them to return. Efforts were made to encourage those 
who had transferred to a primary care facility to return for the final 24-month visit. Additionally, 
during this telephone contact, caregivers were asked if the child was still alive, to help ascertain 
if any deaths were missed. 
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Study variables 
CD4% (LSRII flow cytometer, BD Biosciences) and HIV RNA (Ultrasensitive Amplicor 
HIV Monitor assay, Roche Diagnostic Systems, Basel, Switzerland, lower limit of detection 50 
copies/mL) were measured at or before cART initiation and at every three months during follow-
up. Baseline values were those measured at cART initiation or the closest value within four 
months prior to initiation. Level of immunodeficiency and anemia were defined according to 
WHO age-specific classifications [111, 112]. Severe immunodeficiency was defined as: CD4% 
<25% in children <11 months, CD4% <20% in children 12-35 months, CD4% <15% in children 
36-59 months, and CD4 cell count <200 cells/µL or CD4% <15% in children >5 years [111]. 
Weight-for-age z-scores were calculated using the WHO Anthro (version 3.2.2) SAS macro 
[113] for children <5 years old and the WHO AnthroPlus SAS macro [114] for children 5-8 
years old. 
Virologic suppression was defined as the first documented HIV RNA <50 copies/mL 
following cART initiation. Virologic rebound was defined as HIV RNA >1000 copies/mL 
following a prior measurement <50 copies/mL. The primary measure of immunologic response 
was median increase in CD4% from baseline at 3, 6, 12 and 24 months following cART 
initiation. 
As some children may not have a large number of follow-up HIV RNA measurements, 
we chose to use the more sensitive, but less specific primary outcome definition for virologic 
rebound of HIV RNA >1000 copies/mL, following a prior measurement of <50 copies/mL. 
However, it is possible that a single elevated measurement may be a blip and not indicative of 
true virologic failure. Therefore, we conducted a sensitivity analysis using the more specific 
outcome definition of the first of two consecutive HIV RNA measurements >1000 copies/mL, 
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following a prior measurement of <50 copies/mL. Less children were included in this sensitivity 
analysis, as they were missing repeated HIV RNA measurements or virologic rebound occurred 
at the end of follow-up. 
 
Statistical Analysis 
Wilcoxon rank-sum tests were used to compare continuous demographic and clinical 
variables between groups, Pearson’s X2 test was used for categorical variables, and exact P 
values were calculated when appropriate.  
To examine virologic suppression, the median time to suppression was calculated, 
stratified by TB treatment status. The distributions of event times in each exposure group were 
examined by plotting the Kaplan-Meier estimate of the survivor function; the log-rank test was 
used to compare the two curves. Crude and multivariable Cox proportional hazards regression 
were used to calculate HRs and associated 95% CIs. Time origin was the date of cART initiation 
and patients were censored at the earliest occurrence of death, loss to follow-up (censored on last 
visit date), or 24-month study visit. Covariates considered as effect measure modifiers and/or 
confounders included cART guidelines used (pre-2010 vs. 2010 guidelines), age (<2.1 vs. ≥2.1 
years), sex, weight-for-age z-score (<-3 vs. ≥-3), baseline HIV RNA (<5.5 vs. ≥5.5 log10 
copies/mL), baseline CD4% (continuous), cART regimen (efavirenz-based vs. LPV/r-based), 
baseline hemoglobin (continuous). These variables were identified through the existing literature 
and directed acyclic graph (DAG) analysis (Figure 1). We identified effect measure modifiers by 
considering the exposure-outcome relationship at each level of the covariate by including a 
product interaction term between the exposure and the potential effect measure modifier. Effect 
measure modification was examined only for variables for which stratified estimates would be 
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clinically meaningful. A p-value > 0.10 indicated heterogeneity in the stratum-specific measures 
of association. Similar methods were used to assess virologic rebound, limiting the analysis to 
patients who ever experienced virologic suppression. 
Median increases in CD4% were calculated, both overall and stratified by TB treatment 
status. Median CD4% and median CD4% gains were compared using Wilcoxon rank sum tests. 
Side-by-side box plots of CD4% at each visit in children receiving vs. not receiving TB 
treatment were created. The proportion of children with severe age-specific immunodeficiency 
[111] at each visit was also examined.  
In addition to the overall analysis, we performed exploratory sensitivity analyses 
stratified by (1) cART regimen and (2) timing of cART initiation relative to the 2010 change in 
guidelines. As new guidelines were implemented over several months, children who initiated 
cART from April to October 2010 were classified as initiating care according to the pre-2010 
guidelines if their initial regimen included stavudine or as initiating according to the 2010 
guidelines if their initial regimen contained abacavir. 
Study data were collected and managed using Research Electronic Data Capture 
(REDCap) [115] hosted at The University of North Carolina-Chapel Hill. All analyses were 
performed using SAS (version 9.3, SAS Institute, Cary, North Carolina, USA). 
 
Ethics Approval 
Children were enrolled following parental permission and child assent procedures (for 
children ≥7 years). Institutional Review Boards of University of North Carolina at Chapel Hill 
and University of Witwatersrand approved the study. 
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Figure 1. Directed acyclic graph 
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CHAPTER IV 
THE EFFECT OF TUBERCULOSIS TREATMENT AT COMBINATION 
ANTIRETROVIRAL THERAPY INITIATION ON SUBSEQUENT MORTALITY: A 
SYSTEMATIC REVIEW AND META-ANALYSIS
 
Introduction 
 
Tuberculosis (TB) continues to threaten the health of people living with HIV (PLWH). 
Globally in 2011, 13% of incident TB cases were co-infected with HIV and an estimated 0.4 
million TB deaths occurred among PLWH [1]. Access to combination antiretroviral therapy 
(cART) has dramatically increased survival, but a substantial number of PLWH die during the 
first year of cART. The majority of deaths occur within the first three months [11-13, 116]. 
Autopsy studies have consistently shown TB to be an important cause of death in PLWH, both in 
the pre-cART [117-119] and cART eras [120]. 
In 2010, a meta-analysis of the effect of TB on mortality found PLWH also suffering 
from TB had a greater risk of mortality than TB-free individuals (hazard ratio [HR]: 1.8, 95% 
confidence interval [CI]: 1.4-2.3) [66]. Due to the paucity of studies reporting on patients on 
cART, the authors concluded that the effect of TB on mortality in PLWH exposed to cART must 
be further evaluated once more cohort study results become available. 
Given the World Health Organization’s 2010 recommendation that all PLWH with TB be 
initiated on cART, regardless of CD4 count [2], and the goal of 100% cART coverage of co-
infected patients by 2015 [3], many individuals will be initiating cART while concurrently on 
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treatment for confirmed or clinically suspected active TB. PLWH who are also being treated for 
TB may experience a differential response to cART due to drug-drug interactions [4, 5], an 
increased risk of drug toxicity [4, 5], immune reconstitution inflammatory syndrome [6], and the 
potential for lower adherence due to the high pill burden [5]. The effect of TB treatment and its 
associated potential challenges and complications on a patient’s response to cART is not yet 
clear [121]. 
We aim to describe the impact of receiving TB treatment at the time of cART initiation 
on subsequent mortality among HIV-infected adults. We performed separate analyses to identify 
the effect at 1-3 months, 6-12 months, and 18-98 months. 
 
Methods 
 
Search strategy and selection criteria 
To investigate the effect of TB treatment at the time of cART initiation on mortality, we 
carried out a systematic and sensitive search using an a priori protocol developed according to 
PRISMA guidelines [96]. We searched PubMed and EMBASE, as well as abstract databases 
from the 2009 to 2012 Conferences on Retroviruses and Opportunistic Infections, International 
Union Against Tuberculosis and Lung Disease World Conferences on Lung Health, and 
International AIDS Society conferences. The search terms “HIV AND Tuberculosis AND (Viral 
Load OR CD4 lymphocyte count OR Mortality) AND Antiretroviral therapy” were used to 
identify relevant articles in PubMed and EMBASE. Searches were performed on March 1, 2013 
and included original human subjects cohort studies published since 1997 (the start of the cART 
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era). Additional articles were identified from reference lists, reviews, and Web of Science 
citation lists. 
H.M.S. and A.V.R. independently reviewed titles and abstracts of original studies 
retrieved by the search. H.M.S. reviewed full-text and references of selected articles. H.M.S. and 
M.R.P. independently abstracted study data from full reports; discrepancies were resolved by 
consensus or consultation with A.V.R. and C.P. 
Studies were included if they included both antiretroviral-naïve HIV-infected individuals 
receiving and not receiving TB treatment at cART initiation, and reported mortality after cART 
initiation stratified by TB treatment status at cART initiation. cART was defined as a treatment 
regimen containing three or more antiretrovirals. Though we sought reports of cART-naïve 
patients, studies with ≤10% antiretroviral-experienced patients or patients only previously 
exposed to a single intrapartum dose of nevirapine were also included. Studies of children <14 
years of age were excluded. No additional exclusion criteria or language restrictions were 
imposed. 
 
Data extraction 
The following information, if available, was abstracted from each article: first author 
surname; publication year; study design; study dates; length of follow-up; geographic location; 
clinical setting; sample size; number receiving and not receiving TB treatment; if TB treatment 
was the main exposure of interest; types of TB included; culture confirmation of TB cases; TB 
site; timing of TB treatment in relation to cART initiation; percentage male; mean or median 
participant age; proportion treatment-naïve; cART regimen; baseline median CD4 count and 
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HIV-RNA; measure of effect or event counts; covariate adjustment; proportion lost-to-follow-up; 
and if mortality was confirmed using a national death registry.  
 
Statistical analysis 
Reported mortality effect-measure estimates over any length of time were abstracted. If 
only survival proportions among those receiving or not receiving TB treatment were reported, a 
risk ratio (RR) and 95% CI were calculated, as the RR approximates the HR for an uncommon 
outcome. If an effect-measure estimate was reported for those not receiving vs. receiving TB 
treatment, the inverse of the reported effect-measure estimate and CI were included. If only a p-
value from a univariate logistic regression model was presented, the 2x2 table was reconstructed 
and a RR was calculated. Standard error estimates were inferred from reported CIs by [ln(upper 
limit) – ln(lower limit)]/3.92 [97]. 
As tuberculosis is successfully treated in most patients after six months of treatment, and 
the hazard of mortality following cART initiation is not constant, we grouped available 
cumulative effect estimates according to length of follow-up: 1-3 months, 6-12 months, and 18-
98 months. None of the eligible studies reported estimates at 4-5 months or 13-17 months 
following cART initiation. If a study reported multiple estimates within a time category, the time 
frame closest to the category midpoint was included in the primary analysis and other time 
estimates were examined in sensitivity analyses. 
The method of moments estimate of the among-populations variance (τ2) and random-
effects summarization using unconditional variances were used to combine relative risks in the 
three groups [98]. The p-values for a standard chi-square homogeneity test statistic were used to 
assess overall consistency among the effect estimates. τ2
 
was used to calculate 95% population 
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effects intervals [99] (where 95% of populations are estimated to have their relative risks), 
opposite effects proportions [100] (proportion of populations estimated to experience a relative 
risk on the opposite side of the estimated mean, in this case below unity), and 95% prediction 
intervals [100] (95% of these intervals will cover the true value estimated by a future study). 
Stratified and random-effects meta-regression analyses were used to calculate stratum-specific 
summary measures and 95% CIs, along with ratios of the average RRs as described by 
Thompson and Sharp [101]. Study characteristics with at least two studies per stratum were 
eligible for inclusion in the meta-regression. 
Funnel plots of ln(mortality relative risk) vs. the inverse-variance weight of studies for 
each time category were visually examined for asymmetry and statistically assessed using 
methods proposed by Begg [102] and Egger [103] and the trim-and-fill method of Duval and 
Tweedie [104]. STATA (version 12, Stata corporation, College Station, TX) was used for these 
analyses. 
 
Results 
 
Selected studies 
997 unique abstracts were reviewed: 824 from PubMed, 121 additionally from EMBASE, 
and 52 from conference proceedings (Figure 2). Of these, 119 full-text articles were selected for 
review. In total, 20 articles [11, 14, 68, 69, 72, 79, 81, 82, 106, 122-132] and three conference 
abstracts [133-135] were eligible. Four additional articles met our inclusion criteria: two from 
reference lists [105, 136] and two from Web of Science citation searches [70, 137]. One included 
abstract [134] was subsequently published as a full article [83]; only data from the full article 
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was included. Five eligible studies were excluded: one [131] because a 2012 paper [106] 
provided an updated estimate; four because they included some early incident TB cases in their 
TB treatment-exposed group [123, 127, 128, 130]. 
 
Study and population characteristics 
The 22 final studies provided data on 98,350 PLWH, of which 14,779 (15%) were 
receiving TB treatment at cART initiation. Selected study and population characteristics are 
displayed in Table 1. All were cohort studies. Most publications assessed mortality after cART 
initiation, regardless of regimen type, though some reported estimates specific to nevirapine-[72, 
81, 105, 136] or efavirenz-based [69, 81, 82] therapy. See Table 10 (Appendix) for cART 
regimens used by each study. All studies used cART initiation as the time origin, except one 
which began at the commencement of cART education and adherence sessions, with most 
patients starting cART a month or two later [83]. Four studies included women previously 
exposed to a single intrapartum dose of nevirapine [14, 68, 81, 124], and two studies included 
3% [106] and 6% [126] antiretroviral-experienced patients. 
Ten studies examined TB treatment at cART initiation as the main exposure of interest 
[69, 70, 72, 79, 81-83, 105, 106, 135]. The other twelve studies examined TB treatment as a 
secondary exposure; five examined any predictors of mortality [122, 124, 125, 132, 136], three 
aimed to describe general cART outcomes [11, 14, 68], and one each examined the primary 
exposures of integrated vs. vertical HIV programs [126], positive serum cryptococcal antigen 
[129], age [137], and hepatitis B and C co-infections [133]. The type of TB being treated varied 
across studies (Table 11, Appendix). Only two studies had a substantial subset of 
bacteriologically-confirmed TB cases [70, 83] while others included both confirmed and 
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probable TB cases. Most articles included any TB being treated at the time of cART initiation, 
whereas others used a specific time period such as new TB diagnosis at study entry [69, 127] or 
diagnosis ≥1 month prior to enrollment [72]. Nine studies reported detail on the duration of TB 
treatment at the time of cART initiation (Table 12, Appendix). One study focused solely on 
pulmonary TB [106], and one censored patients in the reference group that developed incident 
TB [81].  
Mortality was mainly assessed using medical records and/or confirmation from family or 
health workers, however two studies additionally used national death registries [14, 106]. In an 
effort to quantify late mortality, two studies excluded deaths occurring in the first three months 
[14, 137]. Overall loss-to-follow-up was reported by 19 studies and ranged from 0% to 21% 
(median 9%). 
Two studies were limited to women only [68, 124]. Mean patient age ranged from 28 to 
40 years (median 35 years), with the youngest included age being 14 years [81]. One study 
stratified mortality estimates according to age [137]. Median baseline HIV-RNA ranged from 4.4 
to 5.7 log10 copies/mL (median 5.1), and baseline CD4 count ranged from 31 to 196 cells/µL 
(median 111). See Table 13 (Appendix) for baseline CD4 count stratified by TB treatment status 
from each study, if available. 
 
Relative risk of mortality 
Thirty-one cumulative mortality relative risks were reported or calculated among those 
receiving vs. not receiving TB treatment at cART initiation (Figure 3). Most were HRs, though 
eight RRs [68, 69, 72, 82, 83, 105, 135], four odds ratios [122, 129, 132, 136], and one incidence 
rate ratio [70] were also included. Among the 21 adjusted estimates, 20 adjusted for baseline 
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CD4 count, 19 for gender, 18 for age, 13 for BMI or weight, eight for hemoglobin, and two for 
adherence (defined as timeliness of pharmacy attendance). Including only the estimate 
corresponding to the longest follow-up time from each study, the summarized relative risk of 
mortality in those receiving vs. not receiving TB treatment across all time periods was 1.24 (95% 
CI 1.05-1.46, τ2 = 0.097). 
 
Eight relative risks of mortality by 1-3 months were reported, without evidence of 
substantial heterogeneity (homogeneity p-value = 0.11, Table 2). The random-effects summary 
estimate was 1.10 (95% CI 0.87-1.40, τ2 = 0.045). The eleven mortality relative risks by 6-12 
months produced a random-effects summary estimate of 1.15 (95% CI 0.94-1.41, τ2 = 0.041). By 
18-98 months, the summarized relative risk indicated increased mortality among patients 
receiving TB treatment (random effects relative risk [RRRE] = 1.33, 95% CI 1.02-1.75, τ2 = 
0.134), based upon 10 estimates. There was evidence of considerable heterogeneity for the 6-12 
and 18-98 month estimates (homogeneity p-values 0.06 and <0.01, respectively). 
 
Meta-regression 
Meta-regression results are displayed in Table 14 (Appendix). For 1-3 month mortality, 
lower median baseline CD4 counts and adjustment for baseline hemoglobin appear to produce 
somewhat higher relative risks. Among the 6-12 month estimates, length of follow-up appeared 
to have the most influence and produced the most homogenous strata, suggesting that this 6-
month window may be too wide. At 6 to 9 months following cART initiation, those receiving vs. 
not receiving TB treatment had a RRRE of 0.93 (95% CI 0.68-1.28, homogeneity p-value = 0.14), 
whereas at 11 to 12 months the RRRE was 1.29 (95% CI 1.06-1.56, homogeneity p-value = 0.61), 
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indicating an increased risk of mortality after completion of TB treatment. Studies limited to 
women only also reported higher RRs (RRRE = 2.57, 95% CI 0.83-7.98). Among 18-98 month 
estimates, a longer follow-up time does not appear to influence the results. However, adjustment 
for BMI or weight tended to move the relative risk toward the null (RRRE = 1.01, 95% CI 0.84-
1.21). 
 
Funnel plot analysis 
For 1-3 month estimates, the funnel plot gives the visual appearance of a slight skew to 
the left (Figure 8, Appendix), but both tests for asymmetry yielded p-values of 0.8, and only one 
hypothetical missing result was imputed on the right by trim-and-fill analysis, with little 
influence on the summary results. In contrast, funnel plots for 6-12 and 18-98 months were 
skewed more noticeably to the right and the tests for asymmetry yielded lower p-values (Begg p 
= 0.2, Egger p = 0.03 for 6-12 months, Begg p = 0.3 and Egger p = 0.4 for 18-98 months). Trim-
and-fill imputed four hypothetically missing results at 6-12 months and two at 18-98 months, all 
on the left. The imputation shifted the estimate of the random-effects average RR from 1.15 to 
1.02 at 6-12 months and from 1.33 to 1.14 at 18-98 months. 
 
Sensitivity analyses 
As Makombe et al. (2007) [105] contained multiple estimates of mortality in the 6-12 
month time frame, only the six-month estimate was included in primary analyses. The analysis 
was then repeated, substituting in the 12-month estimate. As this alternative estimate was similar 
in point estimate and precision to the 6-month estimate, the substitution did not affect the results 
or our conclusions. Likewise, Westreich et al. (2012) [106] reported estimates at 36 months and 
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54 months. Regardless of which was included, the analysis results did not substantially differ. 
Additionally, as some studies reported asymmetrical confidence intervals, a sensitivity analyses 
assessed their impact on the summary measures (Table 15). 
 
Discussion 
 
This systematic review and meta-analysis of studies reporting the effect of TB treatment 
at cART initiation on subsequent mortality among PLWH initiating therapy found that TB 
treatment did not significant affect mortality on cART in the short-term, but was associated with 
increased mortality after about a year of cART. These results are important given the many 
concerns about co-treatment including drug-drug interactions, overlapping drug toxicities, 
immune reconstitution inflammatory syndrome, and high pill burden. Our findings were not 
sensitive to geographical study location (Africa vs. Asia or Europe). 
Overall, the summary estimates for early mortality were lower than estimates for later 
mortality. This finding may be contrary to expectations, but could be due to several factors. First, 
patients on concurrent TB therapy at cART initiation may experience a lower short-term risk of 
all-cause mortality because TB medications are also effective against infectious diseases other 
than TB [138]. Second, most PLWH receiving TB treatment often receive co-trimoxazole 
preventive therapy, which further reduces the risk of death from non-TB infectious diseases. 
Third, prior to cART initiation, PLWH on TB treatment may have been engaged in care for 
longer than other PLWH. Fourth, TB deaths can occur early during TB treatment, i.e., prior to 
the initiation of cART, creating possible left-censoring. However, PLWH not diagnosed with TB 
also may die prior to cART initiation, and studies did not provide enough information to 
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determine if left-censoring was differential between the two groups. Fifth, undiagnosed and 
untreated TB among the comparison group may have biased estimates of early mortality toward 
the null. Autopsy studies consistently show that undiagnosed TB continues to be a major cause 
of death among HIV-infected adults [117-119], even in the cART era [120].  
This meta-analysis has a number of limitations. Since being treated for active TB is not 
an exposure suitable for a randomized controlled trial, all studies included in our meta-analysis 
were observational and subject to biases. First, the outcome of mortality may have been 
misclassified in people lost-to-follow-up. Rates of follow-up loss were variable in the included 
studies, ranging from 0% to 21%. cART programs with high losses of patients and incomplete 
death ascertainment can seriously underestimate mortality, with 12% to 87% of patients loss-to-
follow-up in fact being deceased [139]. Misclassification of deaths would only produce bias in 
the estimated relative risks if this misclassification was differential between compared groups 
[140] or dependent on errors in measuring other variables. This is especially relevant for 
mortality estimates during the first six months of cART, when loss-to-follow-up may be 
differential due to regular follow-up for TB treatment. We attempted to examine if mortality 
confirmation by national death registry affected mortality effect estimates. This was only 
possible for two studies, both with 18-98 months of follow-up.  
Second, the exposure, prevalent TB treatment at cART initiation, captures both 
confirmed active TB disease and exposure to anti-tuberculosis drugs for clinically suspected TB. 
This combined exposure is useful from a health systems perspective, particularly in low-resource 
countries, where active TB cannot always be confirmed, especially in PLWH. The included 
studies used a variety of methods for determining who had active TB and should receive 
treatment, and no studies were exclusively limited to bacteriologically-confirmed TB cases. 
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Consequently, active TB could have been misclassified and some patients included in this meta-
analysis may have received TB treatment even though they did not have TB. In addition, some 
patients with active TB may not have been diagnosed.  
Third, there was much heterogeneity in the duration of TB treatment prior to cART 
initiation, with some patients on TB therapy for six months and others beginning TB treatment 
and cART concurrently. While the timing of TB treatment in relation to cART initiation is an 
important variable to consider when evaluating mortality [47-50, 131], the included studies did 
not provide enough information on duration of TB treatment to systematically evaluate its effect 
on our results. Future studies should describe the duration of TB treatment in more detail to 
facilitate meta-analysis, though a pooled patient-level analysis or randomized controlled trial are 
study designs better suited to assess this. 
Some degree of funnel plot asymmetry was apparent for each time period, possibly due to 
publication bias or other factors. A direct effect measure was not available from each study, and 
published estimation methods [97] were used to calculate the effect measure for five studies. 
These estimation techniques involve a number of assumptions and may have introduced bias or 
affected variance estimates. Additionally, in 12 of 22 studies, TB treatment was not the primary 
exposure and covariates included in multivariate models may differ from ideal confounder 
adjustment for this research question. Some studies only included TB treatment in their 
multivariable model for mortality because it was a statistically significant predictor, which may 
explain some funnel plot asymmetry.  
It was difficult to examine the influence of study or population characteristics on the 
effect estimates, as grouping studies by specific characteristics produced small strata with 
imprecise estimates. Furthermore, some characteristics are correlated. For example, risk ratios 
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and odds ratios tended to be higher than hazard ratios, but the former also tended to be 
unadjusted estimates. Also, as studies adjusted for sets of key covariates, it was difficult or 
impossible to separate out the influence of adjusting for a specific covariate (see footnotes of 
Table 14, Appendix). 
Given the patient characteristics of the included studies, the results are most generalizable 
to therapy-naïve adults in sub-Saharan Africa with relatively low CD4 counts at cART initiation. 
More studies in populations outside of sub-Saharan Africa, particularly in North America, would 
be useful additions to the literature. This review only includes studies among adults; it is 
unknown whether the relationship holds in children. Similarly, it is possible that cART regimen 
would modify the effect of TB treatment due to drug-drug interactions, and regimen-specific 
estimates would be of most use to clinicians treating co-infected patients.  
In conclusion, our results reinforce the concept [106] that TB treatment does not increase 
early mortality after cART initiation — the issue is undiagnosed and untreated TB —  
underscoring the need for intensified case finding to reduce early mortality associated with 
undiagnosed TB in PLWH. After about a year of cART, TB treatment was associated with 
increased mortality, despite the possibility of downward biases. This association should be 
elucidated in future studies, with an emphasis on separating possible effects of TB treatment 
from effects of active TB itself. In the meantime, patients receiving concurrent TB treatment at 
cART initiation may benefit from continued support after TB treatment completion.
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Table 1. Characteristics of 22 studies reporting the effect of TB treatment on mortality after cART initiation among HIV-infected 
adults 
Study 
Publication 
year 
Geographic 
location 
Sample 
size 
TB 
treatment, 
N (%) 
Main 
exposure 
is TB 
Study 
design 
cART 
regimena 
Naïve, 
% 
Male, 
% 
Mean 
age, 
years 
Median 
baseline 
CD4 
countb, 
cells/µL 
Median 
baseline 
HIV RNA, 
log10 
copies/mL 
Lost to 
follow-up, 
% 
Overall 
mortalityc,
% 
Confirmed 
mortality 
with 
national 
death 
registry 
Duration 
of follow-
up, 
months 
Bassett 2012 South Africa 951 343 (36) Yes P All 100 41 36 90 NS 7 10 No 12 
Bera 2009 South Africa 385 25 (7) No P All 100 0 28 173 4.6 4 2 No 8 
Bhowmik 2012 India 743 285 (38) No R All 100 66 35 140 NS NS 7 No 12 
Boulle (a)d 2008 South Africa 1935 209 (11) Yes P NVP 100 21 31 110 5 6 4 No 6 
Boulle (b)d 2008 South Africa 2035 1074 (53) Yes P EFV 100 40 33 78 5.2 6 6 No 6 
Boulle 
(a,b)e 2010 
South 
Africa 7323 2760 (38) No P All 100 32 33 101 5.1 10 NS; 16 Yes 3; 3-60 
Chu 2011 Uganda 15225 1177 (8) Yes P All 100 NS NS NS NS NS 7 No 65 
Dao 2011 Zambia/ Kenya 661 56 (8) No P All 100 0 32 147 5 5 8 No 12 
DeSilva 2009 Nigeria 1552 251 (16) No R All 100 29 34 112 NS 9 7 No 24 
Dronda 2011 Spain 1986 110 (6) Yes P All 100 76 38 196 5.0 7 3 No 47 
Greig 2012 
Sub-
Saharan 
Africa 
14523 1159 (8) No R All 94 35 36 133 NS 12 7 No 30 
Gupta 2013 South Africa 1544 464 (30) Yes P All 100 30 34 98 4.9 21 13 No 100 
Lartey 2011 Ghana 74 34 (46) Yes P EFV 100 49 NS 83 5.4 11 9 No 11 
Liechty 2007 Uganda 377 32 (8) No P All 100 29 38 50 5.5 0 6 No 3 
Makombe 
(a,b)e 2007 Malawi 12485 1339 (11) Yes R NVP 100 NS NS NS NS 11 12; 13 No 6; 12 
Manosuthi 2010 Thailand 140 70 (50) Yes P NVP 100 68 36 31 5.6 11 6 No 48 
Mugusi 
(a,b)e 2012 Tanzania 449 194 (43) Yes P EFV 100 42 40 92 5.7 12 3; 11 No 1; 11 
Mutevedzi 
(a,b)f 2011 
South 
Africa 7927 1752 (22) No R All 100 33 34 117 4.4 11 5; 3 No 3; 3-12 
Mutevedzi 
(c,d)f 2011 
South 
Africa 919 175 (19) No R All 100 44 54 127 4.5 11 6; 6 No 3; 3-12 
Nguyen 2011 Vietnam 370 NS NS No R All 100 66 33 NS NS NS 31 No 60 
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Stringer 
(a,b)e 2006 Zambia 14306 1562 (11) No P All 100 39 35 143 NS 21 6; 9 No 3; 18 
Westreich 
(a,b)e 2012 
South 
Africa 7512 1197 (16) Yes P All 97 34 35 88 NS NS 7; 9 Yes 36; 54 
Zachariah 2006 Malawi 1507 225 (15) No P All 100 34 35 123 NS 3 8 No 3 
Zachariah 2009 Malawi 2289 196 (9) No R NVP 100 31 35 NS NS 5 9 No 3 
Abbreviations: cART, combination antiretroviral therapy; EFV, Efavirenz-based cART; HIV, human immunodeficiency virus; NS, 
not specified; NVP, Nevirapine-based cART; P, prospective study; R, retrospective study; TB, tuberculosis. 
a
 See Table 10 (Appendix) for detailed information on cART regimens from each study, if available 
b
 See Table 13 (Appendix) for baseline CD4 cell count stratified by TB treatment status from each study, if available 
c
 If a study reported relative risks for multiple time periods, an overall mortality estimate is indicated for each respective time period 
d
 (a) Nevirapine-based cART; (b) Efavirenz-based cART 
e
 For these studies, the letters after the author’s name refer to the estimates reported at differing time points. For example, Makombe 
(a) refers to the 6-month estimate and Makombe (b) refers to the 12-month estimate. 
f
 (a,b) patients <50 years old; (c,d) patients ≥50 years old
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Table 2. Meta-analysis results for the effect of TB treatment on mortality, by length of follow-up 
time 
Length of follow-up time 1-3 months 6-12 months 18-98 months 
No. of studies 8 11 10 
Homogeneity p-value 0.106 0.063 <0.001 
Estimate of between-study 
variance (τ2) 
0.045 0.041 0.134 
RRRE (95% CI) 1.10 (0.87, 1.40) 1.15 (0.94, 1.41) 1.33 (1.02, 1.75) 
95% population effects interval (0.73, 1.67) (0.77, 1.71) (0.65, 2.73) 
Opposite effects proportion 32.2% 24.8% 21.6% 
95% prediction interval (0.62, 1.97) (0.69, 1.91) (0.55, 3.23) 
Abbreviations: CI, confidence interval; RRRE, random-effects summary relative risk; TB, 
tuberculosis 
  
  
Figure 2. Identification and selection of eligible studies
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Figure 3. Forest plot of mortality relative risks reported by 22 studies
The relative risks correspond to the estimated effect of receiving vs. not receiving TB treatment 
at the time of cART initiation on subsequent mortality among HIV
ordered according to length of follow
precision used by the original authors
decimal places. Abbreviations: cART, combination antiretroviral therapy; 
interval; HIV, human immunodeficiency vi
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-infected adults. 
-up time. Estimates were abstracted according to the 
; estimates calculated using available data are reported to 2 
CI, confidence 
rus; RR, relative risk; TB, tuberculosis
 
 
Estimates are 
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CHAPTER V 
THE EFFECT OF TUBERCULOSIS TREATMENT ON VIROLOGIC AND CD4 COUNT 
RESPONSE TO COMBINATION ANTIRETROVIRAL THERAPY: A SYSTEMATIC 
REVIEW 
 
Introduction 
Tuberculosis (TB) threatens the health of people living with HIV (PLWH). Globally in 
2011, 13% of incident TB cases were co-infected with HIV and an estimated 0.4 million TB 
deaths occurred among PLWH [1]. Given the World Health Organization’s 2010 
recommendation that all PLWH with TB be initiated on combination antiretroviral therapy 
(cART), regardless of CD4 count [2], and the goal of 100% cART coverage of co-infected 
patients by 2015 [3], many individuals are initiating cART while concurrently on TB therapy. 
PLWH who are also being treated for TB may experience a differential response to cART due to 
drug-drug interactions [4, 5], an increased risk of drug toxicity [4, 5], immune reconstitution 
inflammatory syndrome [6], and the potential for lower adherence due to the high pill burden [5]. 
The effect of TB treatment and its associated potential challenges and complications regarding a 
patient’s response to cART require careful evaluation.  
We aimed to describe the impact of receiving TB treatment at the time of cART initiation 
on virologic and CD4 count response to cART among HIV-infected adults. In addition, we 
highlighted the various outcome measures used in the literature and make recommendations for 
some methodological standards that may ease future between-study comparisons. 
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Methods 
 
Search strategy and selection criteria 
To investigate the effect of TB treatment at time of cART initiation on virologic response 
and CD4 count response, we carried out a systematic and sensitive search using an a priori 
protocol developed according to PRISMA guidelines [96]. We searched PubMed and EMBASE, 
as well as abstract databases from the 2009 to 2012 Conferences on Retroviruses and 
Opportunistic Infections, International Union Against Tuberculosis and Lung Disease World 
Conferences on Lung Health, and International AIDS Society conferences. The search terms 
“HIV AND Tuberculosis AND (Viral Load OR CD4 lymphocyte count OR Mortality) AND 
Antiretroviral therapy” were used to identify relevant articles in PubMed and EMBASE. 
Searches were performed on January 29, 2013 and included original human subjects studies 
published since 1997 (the start of the cART era). Additional articles were identified from 
reference lists, reviews, and Web of Science citation lists.  
H.M.S. and A.V.R. independently reviewed titles and abstracts of original studies 
retrieved by the search. H.M.S. reviewed full-text and references of selected articles. H.M.S. and 
M.R.P. independently abstracted study data from full reports; discrepancies were resolved by 
consensus among co-authors. 
Studies were included if they reported HIV RNA and/or CD4 count response following 
cART initiation among antiretroviral treatment-naïve HIV-infected adults, stratified by TB 
treatment status at cART initiation. Studies with ≤5% antiretroviral-experienced patients or 
patients only previously exposed to a single intrapartum dose of nevirapine were also included. 
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Studies of children <14 years of age were excluded. No additional exclusion criteria or language 
restrictions were imposed. 
 
Data extraction 
The following information, if available, was abstracted from each article: first author 
surname; publication year; study dates; geographic location; study design; clinical setting; 
sample size; number receiving and not receiving TB treatment at cART initiation; if TB 
treatment was the main exposure of interest; types of TB included; culture confirmation of TB 
cases; TB site; timing of TB treatment in relation to cART initiation; length of follow-up; 
proportion antiretroviral-naïve; percentage male; mean or median participant age; criteria for 
cART initiation; cART regimen; baseline median CD4 count and HIV RNA; HIV RNA outcome 
measure(s); CD4 count outcomes measure(s); covariate adjustment; exclusion criteria; 
proportion lost-to-follow-up; and how each study handled loss-to-follow-up, mortality, and 
regimen switching. For this purposes of this review, we abstracted results as presented in the 
specific studies according to their individual methods and assumptions. 
 
Statistical analysis 
Reported effect estimates over any length of time were abstracted. If only count data of 
those who experienced an outcome, stratified by TB treatment status, were reported, a risk ratio 
(RR) and 95% confidence interval (CI) were calculated.  If a study reported an outcome only 
graphically, outcome values were visually estimated [98]. Standard error estimates were inferred 
from reported CIs by [ln(upper limit) – ln(lower limit)]/3.92 [97]. As we aimed to quantify 
virologic suppression, if a study reported on patients who failed to suppress, this information was 
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converted to obtain data on suppression. For CD4 counts, if 2 of 3 of the following measures 
were reported, we calculated the third measure: mean baseline CD4 count, mean change in CD4 
count from baseline, mean absolute CD4 count. We were unable to calculate the missing 
measures if only median CD4 counts were reported. 
For virologic suppression, summarized relative risks were calculated using random-
effects summarization with unconditional variances and the method of moments estimated 
between-study variance (τ2) [98]. As several studies reported estimates at multiple of time points, 
we used the estimate closest to the midpoint of each study’s follow-up time to get an overall 
relative risk for virologic suppression. In addition, to examine short- and long-term virologic 
suppression, summary relative risks at 1-4 months, 6 months, 11-12 months and 18-48 months 
were calculated. The p-values for a standard chi-square homogeneity test statistic were used to 
assess overall consistency among the effect estimates across studies. τ2
 
was used to calculate 
95% population effects intervals [99] (where 95% of populations are estimated to have their 
means), opposite effects proportions [100] (proportion of populations likely to experience a 
relative risk below unity), and 95% prediction intervals [100] (95% of these intervals will cover 
the true value estimated by a future study). Stratified and random-effects meta-regression 
analyses were used to calculate stratum-specific summary measures and 95% CIs, along with 
ratios of the stratum-specific RRs as described by Bassler [107]. 
Funnel plots of ln(virologic suppression relative risk) vs. the inverse-variance weight of 
studies were visually examined for asymmetry and statistically assessed using methods proposed 
by Begg [102] and Egger [103] and the trim-and-fill method [104]. STATA (version 12, Stata 
corporation, College Station, TX) was used for these analyses. 
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Results 
 
Selected studies 
990 unique abstracts were reviewed: 795 from PubMed, 143 from EMBASE, and 52 
from conference proceedings (Figure 4). Of these, 120 full-text articles were selected for review. 
In total, 18 articles [44, 71-74, 76-79, 81, 82, 84-87, 123, 141, 142] and five conference abstracts 
[75, 134, 143-145] were eligible. Five additional articles met our inclusion criteria: two from 
reference lists [14, 146] and three from Web of Science citation searches [80, 147, 148]. One 
included abstract [134] was subsequently published as a full article [83]; only data from the full 
article was included.  Three eligible studies were excluded: one because some patients included 
in the TB treatment-exposed group had completed TB treatment just prior to cART initiation 
[144], and two because they included some early incident TB cases in their TB treatment-
exposed group [123, 141]. Articles reporting on the same study population, but at differing time 
points following cART initiation, were retained [72, 86, 146]. Similarly, we retained both reports 
of a Tanzanian cohort [80, 84]. 
 
Study and population characteristics 
The 25 final studies provided data on 49,578 PLWH, of which 8,826 (18%) were 
receiving TB treatment at cART initiation. Selected study and population characteristics are 
displayed in Table 3. All were cohort studies; four reported virologic response, eight reported 
CD4 count response, and 13 reported both outcomes. While the majority of studies was based in 
sub-Saharan Africa, nine included Asian populations [71-73, 76, 78, 85, 86, 145, 146] and three 
were from Europe or North America [77, 79, 142]. Most publications assessed response to 
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cART, regardless of regimen type, though some reported estimates specific to nevirapine-[44, 
72, 81, 86, 146] or efavirenz-based [44, 76, 80-82, 84] cART (see Table 16, Appendix, which 
provides study-specific details on cART regimens). Though included studies used a variety of 
cART regimens, nevirapine was often used in combination with stavudine and efavirenz was 
often used in combination with zidovudine and lamivudine. All studies used cART initiation as 
the time origin, except one which began at the commencement of cART education and adherence 
sessions, with most patients starting cART a month or two later [83]. Two studies included 
women previously exposed to a single intrapartum dose of nevirapine [14, 81], and one study 
included 3% antiretroviral-experienced patients [73].  
Seventeen studies examined TB treatment at cART initiation as the main exposure of 
interest [44, 71, 72, 75-79, 81-83, 85, 86, 143, 145, 146, 148]. The other eight studies examined 
TB treatment as a secondary exposure; five aimed to describe general cART outcomes [14, 74, 
87, 142, 147], and one each examined the primary exposures of timeliness of clinic attendance 
[73], β-defensin genomic copy number [84], and liver enzyme abnormalities [80]. The type of 
TB being treated varied across studies. Only one study had a subset of bacteriologically-
confirmed TB cases [83], while others included both confirmed and probable TB cases. One 
study focused solely on pulmonary TB [78], and three excluded patients who developed incident 
TB from the reference group [44, 81, 143]. Sixteen studies reported detail on the duration of TB 
treatment at the time of cART initiation (see Table 17, Appendix, which provides study-specific 
information on the timing of TB treatment, if available).  
Overall loss-to-follow-up was reported by 15 studies and ranged from 0% to 64% 
(median 10%, interquartile range 7% to 12%) (see Table 18, Appendix, which details methods 
utilized by studies to handle loss-to-follow-up and mortality). 5 studies limited their analysis to 
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those who completed follow-up [44, 74, 75, 83, 143] and 3 studies considered those who 
discontinued cART for a variety of reasons and/or lacked follow-up laboratory data as treatment 
failures [72, 79, 86]. While most studies did not describe how they handled patients who 
switched cART regimens, one excluded patients who stopped or changed cART during follow-
up [81], three explicitly retained patients who switched [14, 44, 87], and one did a sensitivity 
analysis considering those who discontinued stavudine as treatment failures [72]. 
All studies included both genders, with the proportion male ranging from 21% to 92% 
(median 45%).  All patients were ≥14 years of age; mean patient age ranged from 31 to 41 years 
(median 36). Median baseline CD4 count ranged from 29 to 196 cells/µL (median 94), and 
baseline HIV RNA ranged from 4.9 to 5.8 log10 copies/mL (median 5.3). One study reported 
results stratified by baseline CD4 count [85]. 
 
Virologic suppression 
There was heterogeneity in how each study quantified virologic response with respect to 
the reported effect measure, the cut-off used (50 or 400 copies/mL), and the timing of 
measurement (see Table 19, Appendix, for virologic measures as reported by each study). In 
total, 17 studies reported virologic suppression, either directly or as a measure that allowed 
conversion into virologic suppression. Times of reported virologic suppression ranged from 1 to 
48 months following cART initiation, with some studies reporting multiple time points. While 
most studies had overall suppression proportions >75%, several observed relatively low 
suppression. The study with the shortest follow-up time (1 month) reported the lowest overall 
proportion suppressed (46%) [71]. Manosuthi et al. (2006, 2008, 2010) also reported low 
suppression among Thai patients: 69% at 6 months [146], 59% at 33 months [86] and 51% at 48 
  66
months [72]. Three other studies reported suppression rates between 64 and 70% [74, 78, 79]. 
However, three of these studies that reported low suppression rates considered those who 
discontinued cART or lacked follow-up laboratory data as treatment failures [72, 79, 86]. 
In total, 15 studies reported RRs for virologic suppression in those receiving vs. not 
receiving TB treatment at cART initiation (Figure 5). Overall, the random-effects relative risk 
(RRRE) for suppression was 0.97 (95% CI 0.92-1.03). When estimates were categorized 
according to follow-up time, the RRRE for suppression was 1.06 (0.86-1.29) at 1-4 months, 0.91 
(0.83-1.00) at 6 months, 0.99 (0.94-1.05) at 11-12 months, and 0.99 (0.77-1.28) at 18-48 months 
after cART initiation (Table 4). In meta-regression analysis, a lower limit of detection of 50 or 
400 copies/mL and type of cART regimen did not substantially influence the summary relative 
risks (see Table 20, Appendix, for meta-regression results).  
Additionally, 6 studies provided data on cART regimen-specific relative risks of 
virologic suppression (see Figure 9, Appendix, for forest plot). The three lowest RRs for TB 
treatment exposure all correspond to three follow-up time-points of the nevirapine-based cART 
arm of Boulle et al. (2008) [81]. 
The funnel plot of overall suppression relative risks did not appear asymmetrical due to 
publication bias or other factors, with Begg’s and Egger’s p-values for small study effects of 
0.26 and 0.71, respectively (see Figure 10, Appendix, for the funnel plot).  
 
Virologic failure 
Measures of virologic failure were highly heterogeneous (Table 19, Appendix), with 
studies measuring whether patients reached HIV RNA levels of >5000 copies/mL [73], failed to 
suppress <400 copies/mL [81], rebounded after being previously undetectable or never became 
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undetectable [71, 82, 86], time to first value ≥400 [81], time to 2 consecutive values ≥5000 
copies/mL [81], and time to first value >500 among those who initially suppressed [142]. Six of 
these studies did not find TB treatment to have a significant effect on virologic failure [14, 71, 
73, 81, 82, 86]. Interestingly, Boulle et al. found an association between TB treatment and 
virologic failure among those on nevirapine-based cART, but not among patients on efavirenz-
based cART in their 2008 study [81], but reported the opposite finding in their 2010 study [14]. 
The substantial heterogeneity among virologic failure outcome measures precluded a formal 
meta-analysis. 
 
CD4 count response to cART 
Methods for measuring and reporting CD4 count response were even more heterogeneous 
than those used for virologic response, due to measurements at different time points and use of a 
diversity of outcome measures. Eight studies reported mean or median change in CD4 count 
from baseline, five measured mean or median absolute CD4 count during follow-up, and three 
reported the difference in CD4 count gain from baseline in patients receiving vs. not receiving 
TB treatment at cART initiation (Table 5). In addition, some studies defined a specific measure 
of immunologic success [79, 87] or immunologic failure [87, 147], and two studies described the 
CD4 count recovery trajectory [87, 148] (see Table 21, Appendix, for detailed immunologic 
measures). Two studies limited reporting of CD4 count response to virologically suppressed 
patients [14, 87]. 
Overall, those receiving TB treatment at cART initiation tended to have lower baseline 
CD4 counts, greater increases in CD4 count from baseline, and lower absolute CD4 counts 
during follow-up. Median change in CD4 count from baseline after 6 months of cART (reported 
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by 7 studies) ranged from 97 to 200 cells/µL (median 167) among TB treatment-exposed patients 
and from 89 to 177 cells/µL (median 138) among those not on TB treatment. At 11-12 months, 
median change in CD4 count from baseline (reported by 5 studies) ranged from 124 to 234 
cells/µL (median 155) among TB treatment-exposed patients and from 104 to 205 cells/µL 
(median 165) among those not on TB treatment. This corresponds to a differential gain in CD4 
count between patients receiving vs. not receiving TB treatment at cART initiation ranging from 
-10 to 60 more CD4 cells/µL (median 27) at 6 months and -10 to 29 more CD4 cells/µL (median 
6) at 11-12 months. Heterogeneity among CD4 count response outcomes measures prevented 
formal meta-analysis. 
 
Discussion 
In this systematic review and meta-analysis of the effect of TB treatment on virologic and 
CD4 count response to cART, the first meta-analysis of this topic to our knowledge, we found 
that exposure to TB treatment at cART initiation does not impair virologic suppression or CD4 
count gain. The effect on the risk of virologic failure could not be assessed. Our findings indicate 
that despite concerns about drug-drug interactions, toxicity, high pill burden, and IRIS, TB 
treatment does not appear to reduce the efficacy of cART in regards to virologic suppression and 
CD4 count response. The reported outcome measures were however highly heterogeneous, 
impeding sound between-study comparisons or meta-analytic summarization for outcome 
measures other than virologic suppression. While rigorous meta-analysis methods could not be 
applied for CD4 response, we did observe similar within-study effects of TB treatment, and the 
overall impression is that TB treatment exposure does not have a substantial impact on CD4 
recovery. 
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Furthermore, time points reported by individual studies were also heterogeneous. The 
optimal time point for evaluating the effect of exposure to TB treatment on response to cART is 
unclear.  Follow-up times shorter than 4 months may be too early to accurately describe response 
to cART, and follow-up times longer than two years may underestimate the impact of TB 
treatment at cART initiation, especially if patients who switch treatments or take second-line 
therapy are included in the analysis. For the sake of completeness, all reported outcome measures 
and follow-up times were retained in this review.  
The exposure, TB treatment at cART initiation, captured both exposure to active TB 
disease and exposure to anti-tuberculosis drugs. This combined exposure is useful from a health 
systems perspective, particularly in low-resource countries, where active TB cannot always be 
confirmed, especially in PLWH. This is further highlighted by the fact that the included studies 
used a variety of methods for determining who had active TB and should receive treatment, and 
no studies were limited to bacteriologically-confirmed TB cases and only one study described 
this subset. Consequently, active TB could have been misclassified and some patients included in 
this meta-analysis may have received TB treatment even though they did not have TB.  
Since being treated for active TB cannot be studied in a randomized controlled trial, all 
studies included in our review were observational. Consequently, there was much heterogeneity 
in the duration of TB treatment prior to cART initiation, with some patients on TB therapy for up 
to eight months and others beginning TB treatment and cART concurrently. While the timing of 
TB treatment in relation to cART initiation is an important factor when evaluating mortality [47-
50, 131], it is unclear whether TB treatment timing would influence virologic or CD4 count 
response. Unfortunately, the included studies did not provide enough information on duration of 
TB treatment to systematically evaluate its effect on our results. Similarly, a lack of provided 
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data on cART regimen switching during follow-up precluded a systematic evaluation of this 
factor. 
This systematic review and meta-analysis may have been subject to some biases. First, 
virologic and immunologic response cannot be evaluated in those who have died or were lost-to-
follow-up. Loss rates varied widely, ranging from 0% to 64% though most studies lost ≤12%, 
and studies handled loss-to-follow-up in a variety of ways, which may have influenced their 
results. Missing patients may systematically differ from those retained in the analysis. If 
response to cART among lost or deceased patients was differential by TB treatment status, than 
the results of these studies and our review could have been biased. Second, in 8 of 25 studies, TB 
treatment was not the primary exposure and covariates included in some multivariable models 
may differ from ideal confounder adjustment for this research question. Third, some bias may 
have been introduced by estimation methods used when a study did not directly report an 
outcome measure but provided the necessary data to calculate the desired effect measures [97, 
98].  
In conclusion, this recent comprehensive review of studies assessing the effect of TB 
treatment on response to cART indicates that TB treatment does not affect virologic suppression 
or CD4 count gain after cART initiation and we were unable to assess the effect on virologic 
failure. These findings will allow health care workers to be more confident in their clinical 
decision-making and in their communication to patients about the need to start cART during TB 
treatment. The heterogeneity in outcome measures posed a challenge to the interpretation and 
summarization of the virologic and CD4 count response to cART. Between-study comparisons 
could be greatly facilitated by methodological standardization of outcome measures and their 
time points in future studies. 
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Table 3. Characteristics of 25 studies reporting the effect of TB treatment on virologic and/or CD4 count response to cART among 
HIV-infected adults 
Publication 
year Study 
Geographic 
location 
Sample 
size 
TB 
treatment, 
N (%) 
Main 
exposure 
is TB 
Types of TB 
includeda 
Study 
design 
cART 
regimen
b
 
Naïve, 
% 
Male, 
% 
Mean 
age, 
years 
Median 
baseline 
CD4 
count,  
cells/µL 
Median 
baseline  
HIV 
RNA, 
log10 
copies/mL 
Lost to 
follow-
upc, % 
Outcomes 
reported 
2003 Hung Taiwan 276 46 (17) Yes Definitive, 
probable, or 
possible TB and 
on TB treatment 
at cART 
initiation 
P All 100 92 33 73 5.4 7 Both 
2004 Patel India 255 126 (49) Yes On TB treatment 
for definite or 
probable TB at 
cART initiation 
P EFV 100 73 37 101 NS 0 CD4 
2006 Breen England 164 82 (50) Yes On TB treatment 
at cART 
initiation. TB 
diagnosed by 
culture, nucleic 
acid 
amplification, 
radiography, 
histology or 
clinical 
algorithm. 
R All 100 52 35 77 5.1 0 Both 
2006 Manosuthi Thailand 140 70 (50) Yes Receiving 
rifampicin for 
active TB  ≥1 
month prior to 
cART enrollment 
P NVP 100 68 36 29 5.6 0 HIV RNA 
2008 Boulle (a)d South Africa 1935 209 (11) Yes Concurrent TB 
treatment at 
cART initiation 
and for ≥14 days 
post cART 
P NVP 100 21 31 110 5.0 6 Both 
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initiation. TB 
diagnosed by 
microscopy, 
culture or clinical 
algorithm. 
2008 Boulle (b)d South Africa 2035 1074 (53) Yes Concurrent TB 
treatment at 
cART initiation 
and for ≥14 days 
post cART 
initiation. TB 
diagnosed by 
microscopy, 
culture or clinical 
algorithm. 
P EFV 100 40 33 78 5.2 6 Both 
2008 Manosuthi Thailand 140 70 (50) Yes Receiving 
rifampicin for 
active TB  ≥1 
month prior to 
cART enrollment 
P NVP 100 68 36 29 5.6 10 Both 
2008 Mussini Italy, Spain, 
England, 
Canada 
624 168 (27) No TB as initial 
AIDS diagnosis 
prior to cART 
initiation 
P All 100 78 39 41 5.3 NS HIV RNA 
2008 Sumantri Indonesia 130 87 (67) Yes On TB treatment 
for pulmonary 
TB at cART 
initiation. TB 
was diagnosed 
via chest x-ray or 
microscopy. 
P All 100 80 32 156 NS NS Both 
2009 Shipton Botswana 310 155 (50) Yes On TB treatment 
at cART 
initiation 
R All 100 40 36 79 5.8 64 Both 
2010 Boulle South Africa 7323 2760 (38) No On TB treatment 
at cART 
initiation 
P All 100 32 33 101 5.1 10 Both 
2010 Manosuthi Thailand 140 70 (50) Yes Receiving 
rifampicin for 
active TB  ≥1 
P NVP 100 68 36 31 5.6 11 Both 
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month prior to 
cART enrollment 
2010 Tan Malaysia 42 15 (36) Yes On TB treatment 
at cART 
initiation 
P All 100 NS 41 30 5.0 NS Both 
2010 Wanchu 
(a)e 
India 104 52 (50) Yes Diagnosed with 
TB and started 
TB treatment 1 
month prior to 
cART initiation. 
TB diagnosed by 
microscopy, 
radiography, 
clinical criteria 
or histology. 
R All 100 69 35 155 NS NS CD4 
2010 Wanchu 
(b)e 
India 130 65 (50) Yes Diagnosed with 
TB and started 
TB treatment 1 
month prior to 
cART initiation. 
TB diagnosed by 
microscopy, 
radiography, 
clinical criteria 
or histology. 
R All 100 79 38 50 NS NS CD4 
2011 Almeida Mozambique 89 27 (30) No Confirmed or 
suspected TB at 
cART initiation 
P All 100 45 NS NS NS 31 HIV RNA 
2011 Auld Mozambique 2596 267 (10) No On TB treatment 
at cART 
initiation 
R All 100 38 34 153 NS 22 CD4 
2011 Dronda Spain 1986 110 (6) Yes Definite or 
presumptive 
diagnosis of TB 
in the 6 months 
prior to cART 
initiation 
P All 100 76 38 196 5.0 7 Both 
2011 Hermans Uganda 3797 570 (15) Yes On TB treatment 
at cART 
initiation 
R All 100 34 37 100 NS NS CD4 
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2011 Lartey Ghana 74 34 (46) Yes On TB treatment 
at cART 
initiation 
P EFV 100 49 NS 83 5.4 11 Both 
2012 Bassett South Africa 951 343 (36) Yes Newly diagnosed 
by sputum 
culture at cART 
enrollment or 
previously 
diagnosed and 
currently on 
treatment 
P All 100 41 36 90 NS 7 Both 
2012 Bastard Malawi, 
Kenya, 
Uganda, 
Cambodia 
1580 305 (9) No On TB treatment 
at cART 
initiation 
R All 97 36 36 119 NS NS HIV RNA 
2012 Hardwick 
(a)f 
Ethiopia 
 
649 365 (56) No On TB treatment 
at cART 
initiation 
P EFV 100 NS NS 94 5.4 NS CD4 
2012 Hardwick 
(b)f 
Tanzania 353 147 (42) No On TB treatment 
at cART 
initiation 
P EFV 100 NS NS 99 5.8 NS CD4 
2012 Julg South Africa 442 187 (42) No Concurrent TB 
co-infection at 
cART initiation 
R All 100 39 35 95 NS NS CD4 
2012 Mugusi Tanzania 473 220 (47) No Newly diagnosed 
at cART 
enrollment by 
smear 
microscopy, 
histology or 
clinical criteria 
P EFV 100 43 40 92 5.7 12 CD4 
2012 Odo Nigeria 5338 290 (5) Yes On TB treatment 
at cART 
initiation 
R All 100 38 36 159 NS NS CD4 
2013 Schomaker South Africa 15646 1052 (7) Yes On TB treatment 
for confirmed or 
probable TB at 
cART initiation 
P All 100 32 34 98 4.9 NS Both 
Abbreviations: EFV, Efavirenz-based cART; HIV, human immunodeficiency virus; NS, not specified; NVP, Nevirapine-based cART; 
P, prospective study; R, retrospective study; TB, tuberculosis. 
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a
 See Table 17 (Appendix) for further information on the timing of TB treatment in relation to cART initiation from each study, if 
available 
b
 See Table 16 (Appendix) for detailed information on cART regimens from each study, if available 
c
 See Table 18 (Appendix) for detailed information on methods used by each study to handle mortality and loss-to-follow-up, if 
available 
d
 (a) Nevirapine-based cART; (b) Efavirenz-based cART 
e
 (a) patients with baseline CD4 counts of 100-200 cells/µL; (b) patients with baseline CD4 counts <100 cells/µL  
f
 (a) a cohort from Ethiopia; (b) a cohort from Tanzania 
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Table 4. Meta-analysis results for the effect of TB treatment on virologic suppression after cART initiation, by length of follow-up 
time 
Length of follow-up time 1-4 months 6 months 11-12 months 18-48 months 1-48 months 
No. of estimates 3 8 7 5 13 
Homogeneity p-value 0.088 0.064 0.134 0.718 0.060 
Estimate of between-study 
variance (τ2) 
0.019 0.008 0.002 0.000 0.003 
RRRE (95% CI) 1.06 (0.86, 1.29) 0.91 (0.83, 1.00) 0.99 (0.94, 1.05) 0.99 (0.77, 1.28) 0.97 (0.92, 1.03) 
95% population effects interval (0.81, 1.38) (0.76, 1.09) (0.91, 1.08) Undefineda (0.87, 1.08) 
Opposite effects proportion 34.9% 14.9% 41.1% Undefineda 29.6% 
95% prediction interval (0.70, 1.58) (0.73, 1.14) (0.88, 1.12) (0.74, 1.33) (0.84, 1.12) 
Abbreviations: CI, confidence interval; RRRE, random-effects summary relative risk; TB, tuberculosis 
a
 Undefined because τ2 = 0.000 
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Table 5. Types of outcome measures used by 21 studies to quantify CD4 count response to 
cART 
Measure of CD4 count response 
Number of 
studies reporting 
this measure 
Length of  
follow-up used in 
reporting this measure 
(months) 
Immunologic success   
Change in CD4 count from baselinea 8 1; 3; 6; 9; 11; 12 
Absolute CD4 count at a specific follow-up timeb 5 3; 6; 9; 11; 48 
Difference in the increase in CD4 count from baselinec 3 6; 18; 22 
Increase of ≥50 cells/µL from baseline 1 6 
Increase of ≥100 cells/µL from baseline 1 12 
Absolute CD4 count >200 cells/µL 1 12 
Absolute CD4 count >500 cells/µL 1 30 
Rate of CD4 count increase from baseline (cells/month) 1 30 
Difference in CD4 count recovery slope (cells/6 months) 1 6; 48 
Median on treatment peak CD4 count 1 53 
Median change between baseline and on treatment peak 
CD4 count 
1 53 
Immunologic failure   
CD4 count decline from baseline, CD4 count <100 
cells/µL, or 50% decline from peak CD4 count after ≥6 
months of cART 
1 36 
Rate of immunologic failure 1 36 
Absolute CD4 count <500 cells/µL 1 30 
Abbreviations: cART, combination antiretroviral therapy 
a
 An additional 2 studies provided data that enabled the calculation of this measure. 
b
 An additional 3 studies provided data that enabled the calculation of this measure. 
c
 An additional 10 studies provided data that enabled the calculation of this measure. 
  
  
Figure 4. Identification and selection of eligible studies
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Figure 5. Relative risk of virologic suppression in those receiving vs. not receiving TB treatment at cART initiation by length of 
follow-up time, as reported by 15 studies 
Estimates were abstracted according to the precision and stratification used by the original authors. Estimates calculated using 
available data are reported to 2 decimal places. Abbreviations: cART, combination antiretroviral therapy; CI, confidence interval; 
EFV, efavirenz; NR, not reported; NVP, nevirapine; RR, relative risk. 
 
  80
CHAPTER VI 
THE EFFECT OF TUBERCULOSIS TREATMENT ON VIROLOGIC AND IMMUNOLOGIC 
RESPONSE TO COMBINATION ANTIRETROVIRAL THERAPY AMONG SOUTH 
AFRICAN CHILDREN
 
Introduction 
Though it is difficult to estimate the burden of tuberculosis disease (TB) in children, an 
estimated 500,000 TB cases and 64,000 TB deaths occurred in children <15 years in 2011 [1]. 
TB is common in children with HIV infection, especially in regions endemic for TB. In resource-
limited countries, the prevalence of HIV among children with active TB ranges from 10% to 
62% [4, 29]. In infants and young children, immune system immaturity results in a high risk of 
rapid disease progression of HIV [19, 20] and TB [54].  
In high-burden countries, many individuals begin combination antiretroviral therapy 
(cART) while simultaneously receiving TB treatment. In adults, receiving TB treatment at time 
of cART initiation does not appear to impair virologic or CD4 count response to cART [149], 
though it may be associated with an increased risk of long-term mortality [150]. 
 The 2010 World Health Organization (WHO) guidelines for infants and children 
recommended to start TB treatment immediately, then initiate cART as soon as TB therapy is 
tolerated, regardless of clinical stage and level of immunosuppression [9]. Little is known 
about the effect of receiving TB treatment at time of cART initiation on response to cART in 
infants and children [88]. Results of limited pediatric research to date suggest that starting 
cART during TB treatment improves survival [58-60], and that receiving TB treatment at 
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time of cART initiation does not increase mortality [89-91]. Few studies have assessed the 
effect of concomitant TB treatment on virologic or CD4 response to pediatric cART. Studies 
observed lower rates of virologic suppression in children receiving TB treatment, especially 
in those receiving protease inhibitor (PI)-based cART other than super-boosted 
lopinavir/ritonavir (LPV/r) [91-93], but similar CD4 reconstitution [90, 91, 93, 94] and 
proportion with severe immunodeficiency during cART [95] compared to children not 
receiving TB treatment. 
We aimed to evaluate the impact of receiving TB treatment at time of cART initiation on 
short- and long-term virologic and immunologic response to cART among a cohort of young 
children. 
 
Methods 
 
Study population 
We performed a secondary analysis of data from the TB HIV IRIS and Nutrition in Kids 
(THINK) study. cART-naive children aged 0 to 8 years presenting at the Harriet Shezi outpatient 
pediatric HIV clinic or the Paediatric Wards of Chris Hani Baragwanath Hospital in Soweto, 
South Africa, who were eligible for cART according to South African national treatment 
guidelines were offered participation in the THINK study. The study enrolled children between 
September 2009 and March 2012 and followed children for 24 months or until August 2013, 
when study follow-up ended. In order to be included in this secondary analysis, children had to 
initiate cART and have ≥1 HIV RNA and/or CD4 cell percentage (CD4%) following cART 
initiation. 
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TB and HIV diagnosis 
Children were diagnosed with TB [108] and HIV [26, 109] according to South African 
guidelines. TB diagnosis was made based on a combination of clinical signs, contact with an 
adult with active TB, positive tuberculin skin test, suggestive chest X-ray, or positive sputum 
smear microscopy or culture [108]. The National Health Laboratory Service processed all 
sputum samples. Starting in July 2011, a sputum sample was also evaluated by the Xpert 
MTB/RIF assay. HIV diagnosis was confirmed according to national guidelines. 
 
Clinical care 
 Children were treated according to national guidelines for TB and HIV [26, 108, 
110]. All children diagnosed with active TB were treated and generally received isoniazid, 
rifampicin, pyrazinamide, and ethambutol for two months followed by isoniazid and 
rifampicin for four months. 
Prior to April 2010 in South Africa, children were eligible for cART if they had recurrent 
or prolonged HIV-related hospitalizations, WHO stage II/III disease [111], CD4% <20% (if ≤18 
months), or CD4% <15% (if >18 months) [109]. Children ≤3 years or ≤10 kilograms initiated 
LPV/r-based cART (stavudine + lamivudine + LPV/r), children >3 years and >10 kilograms 
initiated efavirenz-based cART (stavudine + lamivudine + efavirenz). Initiation of cART was 
delayed for at least two months in children receiving TB treatment and they received ritonavir at 
a 1:1 dosage with lopinavir (super-boosted LVP/r).  
In April 2010, the national guidelines changed. All children ≤1 year were eligible for 
cART upon HIV diagnosis [26]. Children 1-5 years were eligible for cART if WHO stage III/IV, 
CD4% ≤25% or CD4 count <750 cells/µL. Children >5 years were eligible if WHO stage III/IV 
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or CD4 count <350 cells/µL. Children ≥3 years and ≥10 kilograms initiate efavirenz-based cART 
(abacavir/lamivudine/efavirenz), and LPV/r-based cART (abacavir/lamivudine/LPV/r) is used 
for children <3 years old or <10 kilograms. Initiation of cART was recommended to be delayed 
for 2-4 weeks after starting TB treatment, and children concurrently on TB treatment and LPV/r-
based cART received added ritonavir: super-boosted LVP/r for younger children, and a double 
LPV/r dose for older children [26]. The updated guidelines also recommended decentralization 
of pediatric cART initiation and follow-up care to primary care clinics.  
 
Patient follow-up 
The THINK study included a pre-cART visit, cART initiation visit, and visits every three 
months thereafter until 24 months post cART initiation. As part of routine care, caregivers of 
children who missed a scheduled visit were contacted 1-2 times via telephone to remind them of 
their missed appointment and encourage them to return. Efforts were made to encourage those 
who had transferred to a primary care facility to return for the final 24-month visit. Patients who 
did not complete the final 24-month visit were considered lost-to-follow-up, and were censored 
at the date of their last HIV RNA and/or CD4% measurement. Three patients were late for their 
24-month visit and had laboratory measurements taken at 25.2, 26.0 and 26.6 months following 
cART initiation; these values were still included in analyses. 
 
Study variables 
CD4% (LSRII flow cytometer, BD Biosciences) and HIV RNA (Ultrasensitive Amplicor 
HIV Monitor assay, Roche Diagnostic Systems, Basel, Switzerland, lower limit of detection 50 
copies/mL) were measured at or before cART initiation and at every three months (+/- one 
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month) during follow-up. Baseline values were those measured at cART initiation or the closest 
value within four months prior to initiation. Level of immunodeficiency and anemia were 
defined according to WHO age-specific classifications [111, 112]. Severe immunodeficiency 
was defined as: CD4% <25% in children <11 months, CD4% <20% in children 12-35 months, 
CD4% <15% in children 36-59 months, and CD4 cell count <200 cells/µL or CD4% <15% in 
children >5 years [111]. Weight-for-age z-scores were calculated using the WHO Anthro 
(version 3.2.2) SAS macro [113] for children <5 years old and the WHO AnthroPlus SAS macro 
[114] for children 5-8 years old. 
Virologic suppression was defined as the first documented HIV RNA <50 copies/mL 
following cART initiation, whether or not confirmed by a subsequent measurement. Virologic 
rebound was defined as any instance of HIV RNA >1000 copies/mL following a prior 
measurement <50. The primary measure of immunologic response was median increase in 
CD4% from baseline at 3, 6, 12 and 24 months following cART initiation.   
 
Statistical analysis 
Wilcoxon rank-sum tests were used to compare continuous demographic and clinical 
variables between groups, Pearson’s X2 test was used for categorical variables, and exact P 
values were calculated when appropriate.  
To examine virologic suppression, the median time to suppression was calculated. The 
distributions of event times in each exposure group were examined by plotting the Kaplan-Meier 
estimate of the survivor function; the log-rank test was used to compare the two curves. Crude 
and multivariable Cox proportional hazards regression were used to calculate hazard ratios (HRs) 
and associated 95% confidence intervals (CIs). Time origin was the date of cART initiation and 
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patients were censored at the earliest occurrence of death, loss to follow-up, or 24-month study 
visit. Covariates considered as effect measure modifiers and/or confounders included cART 
guidelines used (pre-2010 vs. 2010 guidelines), age (<2.1 vs. ≥2.1 years), sex, weight-for-age z-
score (<-3 vs. ≥-3), baseline HIV RNA (<5.5 vs. ≥5.5 log10 copies/mL), baseline CD4% 
(continuous), cART regimen (efavirenz-based vs. LPV/r-based), baseline hemoglobin 
(continuous). Similar methods were used to assess virologic rebound, limiting the analysis to 
patients who ever experienced virologic suppression. 
Median increases in CD4% were calculated, both overall and stratified by TB treatment 
status. Median CD4% and median CD4% gains were compared using Wilcoxon rank sum tests. 
Side-by-side box plots of CD4% at each visit in children receiving vs. not receiving TB 
treatment were created. The proportion of children with severe age-specific immunodeficiency 
[111] at each visit was also examined.  
In addition to the overall analysis, we performed exploratory sensitivity analyses 
stratified by (1) cART regimen and (2) timing of cART initiation relative to the 2010 change in 
guidelines. As new guidelines were implemented over several months, children who initiated 
cART from April to October 2010 were classified as initiating care according to the pre-2010 
guidelines if their initial regimen included stavudine or as initiating according to the 2010 
guidelines if their initial regimen contained abacavir. An additional sensitivity analysis examined 
an alternative virologic suppression cut point of HIV RNA <400 copies/mL. 
Study data were collected and managed using Research Electronic Data Capture 
(REDCap) [115] hosted at The University of North Carolina-Chapel Hill. All analyses were 
performed using SAS (version 9.3, SAS Institute, Cary, North Carolina, USA). 
 
  86
Ethics approval 
Children were enrolled following parental permission and child assent procedures (for 
children ≥7 years). Institutional Review Boards of University of North Carolina at Chapel Hill 
and University of Witwatersrand approved the study. 
 
Results 
 
Patient characteristics 
In total, 246 children enrolled in the THINK study and initiated cART. Of these, 199 
children had ≥1 follow-up HIV RNA and/or CD4%. Children included in analyses were fairly 
representative of all 246 children who initiated cART (Table 22), but had lower median HIV 
RNA and lower median CD4% at cART initiation and were more likely to start an LPV/r-based 
cART regimen. 
92 (46%) children were receiving TB treatment and 107 (54%) were not receiving TB 
treatment at cART initiation. Median age at cART initiation was 2.1 years (interquartile range 
[IQR] 0.9-4.6), and 52% were male (Table 6). At cART initiation, children exhibited a 
significant degree of wasting: median weight-for-age z-score was -1.52 (IQR -2.51 to -0.67); 
12% (n = 24) presented with severe undernutrition (z-score <-3). Median baseline hemoglobin 
was 10.0 g/dl (IQR 9.0-11.0). Anemia was common: 45 (25%) had mild anemia, 91 (50%) 
moderate anemia, and 4 (2%) severe anemia. Baseline median CD4% was 17.1 (IQR 11.6-23.3); 
108 (57%) of children had severe immunodeficiency at cART initiation. Baseline median HIV 
RNA was 5.6 log10 copies/mL (IQR 4.9-6.0). Sixty percent (n = 120) of children initiated an 
LPV/r-based first-line cART regimen; the remainder received efavirenz-based cART (40%, n = 
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79). Children on LPV/r-based cART were younger and more likely to have a weight-for-age z-
score <-3, lower baseline hemoglobin, higher baseline HIV RNA, higher baseline CD4%, and 
more severe age-specific immunodeficiency than children initiating efavirenz-based cART 
(Table 23). 
Median duration of TB treatment at time of cART initiation was 23 days (IQR 15-39, 
range 0-180). Most children received a clinical TB diagnosis. Children receiving TB treatment 
were more likely to be male (60% vs. 45%, P = 0.04), were slightly older, and had lower 
baseline hemoglobin (9.6 vs. 10.3 g/dL, P = 0.01), weight-for-age z-scores (-1.81 vs. -1.29, P = 
0.02), and median CD4% (15.3% vs. 18.8%, P <0.01) than children not on TB treatment. 
Baseline median HIV RNA levels among those receiving vs. not receiving TB treatment were 
similar (5.4 vs. 5.6 log10 copies/mL, P = 0.3). 
The majority of children (n = 132, 66%) initiated cART according to 2010 guidelines. 
Duration of follow-up ranged from 2.2 to 26.6 months (median 23.8 months, IQR 20.6-24.1), 
and did not differ by TB treatment status (P = 0.6). Sixty (30%) children did not complete the 
final 24-month follow-up visit and were censored at their date of last visit. Of these, 29 (48%) 
were receiving TB treatment at cART initiation. Only 1 child died during follow-up. Over 24 
months of follow-up, 24 (12%) children switched cART regimens. 7 switched from an efavirenz-
based regimen to a LPV/r-based regimen, 1 switched from LPV/r-based to efavirenz-based 
cART, 12 switched within LPV/r-based cART, and 4 switched within efavirenz-based regimens. 
Receiving TB treatment was not associated with regimen switching (15% vs. 9%, P = 0.2). 
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Virologic suppression 
Time to first documented virologic suppression ranged from 0.5 to 25.2 months overall, 
with a median of 6.2 months among both children receiving vs. not receiving TB treatment 
(Table 7). By 12 months post cART initiation, 121 (61%) of children experienced virologic 
suppression and had not yet experienced viral rebound >1000 copies/mL. This proportion was 
similar among children receiving vs. not receiving TB treatment (60% vs. 62%). Kaplan-Meier 
curves in the two groups are consistently overlapping (logrank P = 0.7, Figure 6a). TB treatment 
did not significantly affect the hazard of virologic suppression.  Using a alternative suppression 
cut point of <400 copies/mL instead of <50 copies/mL resulted in decreased time to suppression 
and decreased time to rebound, but does not change the proportion that rebound or any of the 
HRs of interest (Table 24, Table 25, Table 26). 
 
Virologic rebound 
Overall, 164 (82%) patients were eligible for inclusion in virologic rebound analyses as 
they had experienced virologic suppression (Table 7). Similar proportions of patients receiving 
vs. not receiving TB treatment experienced virologic rebound (23% vs. 24%, P = 0.9), with 
substantial overlap between the Kaplan-Meier curves (logrank P = 0.8, Figure 6b). Overall, time 
to virologic rebound ranged from 6.8 to 26.0 months from cART initiation. TB treatment did not 
affect time to virologic rebound (18.3 months vs. 17.8 months, P = 0.9) or hazard of virologic 
rebound over 24 months following cART initiation (aHR 1.53, 95% CI 0.71, 3.30). 
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CD4% response 
Children on TB treatment had lower CD4% in the first 12 months after cART initiation, 
after which they caught up to children who were not on TB treatment at cART initiation (Figure 
7a). Those receiving TB treatment had a similar median increase in CD4% at 3 months (7.2% vs. 
6.5%), 6 months (9.9% vs. 9.6%), 12 months (14.2% vs. 11.9%) and 24 months (14.5% vs. 
14.2%) to children not receiving TB treatment at cART initiation (all P ≥0.06) (Table 7). A 
higher proportion of children on TB treatment had severe age-specific immunodeficiency, with 
statistically significant differences at baseline, 6 months, and 24 months (Figure 7b). 
 
Outcomes stratified by efavirenz- versus LPV/r-based cART 
In an exploratory stratified sensitivity analysis, cART regimen had a greater effect on the 
virologic suppression than TB treatment: those on efavirenz-based regimens experienced shorter 
median time to virologic suppression (5.5 months vs. 7.7 months, P <0.01) as compared to 
children on LPV/R-based cART regimens (Table 8, Figure 11). Children on efavirenz-based 
cART also had a higher crude hazard of suppression over 24 months (HR 95% CI 1.78 1.30, 
2.43), though adjustment moved this effect toward the null (aHR 1.26, 95% CI 0.63, 2.51). 
cART regimen did not appear to influence virologic rebound or CD4% reconstitution.  
Among children on LPV/r-based regimens, children on TB treatment tended to have 
increased virologic rebound (29% vs. 20%, P = 0.3) and hazard of rebound (aHR 2.34, 95% CI 
0.80, 6.83), but these differences were not statistically significant. They also had lower CD4% at 
3 (23.5% vs. 29.1%, P = 0.02), 6 (23.7% vs. 32.7%, P <0.01), and 12 months (24.7% vs. 31.7%, 
P = 0.03), and higher proportions with severe immunodeficiency at 6 (58% vs. 15%, P <0.01), 
12 (37% vs. 15%, P = 0.05), and 24 months (23% vs. 0%, P = 0.02) compared to children not 
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receiving TB treatment. Among children on efavirenz-based cART, no significant effect of TB 
treatment was observed. 
 
Outcomes according to timing of cART initiation relative to change in guidelines 
The national cART guidelines underwent substantial changes on April 1, 2010, and 
implementation occurred over the next few months. Those children initiating according to pre-
2010 guidelines had a shorter median time to suppression (5.7 vs. 6.5 months, P = 0.01) and 
increased suppression over time (aHR 1.94, 95% CI 1.35, 2.80 than those initiating cART 
according to 2010 guidelines (Table 9). They also consistently experienced lower CD4% 
increases and higher proportions of severe immunodeficiency, though the differences were not 
statistically significant. 
 
Discussion 
This study showed that, despite having more advanced disease at baseline, children 
receiving TB treatment at cART initiation did not have a substantially different response to 
cART. Overall, children receiving TB treatment experienced similar rates of virologic 
suppression, virologic rebound, and CD4% increase. However, children initiating cART while 
on TB treatment remained more vulnerable as they continued to have lower CD4% and a higher 
prevalence of severe immunodeficiency throughout the first 2 years of cART. Similar to 
observed responses in adults, efavirenz-based cART was superior to LPV/r-based cART [151]. 
Furthermore, while underpowered, our exploratory sensitivity analysis indicates that we cannot 
rule out the possibility that the combination of TB treatment and LPV/r-based cART may 
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increase the risk of rebound and diminish CD4% reconstitution in younger children, a finding 
which fits with observations in prior studies [91, 93]. 
These findings add to the limited literature regarding the effect of TB treatment on 
response to cART in infants and children, though it is difficult to directly compare results due to 
varying age ranges and cART regimens between studies. Virologic suppression allows immune 
reconstitution and is a key measure of successful cART [4]. In our cohort, we did not observe an 
effect of TB treatment on suppression. However, children on efavirenz-based cART experienced 
more and quicker virologic suppression than those on LPV/r-based regimens. Among children 
<3 years, Zanoni et al. similarly found that children on super-boosted or double-dosed PI-based 
cART and concomitant TB treatment experienced decreased virologic suppression compared to 
children not receiving TB treatment [92]. Frohoff et al. also observed that TB treatment 
decreased suppression among young children (aged 6-24 months) on double-dose LPV/r and 
ritonavir-based cART [91]. Similarly, Reitz et al. found decreased suppression by 39 weeks 
among children <2 years on ritonavir or unboosted LPV/r-based cART being co-treated for TB 
[93]. 
Virologic rebound may indicate an unsuccessful cART regimen, inadequate adherence, or 
the emergence of drug-resistant virus, and is an especially important indicator in children due to 
limited treatment options [4]. We did not find TB treatment to have an effect on virologic 
rebound overall, though there was a clinically meaningful rebound increase among children <3 
on LPV/r-based cART. Another South African study found a lower incidence of virologic 
rebound among children on PI-based cART and TB treatment within 16 weeks after suppression 
(2.8% vs. 12%) [93], while we found no significant difference at this time point (4.8% vs. 2.0%, 
P = 0.6). 
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Immune reconstitution is crucial, as a longer time spent at low CD4% is associated with 
increased risk of morbidity and mortality [4]. We found children receiving TB treatment to have 
lower CD4% in the short-term, but no impairment of median increase in CD4%. This finding is 
in accordance with previous studies [90, 91, 93, 94], and extends this observation from 39 weeks 
[93] and a year [91, 94] to 24 months of cART.  
This study possessed a number of important strengths. First, the THINK study was 
conducted prospectively, enabling us to firmly establish the timing between TB treatment and 
cART initiation and to obtain regular HIV RNA and CD4% measurements during follow-up. 
Second, this study had two years of follow-up, allowing us to distinguish between potential 
short- and long-term effects of TB treatment and to measure longer-term outcomes. Third, the 
occurrence of only one death allowed us to study response to cART without survival bias. 
Fourth, the median age of 2.1 years allowed us to report on treatment outcomes in very young 
children, a group which tends to be underrepresented in cART programs and research studies, 
and is becoming larger with increasing access to early infant diagnosis [95]. 
This study was however not without limitations. First, the THINK study was 
observational, resulting in loss-to-follow-up and missing data, which prevented us from reliably 
estimating certain outcomes, such as sustained virologic suppression. Second, confirming TB 
diagnosis in children is inherently difficult. Similar to other pediatric studies, most TB diagnoses 
in our cohort were presumptive, resulting in potential misclassification of active TB. As we 
focused on the effect of TB treatment on response to cART, misclassification is less of a concern 
and the results are applicable to any children on TB treatment at cART initiation. Third, our 
modest sample size limited our ability to find significant effects, particularly upon stratification. 
Fourth, while the duration of TB treatment prior to cART initiation may affect response to 
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cART, we could not assess this factor due to limited variability in this population. Fifth, this 
study required adaptations to changing guidelines over time, which complicates straightforward 
interpretation of results. A sensitivity analysis of the changing guidelines helped us disentangle 
specific results. Sixth, TB/HIV co-treatment in children has a number of obstacles including 
limited pediatric drug formulations, lack of dosing information, and adherence concerns. The use 
of syrups in young children also complicates measurement of adherence. While adherence may 
be differential in the two groups, it was not measured by this study and may have biased our 
results. Seventh, a single elevated measurement of HIV RNA >1000 copies/mL may be a blip 
and not indicative of true virologic rebound. Rebound could only be confirmed by a second 
measurement in six children, three of which were on TB treatment at cART initiation. Finally, as 
cART regimen was prescribed according to age and weight, it was difficult to separate the 
individual effects of these exposures. 
In conclusion, despite a multitude of challenges posed by concomitant TB and HIV 
treatment in young children [30, 152], our findings indicate that children ≥3 years on efavirenz-
based cART and TB treatment do not experience an inferior cART response. This is similar to 
the situation in adults [149] and reinforces WHO recommendations to initiate cART soon after 
TB treatment is tolerated [9]. As guidelines and treatment options continue to change, further 
research is needed to determine optimal HIV/TB co-treatment regimens for young children. 
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Table 6. Baseline characteristics of 199 children who initiated cART and had at least one follow-
up HIV and/or CD4 cell percentage, stratified by TB treatment status 
Characteristic All patients 
Children receiving  
TB treatment 
Children not 
receiving TB 
treatment Pa 
No. of patients (%) 199 (100) 92 (46.2) 107 (53.8)  
Median age, years (IQR) 2.1 (0.9 – 4.6) 2.2 (1.4 – 4.5) 1.9 (0.5 – 4.7) 0.07 
   <1 54 (27.1) 16 (17.4) 33 (35.5) 0.03 
   1-2 64 (32.2) 37 (40.2) 27 (25.2)  
   3-4 36 (18.1) 19 (20.7) 17 (15.9)  
   5-6 31 (15.6) 14 (15.2) 17 (15.9)  
   7-8 14 (7.0) 6 (6.5) 8 (7.5)  
Male sex, no. (%) 103 (51.8) 55 (59.8) 48 (44.9) 0.04 
Weight-for-age z-score, 
median (IQR) 
-1.52 (-2.51 – -0.67) -1.81 (-2.63 – -0.97) -1.29 (-2.35 – -0.48) 0.02 
   <-2, underweight for age 72 (36.2) 40 (43.5) 32 (29.9) 0.05 
   <-3, very low weight for age 24 (12.1) 13 (14.1) 11 (10.3) 0.41 
Median hemoglobin, g/dl 
(IQR)b 
10.0 (9.0 – 11.0) 9.6 (8.9 – 10.6) 10.3 (9.4 – 11.1) 0.01 
   Mild anemia, no. (%)c 45 (24.9) 17 (19.8) 28 (29.5) 0.24 
   Moderate anemia, no. (%)d 91 (50.3) 50 (58.1) 41 (43.2)  
   Severe anemia, no. (%)e 4 (2.2) 2 (2.3) 2 (2.1)  
Median HIV RNA, log10 
copies/mL (IQR)f 
5.6 (4.9 – 6.0) 5.4 (4.8 – 5.9) 5.6 (5.0 – 6.1) 0.33 
Median CD4 count, cells/µL 
(IQR)g 
665 (340 – 1069) 591 (300 – 914) 769 (407 – 1442) <0.01 
Median CD4 cell percentage 
(IQR)g 
17.1 (11.6 – 23.3) 15.3 (9.5 – 21.0) 18.8 (14.3 – 25.3) <0.01 
WHO age-specific severity of 
immunodeficiency, no. (%) 
       
   Not significant 28 (14.7) 10 (11.1) 18 (17.8) 0.14 
   Mild 22 (11.5) 7 (7.8) 15 (14.9)  
   Advanced 33 (17.3) 15 (16.7) 18 (17.8)  
   Severe 108 (56.5) 58 (64.4) 50 (49.5)  
First-line cART regimen, no. 
(%)h 
       
   Efavirenz-basedi 79 (39.7) 39 (42.4) 40 (37.4) 0.47 
   LPV/r-basedj 120 (60.3) 53 (57.6) 67 (62.6)  
Timing of cART initiation, no. 
(%) 
       
   According to pre-2010 
guidelines 
67 (33.7) 34 (37.0) 33 (30.8) 0.36 
   According to 2010 
guidelines 
132 (66.3) 58 (63.0) 74 (69.2)  
Median follow-up time, 
months (IQR) 
23.8 (20.6 – 24.1) 23.8 (20.2 – 24.1) 23.8 (20.7 – 24.2) 0.61 
Median duration of TB 
treatment at cART initiation, 
days (IQR) 
  23 (15 – 39)    
Abbreviations: cART, combination antiretroviral therapy; IQR, interquartile range; LPV/r, 
lopinavir/ritonavir; TB, tuberculosis; WHO, World Health Organization. 
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a
 Wilcoxon rank-sum testing was used to compare continuous variables; Pearson’s X2 test was 
used for categorical variables. Statistical significance defined as P <0.05 for all tests. 
b Baseline hemoglobin values were not available for 18 patients. 
c Mild anemia was defined as hemoglobin 10.0-10.9 g/dl in children <5 years or 11.0-11.4 g/dl in 
children ≥5 years. 
d Moderate anemia was defined as hemoglobin 7.0-9.9 g/dl in children <5 years or 8.0-10.9 g/dl 
in children ≥5 years. 
e Severe anemia was defined as hemoglobin <7.0 g/dl in children <5 years or <8.0 g/dl in 
children ≥5 years. 
f
 Baseline HIV RNA values were not available for 22 patients. 
g Baseline CD4 cell percentages and CD4 counts were not available for 8 patients. 
h cART regimen was not available for 1 patient. 
i Efavirenz-based cART was generally used for children ≥3 years and ≥10 kilograms. 
k Protease inhibitor-based cART was generally used for children <3 years or <10 kilograms. 
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Table 7. Virologic and immunologic response outcomes, stratified by TB treatment status 
Outcome All patients 
Children receiving  
TB treatment 
Children not 
receiving TB 
treatment P 
Virologic suppression        
Time to suppression, median 
months (IQR) 
6.2 (3.9 – 11.5) 6.2 (4.6 – 11.7) 6.2 (3.5 – 10.7) 0.50 
HR (95% CI)        
   6 months (crude)   1.09 (0.67, 1.77) 1.0  0.73 
   6 months (adjusted)a   1.20 (0.69, 2.08) 1.0  0.53 
   12 months (crude)   1.04 (0.72, 1.49) 1.0  0.85 
   12 months (adjusted)a   1.23 (0.82, 1.84) 1.0  0.32 
   24 months (crude)   0.94 (0.69, 1.28) 1.0  0.68 
   24 months (adjusted)a   1.36 (0.94, 1.96) 1.0  0.10 
        
Virologic reboundb        
HIV RNA >1000 copies/mL, 
no. (%) 
39/164 (23.8) 18/77 (23.4) 21/87 (24.1) 0.91 
Time to rebound, median 
months (IQR) 
18.3 (12.2 – 23.5) 18.3 (15.0 – 21.0) 17.8 (12.0 – 23.7) 0.89 
Crude HR (95% CI)c   1.10 (0.58, 2.08) 1.0  0.77 
Adjusted HR (95% CI)a,c   1.53 (0.71, 3.30) 1.0  0.27 
 
       
Immunologic response        
CD4%, median (IQR)        
   cART initiation 17.1 (11.6 – 23.3) 15.3 (9.5 – 21.0) 18.8 (14.3 – 25.3) <0.01 
   3 months 25.5 (19.1 – 32.3) 22.6 (16.7 – 29.1) 26.5 (20.0 – 33.7) 0.03 
   6 months 27.8 (20.6 – 34.2) 24.8 (18.6 – 30.9) 30.1 (24.8 – 36.9) <0.01 
   12 months 29.5 (23.6 – 34.7) 27.3 (21.4 – 33.2) 30.9 (25.0 – 36.2) 0.04 
   24 months 33.6 (26.2 – 37.5) 31.3 (21.9 – 36.7) 34.5 (27.0 – 38.2) 0.09 
Increase in CD4%, median 
(IQR) 
       
   3 months 7.2 (3.3 – 11.4) 7.2 (3.6 – 11.0) 6.5 (3.3 – 11.9) 0.90 
   6 months 9.7 (5.4 – 14.1) 9.9 (5.2 – 14.4) 9.6 (5.6 – 14.0) 0.85 
   12 months 13.3 (7.9 – 17.5) 14.2 (9.2 – 18.7) 11.9 (7.0 -16.3) 0.06 
   24 months 14.4 (9.1 – 19.7) 14.5 (9.6 – 19.2) 14.2 (8.0 – 20.0) 0.87 
Severe immunodeficiency, no. 
(%)d 
       
   3 months 57/115 (49.6) 31/54 (57.4) 26/61 (42.6) 0.11 
   6 months 58/151 (38.4) 38/73 (52.1) 20/78 (25.6) <0.01 
   12 months 27/116 (23.3) 15/48 (31.3) 12/68 (17.6) 0.09 
   24 months 7/101 (6.9) 7/48 (14.6) 0/53 (0.0) <0.01 
Abbreviations: cART, combination antiretroviral therapy; CD4%, CD4 cell percentage; CI, 
confidence interval; HR, hazard ratio; IQR, interquartile range; TB, tuberculosis. 
a
 Multivariable models adjusted for timing of cART initiation relative to the 2010 change in 
guidelines, age at cART initiation, sex, cART regimen, and baseline HIV RNA, CD4 cell 
percentage, hemoglobin, and weight-for-age z-score. Adjusted models include individuals who 
had complete covariate data: n=164 for the suppression model and n=139 for the rebound model. 
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b
 Virologic rebound was assessed among the 164 individuals who suppressed <50 copies/mL at 
any point following cART initiation. 
c
 Hazard ratios account for 24 months of follow-up after cART initiation. 
d
 Severe immunodeficiency was defined according to World Health Organization age-specific 
classifications [111]: CD4% <25% in children <11 months, CD4% <20% in children 12-35 
months, CD4% <15% in children 36-59 months, and CD4 cell count <200 cells/µL or CD4% 
<15% in children >5 years. 
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Table 8. The effect of TB treatment on virologic and immunologic response outcomes, stratified by cART regimen 
Outcome Efavirenz-based 
cART (n=79) 
LPV/r-based 
cART (n=120) 
Efavirenz-based cART (n=70) LPV/r-based cART (n=120) 
Children 
receiving  
TB treatment 
(n=39) 
Children not 
receiving TB 
treatment (n=40) 
Children receiving  
TB treatment 
(n=52) 
Children not 
receiving TB 
treatment (n=69) 
Virologic suppression             
Time to suppression, median 
months (IQR) 
5.5 (3.1 – 7.6)a 7.7 (5.7 – 13.4) 5.3 (3.3 – 7.6) 5.8 (3.1 – 6.9) 9.5 (5.8 – 16.7) 6.8 (5.2 – 12.4) 
Crude HR (95% CI)c 1.78 (1.30, 2.43)a 1.0  1.06 (0.66, 1.69) 1.0  0.83 (0.55, 1.26) 1.0  
Adjusted HR (95% CI)c 1.26 (0.63, 2.51)d 1.0  1.66 (0.88, 3.16)e,f 1.0  1.04 (0.64, 1.69)e,g 1.0  
 
            
Virologic reboundh             
HIV RNA >1000 copies/mL, 
no. (%) 
17/71 (23.9) 22/93 (23.7) 6/35 (17.1) 11/36 (30.6) 12/42 (28.6) 10/51 (19.6) 
Time to rebound, median 
months (IQR) 
18.4 (15.1 – 23.7) 17.8 (12.0 – 21.3) 19.2 (17.4 – 21.0) 18.4 (14.5 – 23.8) 18.0 (13.6 – 21.1) 15.1 (11.7 – 23.5) 
Crude HR (95% CI)c 1.11 (0.59, 2.11) 1.0  0.65 (0.24, 1.76) 1.0  1.66 (0.70, 4.00) 1.0  
Adjusted HR (95% CI)c 0.62 (0.15, 2.52)d 1.0  1.03 (0.26, 4.12)e,f 1.0  2.34 (0.80, 6.83)e,g 1.0  
 
            
Immunologic response             
CD4%, median (IQR)             
   cART initiation 15.8 (9.6 – 20.7)a 18.5 (13.0 – 25.1) 15.5 (7.5 – 20.6) 16.6 (12.4 – 21.7) 15.2 (10.2 – 21.1)b 22.0 (16.0 – 27.4) 
   3 months 21.6 (15.3 – 32.2) 26.1 (20.2 – 32.4) 21.6 (14.0 – 30.3) 22.0 (15.8 – 33.4) 23.5 (18.8 – 29.1)b 29.1 (22.2 – 35.6) 
   6 months 26.2 (20.4 – 32.2) 28.5 (22.0 – 34.9) 26.2 (19.7 – 31.3) 26.1 (20.9 – 34.6) 23.7 (14.5 – 30.9)b 32.7 (26.7 – 36.9) 
   12 months 28.6 (23.7 – 33.1) 30.6 (23.6 – 37.1) 28.0 (23.7 – 32.0) 29.4 (23.6 – 33.1) 24.7 (21.4 – 33.6)b 31.7 (28.0 – 39.5) 
   24 months 34.0 (26.1 – 38.4) 32.7 (26.2 – 37.3) 32.8 (25.0 – 36.5) 35.6 (26.4 – 41.3) 30.8 (20.4 – 38.1) 33.6 (27.8 – 36.8) 
Increase in CD4%, median 
(IQR) 
            
   3 months 6.5 (4.7 – 10.3) 7.4 (2.5 – 12.4) 6.9 (3.6 – 10.5) 6.4 (4.9 – 9.8) 7.7 (3.1 – 11.3) 7.3 (2.5 – 13.7) 
   6 months 10.9 (6.9 – 14.8) 9.7 (5.1 – 14.0) 11.6 (6.7 – 15.3) 9.3 (7.2 – 13.5) 9.7 (4.7 – 12.2) 10.0 (5.3 – 14.2) 
   12 months 14.5 (9.7 – 18.3) 12.2 (6.8 – 16.3) 16.7 (10.8 – 19.1) 13.3 (9.1 – 16.7) 13.6 (7.6 – 18.2) 10.7 (4.7 – 16.2) 
   24 months 15.6 (12.2 – 20.7) 13.2 (5.2 – 19.1) 15.5 (12.3 – 19.3) 15.6 (8.6 – 20.8) 12.9 (7.0 – 19.1) 13.2 (3.2 – 18.7) 
Severe immunodeficiency, no. 
(%)i 
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   3 months 26/43 (60.5) 31/72 (43.1) 13/21 (61.9) 13/22 (59.1) 18/33 (54.5) 13/39 (33.3) 
   6 months 28/65 (43.1) 30/86 (34.9) 15/33 (45.5) 13/32 (40.6) 23/40 (57.5)b 7/46 (15.2) 
   12 months 11/49 (22.4) 16/67 (23.9) 5/21 (23.8) 6/28 (21.4) 10/27 (37.0)b 6/40 (15.0) 
   24 months 1/50 (2.0) 6/51 (11.8) 1/22 (4.5) 0/28 (0.0) 6/26 (23.1)b 0/25 (0.0) 
Abbreviations: cART, combination antiretroviral therapy; CD4%, CD4 cell percentage; CI, confidence interval; HR, hazard ratio; 
IQR, interquartile range; LPV/r, lopinavir/ritonavir; TB, tuberculosis. 
a
 The efavirenz-based vs. LPV/r-based cART comparison was statistically significant (P <0.05). 
b
 The TB treatment vs. no TB treatment comparison was statistically significant (P <0.05). 
c
 Hazard ratios account for 24 months of follow-up after cART initiation. 
d
 Multivariable models included TB treatment at cART initiation, timing of cART initiation relative to the 2010 change in guidelines, 
age at cART initiation, sex, cART regimen, and baseline HIV RNA, CD4 cell percentage, hemoglobin, and weight-for-age z-score. 
Adjusted models include individuals who had complete covariate data: n=164 for the suppression model and n=139 for the rebound 
model. 
e Multivariable models included TB treatment at cART initiation, timing of cART initiation relative to the 2010 change in guidelines, 
age at cART initiation, sex, and baseline HIV RNA, CD4 cell percentage, hemoglobin, and weight-for-age z-score. 
f Adjusted models include individuals who had complete covariate data: n=61 for the suppression model and n=56 for the rebound 
model. 
g Adjusted models include individuals who had complete covariate data: n=103 for the suppression model and n=83 for the rebound 
model. 
h Virologic rebound was assessed among the 165 individuals who suppressed <50 copies/mL at any point following cART initiation. 
i
 Severe immunodeficiency was defined according to World Health Organization age-specific classifications [111]: CD4% <25% in 
children <11 months, CD4% <20% in children 12-35 months, CD4% <15% in children 36-59 months, and CD4 cell count <200 
cells/µL or CD4% <15% in children >5 years.
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Table 9. The effect of TB treatment on virologic and immunologic response outcomes, stratified by timing of cART initiation 
Outcome 
According to 
pre-2010 
guidelines 
(n=67) 
According to the 
2010 guidelines 
(n=132) 
According to pre-2010 guidelines 
(n=67) According to the 2010 guidelines (n=132) 
Children 
receiving  
TB treatment 
(n=34) 
Children not 
receiving TB 
treatment (n=33) 
Children receiving  
TB treatment 
(n=57) 
Children not 
receiving TB 
treatment (n=74) 
Virologic suppression             
Time to suppression, 
median months (IQR) 
5.7 (3.1 – 9.1)a 6.5 (5.3 – 11.9) 5.6 (3.3 – 9.3) 6.0 (3.0 – 9.0) 7.6 (5.5 – 12.3) 6.4 (5.0 – 11.8) 
Crude HR (95% CI)c 1.59 (1.16, 2.20)a 1.0  0.87 (0.52, 1.45) 1.0  0.92 (0.62, 1.36) 1.0  
Adjusted HR (95% CI)c 1.94 (1.35, 2.80)a,d 1.0  1.04 (0.59, 1.85)e,f 1.0  1.45 (0.90, 2.35)e,g 1.0  
 
            
Virologic rebounde             
HIV RNA >1000 
copies/mL, no. (%) 
18/59 (30.5) 21/105 (20.0) 12/30 (40.0) 6/29 (20.7) 6/47 (12.8) 15/58 (25.9) 
Time to rebound, median 
months (IQR) 
18.3 (15.0 – 21.3) 17.8 (11.7 – 23.5) 17.8 (13.6 – 21.0) 21.0 (17.8 – 24.8) 19.2 (17.7 – 23.7) 15.1 (11.6 – 23.5) 
Crude HR (95% CI)c 0.93 (0.49, 1.79) 1.0  3.29 (1.15, 9.41)b 1.0  0.41 (0.16, 1.05) 1.0  
Adjusted HR (95% CI)c,d 1.10 (0.53, 2.32)d 1.0  3.00 (0.94, 9.60)e,f 1.0  0.71 (0.21, 2.40)e,g 1.0  
 
            
Immunologic response             
CD4%, median (IQR)             
   cART initiation 18.4 (11.4 – 23.0) 16.7 (11.8 – 23.3) 16.2 (9.6 – 21.1) 19.5 (15.0 – 26.5) 14.2 (9.5 – 20.6)b 18.5 (14.2 – 25.2) 
   3 months 23.4 (15.2 – 30.7) 25.9 (19.8 – 33.4) 19.5 (14.1 – 25.8)b 26.6 (21.5 – 32.9) 25.5 (19.3 – 30.3) 26.1 (19.9 – 34.7) 
   6 months 27.4 (18.4 – 35.8) 28.2 (22.8 – 34.1) 22.6 (14.0 – 33.1) 28.0 (24.6 – 36.8) 25.0 (19.4 – 30.9)b 30.4 (25.6 – 36.9) 
   12 months 28.0 (21.3 – 36.8) 30.1 (25.3 – 34.1) 22.8 (18.6 – 37.9) 29.3 (23.5 – 34.9) 27.8 (24.0 – 32.4) 31.6 (26.5 – 36.6) 
   24 months 34.0 (26.2 – 37.3) 32.9 (26.3 – 38.1) 33.2 (20.8 – 36.4) 35.0 (28.8 – 37.3) 31.0 (25.7 – 37.1) 33.9 (26.5 – 38.3) 
Increase in CD4%, median 
(IQR) 
            
   3 months 5.1 (2.3 – 8.8)a 8.4 (5.6 – 12.8) 6.2 (2.3 – 9.2) 5.0 (2.5 – 7.9) 8.5 (5.9 – 12.7) 8.4 (4.6 – 14.5) 
   6 months 9.3 (5.5 – 13.7) 10.5 (5.2 – 14.1) 8.3 (3.6 – 15.2) 9.3 (6.2 – 13.5) 10.8 (6.6 – 14.0) 10.4 (5.1 – 14.4) 
   12 months 10.8 (6.5 – 15.8) 13.8 (8.5 – 18.2) 10.8 (6.1 – 17.6) 11.2 (6.5 – 15.7) 15.5 (11.6 – 18.7) 12.8 (7.2 – 16.8) 
   24 months 13.2 (8.7 – 17.1) 15.8 (10.1 – 21.3) 12.6 (9.0 – 16.0) 13.6 (8.0 – 18.3) 16.8 (10.7 – 24.2) 15.2 (8.1 – 20.7) 
Severe immunodeficiency, 
no. (%)i 
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   3 months 24/42 (57.1) 33/73 (45.2) 15/21 (71.4) 9/21 (42.9) 16/33 (48.5) 17/40 (42.5) 
   6 months 22/51 (43.1) 36/100 (36.0) 14/26 (53.8) 8/25 (32.0) 24/47 (51.1)b 12/53 (22.6) 
   12 months 11/39 (28.2) 16/77 (20.8) 6/16 (37.5) 5/23 (21.7) 9/32 (28.1) 7/45 (15.6) 
   24 months 4/45 (8.9) 3/56 (5.4) 4/24 (16.7) 0/21 (0.0) 3/24 (12.5) 0/32 (0.0) 
Abbreviations: cART, combination antiretroviral therapy; CD4%, CD4 cell percentage; CI, confidence interval; HR, hazard ratio; 
IQR, interquartile range; TB, tuberculosis. 
a
 The old guidelines vs. new guidelines comparison was statistically significant (P <0.05). 
b
 The TB treatment vs. no TB treatment comparison was statistically significant (P <0.05). 
c
 Hazard ratios account for 24 months of follow-up after cART initiation. 
d
 Multivariable models included TB treatment at cART initiation, timing of cART initiation relative to the 2010 change in guidelines, 
age at cART initiation, sex, cART regimen, and baseline HIV RNA, CD4 cell percentage, hemoglobin, and weight-for-age z-score. 
Adjusted models include individuals who had complete covariate data: n=164 for the suppression model and n=139 for the rebound 
model. 
e Multivariable models included TB treatment at cART initiation, age at cART initiation, sex, cART regimen, and baseline HIV RNA, 
CD4 cell percentage, hemoglobin, and weight-for-age z-score. 
f Adjusted models include individuals who had complete covariate data: n=60 for the suppression model and n=53 for the rebound 
model. 
g Adjusted models include individuals who had complete covariate data: n=104 for the suppression model and n=86 for the rebound 
model. 
h Virologic rebound was assessed among the 165 individuals who suppressed <50 copies/mL at any point following cART initiation. 
i
 Severe immunodeficiency was defined according to World Health Organization age-specific classifications [111]: CD4% <25% in 
children <11 months, CD4% <20% in children 12-35 months, CD4% <15% in children 36-59 months, and CD4 cell count <200 
cells/µL or CD4% <15% in children >5 years. 
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a)  
 
b) 
 
Figure 6. Kaplan-Meier graphs of virologic response, stratified by TB treatment status at cART 
initiation 
(a) Time to first virologic suppression. (b) Time to virologic rebound. Abbreviations: cART, 
combination antiretroviral therapy; TB, tuberculosis; TB+, receiving TB treatment at cART 
initiation; TB-, not receiving TB treatment at cART initiation. 
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a)  
 
b)  
 
Figure 7. Graphs of immunologic response, stratified by TB treatment status at cART initiation 
(a) Observed CD4 cell percentage evolutions among children receiving TB treatment and 
children not receiving TB treatment. Each box plot depicts the median and interquartile range, 
with the error bars marking the 10th and 90th percentiles. Time is indicated in months since cART 
initiation. The number of children in each group with a CD4 cell percentage measurement at 
each time point is indicated. (b) Proportion of children with severe age-specific 
immunodeficiency, with exact 95% confidence limits. * indicates a statistically significant 
difference between those receiving vs. not receiving TB treatment at that time point (P <0.05). 
Abbreviations: cART, combination antiretroviral therapy; TB, tuberculosis; TB+, receiving TB 
treatment at cART initiation; TB-, not receiving TB treatment at cART initiation.
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CHAPTER VII 
DISCUSSION 
 
Summary of Findings 
Given the WHO 2010 recommendation that all PLWH with TB be initiated on cART, 
regardless of CD4 count [2], and the goal of 100% cART coverage of co-infected patients by 
2015 [3], many individuals have initiated and will be initiating cART while concurrently on TB 
therapy. PLWH who are also being treated for TB may experience a differential response to 
cART due to drug-drug interactions [4, 5], an increased risk of drug toxicity [4, 5], IRIS [6], and 
the potential for lower adherence due to the high pill burden [5]. The effect of TB treatment and 
its associated potential challenges and complications regarding a patient’s response to cART 
require careful evaluation. 
Therefore, this research aimed to assess the effect of receiving TB treatment at the time 
of cART initiation on virologic and immunologic response to cART along with subsequent 
mortality among adults and children. This was accomplished using three aims. Specific aims 1 
and 2 used systematic reviews and meta-analyses of the published literature to examine the 
outcomes of mortality (Specific Aim 1) and virologic and CD4 count response (Specific Aim 2). 
The third specific aim used data from the THINK cohort study to examine the impact of TB 
treatment on virologic and immunologic response to cART among HIV-infected children. These 
investigations have a direct and important relevance to the care and management of HIV-infected 
individuals receiving TB treatment at cART initiation. 
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In our first specific aim, we found that adults receiving TB treatment at cART initiation 
did not have a statistically significant estimated increase in short-term risk of all-cause mortality 
as compared to those not receiving TB treatment. TB treatment was significantly associated with 
increased mortality after about a year of cART, suggesting that patients with concurrent TB 
treatment at cART initiation may benefit from continued support after TB treatment completion. 
However, there was a wide range of estimates and those at later time points were markedly 
heterogeneous.  
In our second specific aim, our results indicated that TB treatment did not influence the 
risk of virologic suppression at any time point from 1 to 48 months following cART initiation 
among adult PLWH. Patients receiving TB treatment also experienced comparable immune 
reconstitution, as defined by median CD4 count gain from cART initiation, to patients not 
receiving TB treatment at cART initiation. There was not enough available information to make 
conclusions regarding the effect of TB treatment on virologic failure, and we concluded that 
future between-study comparisons could be facilitated by standardization of reported outcomes. 
In our third specific aim, we found that, despite having more advanced disease at 
baseline, children receiving TB treatment at cART initiation did not have a substantially different 
response to cART. Overall, children receiving TB treatment experienced similar rates of 
virologic suppression, virologic rebound, and CD4% increase. However, children initiating 
cART while on TB treatment remained more vulnerable as they continued to have lower CD4% 
and a higher prevalence of severe immunodeficiency throughout the first 2 years of cART. 
Similar to observed responses in adults, efavirenz-based cART was superior to LPV/r-based 
cART [151]. Furthermore, while underpowered, our exploratory sensitivity analysis indicates 
that we cannot rule out the possibility that the combination of TB treatment and LPV/r-based 
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cART may increase the risk of rebound and diminish CD4% reconstitution in younger children, a 
finding which fits with observations in prior studies [91, 93]. 
 
Contributions of Findings 
Overall, we found that despite the many concerns about HIV/TB co-treatment, TB 
treatment does not appear to significantly impair response to cART. These findings add 
substantial contributions to the published literature in this field. 
Regarding the outcome of mortality, there has been an on-going debate regarding 
whether or not having active TB disease at cART initiation increases the risk of subsequent 
mortality. Multiple studies and letters to the editor have been published supporting both sides of 
this issue. In particular, Lawn and colleagues have asserted that prevalent TB at cART initiation 
does increase mortality on cART [70, 153] while Westreich and colleagues report evidence that 
prevalent TB does not cause higher mortality [106, 131]. However, there have been different 
methodological approaches on both sides of this discussion. Lawn and colleagues have focused 
on bacteriologically-confirmed TB, which is often smear-positive TB and therefore often 
pulmonary TB. This is a subset of all TB patients, and perhaps a less sick subset, as it excludes 
many cases of extrapulmonary or disseminated TB or patients who are too sick to produce a 
sputum. On the other hand, Westreich and colleagues, along with others who have published on 
this topic, have defined ‘prevalent TB’ as any patient with a confirmed or clinical diagnosis of 
TB at cART initiation. This exposure definition is more sensitive, but less specific, as it is 
possible that some of the diagnosed cases do not actually have TB and some cases of TB may 
remain undiagnosed. Additionally, factors such as whether or not estimates are appropriately 
adjusted for covariates such as baseline immunodeficiency and survival bias due to patients with 
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TB dying prior to cART initiation complicate the issue and are potential reasons for discrepant 
results [70]. 
We sought to avoid this conflict and produce an analysis useful to clinicians and those 
operating health systems particularly in a high-burden setting by defining our outcome as 
patients on TB treatment at cART initiation. This attempts to isolate the effect of TB treatment 
on cART response, which may differ from the effect of active TB disease on cART response. 
The potential for misclassifying those on TB treatment is much lower than that for actual TB 
disease, and this definition includes all patients being treated for TB as opposed to a particular 
subset of TB cases. The results from analyses looking at the effect of TB treatment on cART 
response can help answer the question of whether or not a health system should provide 
additional support to HIV-infected patients on TB treatment at cART initiation.  
In terms of this particular question, our research indicates that patients on TB treatment 
experience similar short-term mortality on cART, virologic suppression, and increase in CD4 
count from baseline. These findings will allow health care workers to be more confident in their 
clinical decision-making and in their communication to patients about the need to start cART 
during TB treatment. Our finding that patients on TB treatment did not experience increased 
short-term mortality is in accordance with a recent study by van der Plas et al. (2013) which 
found paradoxical TB-IRIS to be an uncommon cause of mortality, even in very ill patients co-
infected with active TB and HIV who initiated cART while hospitalized [154]. In their study 
cohort, bacterial infections were in fact the most important cause of death, provided patients 
were on appropriate TB treatment, cART, and cotrimoxazole preventive therapy. 
We could not definitively analyze the effect of TB treatment on virologic rebound due to 
study heterogeneity. We found an increase in long-term mortality that is difficult to explain 
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considering that TB treatment has already been completed. More research regarding the effect of 
TB treatment on virologic rebound and long-term mortality is required.  
The observed increase in long-term mortality among patients receiving TB treatment at 
cART initiation could perhaps be due to several factors. First, patients on concurrent TB therapy 
at cART initiation may experience a lower short-term risk of all-cause mortality because TB 
medications are also effective against infectious diseases other than TB [138]. Second, most 
PLWH receiving TB treatment often receive co-trimoxazole preventive therapy, which further 
reduces the risk of death from non-TB infectious diseases. Third, prior to cART initiation, 
PLWH on TB treatment may have been engaged in care for longer than other PLWH. Fourth, TB 
deaths can occur early during TB treatment, i.e., prior to the initiation of cART, creating possible 
left-censoring. However, PLWH not diagnosed with TB also may die prior to cART initiation, 
and studies did not provide enough information to determine if left-censoring was differential 
between the two groups. Fifth, undiagnosed and untreated TB among the comparison group may 
have biased estimates of early mortality toward the null. Autopsy studies consistently show that 
undiagnosed TB continues to be a major cause of death among HIV-infected adults [117-119], 
even in the cART era [120]. Sixth, it is possible that TB patients have other life factors, such as a 
lower socio-economic status, poverty, alcoholism, homelessness, or drug abuse. These factors 
continue to place the individual at an increased risk of mortality, which may contribute to our 
observed increase in long-term mortality after the completion of TB treatment. 
As obtaining a bacteriologically-confirmed TB diagnosis in children is even more 
difficult than in adults, defining the exposure for our pediatric analysis as receiving TB treatment 
at cART initiation is similarly appropriate. Though the THINK study data did not support 
calculating the number of TB cases that were in fact bacteriologically-confirmed, most of the 
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children in our analysis initiated TB treatment due to a clinical diagnosis of TB. Overall, children 
on TB treatment were more immunosuppressed at cART initiation, and continued to have lower 
CD4% and a higher proportion with severe immunodeficiency over the course of follow-up. 
However, their actual response to cART was similar to children not on TB treatment in that they 
had similar proportions of and time to virologic suppression, similar virologic rebound, and 
similar increases in CD4%.  
These findings add to the limited literature regarding the effect of TB treatment on 
response to cART in infants and children, though it is difficult to directly compare results due to 
varying age ranges and cART regimens between studies. Virologic suppression allows immune 
reconstitution and is a key measure of successful cART [4]. In our cohort, we did not observe an 
effect of TB treatment on suppression. However, children on efavirenz-based cART experienced 
more and quicker virologic suppression than those on LPV/r-based regimens. Among children 
<3 years, Zanoni et al. (2011) similarly found that children on super-boosted or double-dosed PI-
based cART and concomitant TB treatment experienced decreased virologic suppression as 
compared to children not receiving TB treatment [92]. Frohoff et al. (2011) also observed that 
TB treatment decreased suppression among young children (aged 6-24 months) on double-dose 
LPV/r and ritonavir-based cART [91]. Similarly, Reitz et al. (2010) found decreased suppression 
by 39 weeks among children <2 years on ritonavir or unboosted LPV/r-based cART being co-
treated for TB [93]. 
Virologic rebound may indicate an unsuccessful cART regimen, inadequate adherence, or 
the emergence of drug-resistant virus, and is an especially important indicator in children due to 
limited treatment options [4]. We did not find TB treatment to have an effect on virologic 
rebound overall, though there was a clinically meaningful rebound increase among children <3 
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years on LPV/r-based cART. Another South African study found a lower incidence of virologic 
rebound among children on PI-based cART and TB treatment within 16 weeks after suppression 
(2.8% vs. 12%) [93], while we found no significant difference at this time point (4.8% vs. 1.9%, 
P = 0.6). 
Immune reconstitution is crucial, as a longer time spent at low CD4% is associated with 
increased risk of morbidity and mortality [4]. We found children receiving TB treatment to have 
lower CD4% in the short-term, but no impairment of median increase in CD4%. This finding is 
in accordance with previous studies [90, 91, 93, 94], and extends this observation from 39 weeks 
[93] and a year [91, 94] to 24 months of cART.  
Despite a multitude of challenges posed by concomitant TB and HIV treatment in young 
children [30, 152], our findings indicate that children ≥3 years on efavirenz-based cART and TB 
treatment do not experience an inferior cART response. This is similar to our findings in adults 
[149] and reinforces WHO recommendations to initiate cART soon after TB treatment is 
tolerated [9]. However, TB treatment may impair cART response among children <3 years, who 
currently receive LPV/r-based cART. As guidelines and treatment options continue to change, 
further research is needed to determine optimal HIV/TB co-treatment regimens for young 
children. 
Finally, in all three specific aims, we are looking at average effects, however each 
individual has a unique response to therapy. Therefore, the overall trends we observed may not 
directly translate to the individual experience.  
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Strengths and Limitations 
 
These three studies featured various strengths and limitations. Since being treated for 
active TB is not an exposure suitable for a randomized controlled trial, all studies included in our 
systematic reviews and meta-analyses and our secondary analysis of THINK data were 
observational and subject to biases.  
 
Specific Aim 1 
In terms of specific aim 1, the outcome of mortality may have been misclassified in 
people lost-to-follow-up. Rates of follow-up loss were variable in the included studies, ranging 
from 0% to 21%. cART programs with high losses of patients and incomplete death 
ascertainment can seriously underestimate mortality, with 12% to 87% of patients loss-to-follow-
up in fact being deceased [139]. Misclassification of deaths would only produce bias in the 
estimated relative risks if this misclassification was differential between compared groups [140] 
or dependent on errors in measuring other variables. This is especially relevant for mortality 
estimates during the first six months of cART, when loss-to-follow-up may be differential due to 
regular follow-up for TB treatment. We attempted to examine if mortality confirmation by 
national death registry affected mortality effect estimates. This was only possible for two studies, 
both with 18-98 months of follow-up, which tended to have lower mortality relative risks than 
studies that did not confirm mortality using a national death registry. This indicates that, in 
studies not using a national death registry, perhaps mortality was more completed assessed 
among patients on TB treatment than among other patients. 
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Second, the exposure, TB treatment at cART initiation, captures both confirmed active 
TB disease and exposure to anti-tuberculosis drugs for clinically suspected TB. This combined 
exposure is useful from a health systems perspective, particularly in low-resource countries, 
where active TB cannot always be confirmed, especially in PLWH. The included studies used a 
variety of methods for determining who had active TB and should receive treatment, and no 
studies were exclusively limited to bacteriologically-confirmed TB cases. Consequently, active 
TB could have been misclassified and some patients included in this meta-analysis may have 
received TB treatment even though they did not have TB. In addition, some patients with active 
TB may not have been diagnosed.  
Third, there was much heterogeneity in the duration of TB treatment prior to cART 
initiation, with some patients on TB therapy for six months and others beginning TB treatment 
and cART concurrently. While the timing of TB treatment in relation to cART initiation is an 
important variable to consider when evaluating mortality [47-50, 131], the included studies did 
not provide enough information on duration of TB treatment to systematically evaluate its effect 
on our results. Future studies should describe the duration of TB treatment in more detail to 
facilitate meta-analysis, though a pooled patient-level analysis or randomized controlled trial are 
study designs better suited to assess this factor. 
Methods involved in conducting a meta-analysis may have introduced some biases. A 
direct effect measure was not available from each study, and published estimation methods [97] 
were used to calculate the effect measure for five studies. These estimation techniques involve a 
number of assumptions and may have introduced bias or affected variance estimates. 
Additionally, in 12 of 22 studies, TB treatment was not the primary exposure and covariates 
included in multivariate models may differ from ideal confounder adjustment for this research 
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question. Some studies only included TB treatment in their multivariable model for mortality 
because it was a statistically significant predictor, which may explain some funnel plot 
asymmetry.  
Additionally, it was difficult to examine the influence of study or population 
characteristics on the effect estimates, as grouping studies by specific characteristics produced 
small strata with imprecise estimates. Furthermore, some characteristics are correlated. For 
example, RRs and ORs tended to be higher than HRs, but the former also tended to be 
unadjusted estimates. Also, as studies adjusted for sets of key covariates, it was difficult or 
impossible to separate out the influence of adjusting for a specific covariate. 
Given the limitations of the available literature, our systematic review and meta-analysis 
of mortality made an organized and cohesive effort to report and evaluate the available literature, 
explore factors associated with heterogeneity, and arrive at tentative conclusions regarding the 
effect of TB treatment on mortality on cART.   
 
Specific Aim 2 
In specific aim 2, we found that the reported outcome measures regarding virologic and 
immunologic response to cART were highly heterogeneous, impeding sound between-study 
comparisons or meta-analytic summarization for outcome measures other than virologic 
suppression. While rigorous meta-analysis methods could not be applied for CD4 response, we 
did observe similar within-study effects of TB treatment, and the overall impression is that TB 
treatment exposure does not have a substantial impact on CD4 recovery.  
This systematic review had the same strengths and weaknesses of defining the exposure 
as being on TB treatment at cART initiation, as was discussed regarding specific aim 1. 
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Furthermore, time points reported by individual studies were also heterogeneous. The 
optimal time point for evaluating the effect of exposure to TB treatment on response to cART is 
unclear.  Follow-up times shorter than 4 months may be too early to accurately describe response 
to cART, and follow-up times longer than two years may underestimate the impact of TB 
treatment at cART initiation, especially if patients who switch treatments or take second-line 
therapy are included in the analysis. For the sake of completeness, all reported outcome measures 
and follow-up times were retained in this review.  
There was much heterogeneity in the duration of TB treatment prior to cART initiation, 
with some patients on TB therapy for up to eight months and others beginning TB treatment and 
cART concurrently. While the timing of TB treatment in relation to cART initiation is an 
important factor when evaluating mortality [47-50, 131], it is unclear whether TB treatment 
timing would influence virologic or CD4 count response. Unfortunately, the included studies did 
not provide enough information on duration of TB treatment to systematically evaluate its effect 
on our results. Similarly, a lack of provided data on cART regimen switching during follow-up 
precluded a systematic evaluation of this factor. 
This systematic review and meta-analysis may have been subject to some biases. First, 
virologic and immunologic response cannot be evaluated in those who have died or were lost-to-
follow-up. Loss rates varied widely, ranging from 0% to 64% though most studies lost ≤12%, 
and studies handled loss-to-follow-up in a variety of ways, which may have influenced their 
results. Missing patients may systematically differ from those retained in the analysis. If 
response to cART among lost or deceased patients was differential by TB treatment status, than 
the results of these studies and our review could have been biased. Second, in 8 of 25 studies, TB 
treatment was not the primary exposure and covariates included in some multivariable models 
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may differ from ideal confounder adjustment for this research question. Third, some bias may 
have been introduced by estimation methods used when a study did not directly report an 
outcome measure but provided the necessary data to calculate the desired effect measures [97, 
98].  
Similar to our review of mortality, this review presented an organized overview of the 
published literature and came to some conclusions regarding the effect of TB treatment on 
virologic and immunologic response to cART. However, it also served to identify gaps in the 
current research and to highlight the difficulties in comparing studies with different outcome 
measurements and the need for methodological standardization before further conclusions can be 
drawn. 
 
Specific Aim 3 
Our specific aim 3 analysis possessed a number of important strengths. First, the THINK 
study was conducted prospectively, enabling us to firmly establish the timing between TB 
treatment and cART initiation and to obtain regular HIV RNA and CD4% measurements during 
follow-up. Second, this study had two years of follow-up, allowing us to distinguish between 
potential short- and long-term effects of TB treatment and to measure longer-term outcomes. 
Third, the occurrence of only one death allowed us to study response to cART without survival 
bias. Fourth, the median age of 2.1 years allowed us to report on treatment outcomes in very 
young children, a group which tends to be underrepresented in cART programs and research 
studies, and is becoming larger with increasing access to early infant diagnosis [95]. 
This study was however not without limitations. First, the THINK study was 
observational, resulting in loss-to-follow-up and missing data, which prevented us from reliably 
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estimating certain outcomes, such as sustained virologic suppression. Second, confirming TB 
diagnosis in children is inherently difficult. Similar to other pediatric studies, most TB diagnoses 
in our cohort were presumptive, resulting in potential misclassification of active TB. As we 
focused on the effect of TB treatment on response to cART, misclassification is less of a concern 
and the results are applicable to any children on TB treatment at cART initiation. Third, our 
modest sample size limited our ability to find significant effects, particularly upon stratification. 
Fourth, while the duration of TB treatment prior to cART initiation may affect response to 
cART, we could not assess this factor due to limited variability in this population. Fifth, this 
study required adaptations to changing guidelines over time, which complicates straightforward 
interpretation of results. A sensitivity analysis of the changing guidelines helped us disentangle 
specific results. Sixth, TB/HIV co-treatment in children has a number of obstacles including 
limited pediatric drug formulations, lack of dosing information, and adherence concerns. The use 
of syrups in young children also complicates measurement of adherence. While adherence may 
be differential in the two groups, it was not measured by this study and may have biased our 
results. Seventh, a single elevated measurement of HIV RNA >1000 copies/mL may be a blip 
and not indicative of true virologic rebound. Rebound could only be confirmed by a second 
measurement in six children, three of which were on TB treatment at cART initiation. Finally, as 
cART regimen was prescribed according to age and weight, it was difficult to separate the 
individual effects of these exposures. 
 Despite these limitations, this analysis was a useful addition to the limited literature 
regarding the effect of TB treatment on response to cART in children. Our results was presented 
in multiple different ways, to ease comparison with past and future studies, and our exploratory 
stratified analyses served to highlight areas for future investigation. 
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Recent Research 
 In this era, any meta-analysis is quickly outdated due to the fact that studies are 
continually being published. In particular, research regarding the effect of TB treatment on 
response to cART is a current topic of interest and many studies have been published within the 
past few years and more continue to be published. For this reason, we examined recently 
published research to see if the new studies fit with conclusions reached during our meta-
analyses. 
Since this research has been conducted, some related studies have been published: 4 
reporting mortality and 1 reporting virologic and immunologic response. Graham et al. (2013) 
published on a prospective cohort of 102 ART-naïve, non-pregnant Kenyan women who initiated 
nevirapine-based cART from 2005 to 2008 [155]. Of these women, 19 (19%) were on TB 
treatment at cART initiation. Though not the primary aim of the study, they did report the effect 
of TB treatment on mortality. Five women died during 12 months of follow-up, of which two 
were on TB treatment at cART initiation. The authors report a crude HR for the effect of TB 
treatment on mortality of 3.0 (95% CI 0.5, 18.0).  
 Alvarez-Uria et al. (2013) followed 3,519 PLWH initiating cART in India from 2007 to 
2011 for up to 5 years post cART initiation [156]. 388 (12.3%) had been diagnosed with active 
TB <3 months prior to cART initiation and were presumably on TB treatment at cART initiation. 
Patients with prevalent TB had a higher rate of mortality than those who were TB-free 
throughout follow-up (10.7 vs. 5.7 deaths/100 person-years, no p-value reported), with a 
mortality HR of 1.08 (95% CI 0.84, 1.40). 
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 Poka-Mayap et al. (2013) investigated predictors of mortality among 1,444 adults who 
initiated NNRTI-based cART between 2007 and 2008 in Cameroon [157]. 428 (30%) were 
receiving TB treatment at cART initiation, and TB treatment was found to be a significant 
predictor of mortality during the 5 years following cART initiation in multivariable analyses 
(aHR 2.35, 95% CI 1.40, 3.92). 
 Chu et al. (2013) also found TB treatment at cART initiation to be a significant predictor 
of long-term mortality over up to 9 years of follow-up among 22,477 adults who initiated cART 
between 2000 and 2009 in Uganda [158]. Patients on TB treatment experienced a higher 
proportion of mortality than those not on TB treatment (10% vs. 6%), with a significant HR 
using propensity-score matched pairs of 1.37 (95% CI 1.08, 1.75). 
 Putting these recent results in context with findings from our specific aim 1 meta-
analysis, Graham et al.’s 12-month mortality estimate was non-significant, which is consistent 
with our estimate RRRE of 6-12 month mortality of 1.15 (95% CI 0.94, 1.41) (Table 2). While 
this point estimate is not within our calculated 95% prediction interval of (0.69, 1.91) that we 
calculated for 6-12 month mortality, it is a crude estimate with an extremely wide CI. In terms of 
the later mortality estimates, two out of three studies reported an elevated risk of long-term 
mortality among patients receiving TB treatment at cART initiation. This is also consistent with 
our estimated RRRE of 18-98 month mortality of 1.33 (95% CI 1.02, 1.75). In fact, the HR 
estimated by Chu et al. among a large cohort of over 22,000 patients is nearly identical to our 
estimated RRRE (1.37 [95% CI 1.08, 1.75]). All three long-term mortality estimates fall within 
our calculated 95% prediction interval for 18-98 month mortality of (0.55, 3.23). 
 Only one recent study reported on virologic and immunologic response to cART. Kassa 
et al. (2013) investigated response to mainly nevirapine-based cART among 113 Ethiopian 
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adults, of which 28 were being treated for TB at cART initiation from 2007 to 2011 [159]. They 
found similar proportions of patients with virologic suppression <50 copies/mL, similar 
increases in CD4 count, and similar absolute CD4 counts at 6, 18, and 24 months of cART. They 
also reported crude ORs for the effect of TB treatment on immunologic failure (CD4 count 
increase <50 cells/µL at 6 months, 1.4 [95% CI 0.4, 1.8]) and virologic failure (HIV RNA >5000 
copies/mL at 6 months, 0.23 [95% CI 0.03, 1.9]). The authors noted that the absolute CD4 count 
achieved by 24 months was twice as high in patients on TB treatment with a baseline CD4 count 
>200 as compared to patients on TB treatment with a baseline CD4 count <200, indicating that 
baseline immunodeficiency is the more important predictor of diminished CD4 count 
reconstitution on cART. This study also had substantial loss-to-follow-up (42% at 24 months). 
 As these recent studies are fairly consistent with our meta-analysis results, we are 
confident that our results would not have significantly changed had these studies been included 
and therefore our conclusions are still valid. 
 
Future Research Directions 
Given the limitations of available literature, we believe that the question of whether or 
not TB treatment increases short-term mortality has been adequately explored in the literature. 
More work could be done to elucidate reasons why TB treatment may be associated with an 
increase in long-term mortality, with an emphasis on separating possible effects of TB treatment 
from effects of active TB itself. In the meantime, patients receiving concurrent TB treatment at 
cART initiation may benefit from continued support after TB treatment completion. 
Given the patient characteristics of the studies included in specific aims 1 and 2, the 
results are most generalizable to therapy-naïve adults in sub-Saharan Africa and Asia with 
  120
relatively low CD4 counts at cART initiation. More studies in populations outside of sub-
Saharan Africa, particularly in North and South America, would be useful additions to the 
literature. Also, it is possible that cART regimen would modify the effect of TB treatment due to 
drug-drug interactions, and regimen-specific estimates would be of most use to clinicians 
treating co-infected patients.  
As mentioned previously, the heterogeneity in outcome measures posed a challenge to 
the interpretation and summarization of the virologic and CD4 count response to cART. 
Between-study comparisons could be greatly facilitated by methodological standardization of 
outcome measures and their time points in future studies. 
In terms of specific aim 3, our results are most generalizable to children in resource-
limited settings. Due to the paucity of pediatric research in this area, any future studies 
examining the effect of TB treatment on pediatric response to cART, particularly among young 
children on PI-based cART, would be useful additions to the literature. As the optimal co-
treatment strategy for children with HIV and TB has not been settled, much work remains to be 
done in this area. 
 In conclusion, our results suggest that TB treatment does not impair response to cART in 
adults and children, and cART should continue to be initiated as soon as TB treatment is 
tolerated. However, those receiving concurrent TB and HIV treatment should continue to be 
monitored, especially for virologic rebound and long-term mortality after TB treatment has been 
completed. More research is needed to determine whether TB treatment is associated with sub-
optimal cART response among young children on PI-based cART.  
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APPENDIX: SUPPLEMENTAL MATERIAL
 
Supplemental Material: Aim 1 
 
Table 10. cART regimens utilized in each study 
Study cART regimen(s) 
Bassett 2012 “standard ART regimens as per contemporaneous South African guidelines” 
Bera 2009 96.4% EFV-based cART 
4.2% NVP-based cART 
2.9% ZDV-based cART 
97.4% d4T-based cART 
Bhowmik 2012 First-line: EFV/NVP + ZDV/d4T + 3TC 
Boulle 2008 (a) NVP + 2 NRTIs 
Boulle 2008 (b)  EFV + 2 NRTIs 
Boulle 2010 (a,b)  8.8% EFV + ZDV + 3TC 
8.4% NVP + ZDV + 3TC 
43.6% EFV + d4T + 3TC 
38.5% NVP + d4T + 3TC 
0.8% other 
Chu 2011 Not specified 
Dao 2011 First-line: EFV/NVP + ZDV/d4T + 3TC 
DeSilva 2009 Most patients on first-line regimens (most common: NVP + d4T + 3TC) 
10 patients received combined lopinavir/ritonavir as part of their regimen 
Dronda 2011 Not specified 
Gupta 2013 “predominantly EFV-based cART” 
Greig 2012 Not specified 
Lartey 2011 600 mg EFV + 400/300mg didanosine + 300 mg 3TC once daily 
Liechty 2007 First-line: EFV/NVP + d4T + 3TC 
Makombe 2007 (a,b) First-line: NVP + d4T + 3TC 
Manosuthi 2010 NVP + d4T + 3TC 
d4T switched to tenofovir or ZDV if d4T-related adverse events developed 
Mugusi 2012 (a,b)  With prevalent TB:  50.7% EFV + d4T + 3TC, 49.3% EFV + ZDV + 3TC 
Without prevalent TB:  16.9% EFV + d4T + 3TC, 83.1% EFV + ZDV + 3TC 
Mutevedzi 2011 
(a,b,c,d) 
First-line: EFV/NVP + d4T + 3TC 
Nguyen 2011 Not specified 
Stringer 2006 (a,b)  First-line: NVP + ZDV/d4T + 3TC 
In patients receiving acute-phase TB therapy with CD4 cell count <50 cells/µL: EFV-
based cART 
Westreich 2012 (a,b)  With prevalent TB: 95.2% EFV-based cART, 3.0% NVP-based cART, 1.8% other 
Without prevalent TB: 79.5% EFV-based cART, 9.5% NVP-based cART, 11.1% 
other 
Zachariah 2006 93.7% fixed dose NVP + d4T + 3TC 
4.4% EFV + d4T + 3TC 
1.3% NVP + ZDV + 3TC 
0.3% EFV + ZDV + 3TC 
0.3% ZDV + didanosine + nelfinavir 
Zachariah 2009 99.8% NVP + d4T + 3TC 
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0.2% NVP + ZDV + 3TC 
Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; cART, combination antiretroviral 
therapy; d4T, stavudine; EFV, efavirenz; NRTI, nucleos(t)ide reverse-transcriptase inhibitor; 
NVP, nevirapine; TB, tuberculosis; ZDV, zidovudine 
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Table 11. Types of TB included, by study 
Study Types of TB included 
Bassett 2012 Newly diagnosed by sputum culture at cART enrollment or previously diagnosed and 
currently on treatment  
Bera 2009 Concurrently on TB treatment at cART initiation 
Bhowmik 2012 Concurrently on TB treatment at cART initiation 
Boulle 2008 (a) Concurrent TB treatment at cART initiation and for ≥14 days post cART initiation. TB 
diagnosed by microscopy, culture or clinical algorithm. 
Boulle 2008 (b)  Concurrent TB treatment at cART initiation and for ≥14 days post cART initiation. TB 
diagnosed by microscopy, culture or clinical algorithm. 
Boulle 2010 (a,b)  On TB treatment at cART initiation 
Chu 2011 Concurrent active TB diagnosis at cART initiation 
Dao 2011 Concurrent active TB diagnosis at cART initiation 
DeSilva 2009 Concurrent TB diagnosis and treatment at cART initiation. TB co-infection assessed 
using patient files and pharmacy records. 
Dronda 2011 Definite or presumptive diagnosis of TB in 6 months prior to cART initiation 
Greig 2012 Current TB diagnosis at cART initiation 
Gupta 2013 On TB treatment at cART initiation 
Lartey 2011 On TB treatment at cART initiation 
Liechty 2007 Concurrent active TB diagnosis at cART initiation 
Makombe 2007 (a,b) Concurrent active TB diagnosis at cART initiation 
Manosuthi 2010 Receiving rifampicin for active TB  ≥1 month prior to cART enrollment 
Mugusi 2012 (a,b)  Newly diagnosed at cART enrollment by smear microscopy, histology or clinical criteria 
Mutevedzi 2011 
(a,b,c,d) 
Concurrent TB treatment at cART initiation 
Nguyen 2011 Active TB at cART initiation 
Stringer 2006 (a,b)  Active TB at cART initiation 
Westreich 2012 (a,b)  On treatment for pulmonary TB at cART initiation 
Zachariah 2006 On treatment for active TB at cART initiation 
Zachariah 2009 Active TB at cART initiation 
Abbreviations: cART, combination antiretroviral therapy; TB, tuberculosis 
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Table 12. Timing of TB treatment in relation to cART initiation, by study 
Study Timing of TB treatment in relation to cART initiation 
Bassett 2012 144 newly diagnosed by sputum culture at cART enrollment 
199 previously diagnosed and on TB treatment at cART enrollment 
Bera 2009 Not specified 
Bhowmik 2012 Not specified 
Boulle 2008 (a) Patients only included as prevalent TB in the analysis if they continued TB treatment 
past 14 days post cART initiation.  
Duration of TB treatment at cART initiation [median (IQR)]: 87 (60-135) days 
Boulle 2008 (b)  Patients only included as prevalent TB in the analysis if they continued TB treatment 
past 14 days post cART initiation.  
Duration of TB treatment at cART initiation [median (IQR)]: 73 (44-115) days 
Boulle 2010 (a,b)  Not specified 
Chu 2011 Not specified 
Dao 2011 Not specified 
DeSilva 2009 Not specified 
Dronda 2011 Duration of TB treatment at cART initiation [median (IQR)]: 53 (25.75-83.25) days 
Greig 2012 Not specified 
Gupta 2013 Not specified 
Lartey 2011 Duration of TB treatment at cART initiation ranged from 4 to 90 days (median: 33) 
Liechty 2007 Not specified 
Makombe 2007 (a,b) cART was deferred until the continuation phase of TB treatment (2 months) was 
complete. 
Manosuthi 2010 Median (IQR) duration of concurrent administration of nevirapine and rifampin: 5.4 
(4.6-6.1) months 
Mugusi 2012 (a,b)  All patients diagnosed with TB started cART after 4 weeks of TB treatment. 
Mutevedzi 2011 
(a,b,c,d) 
Not specified 
Nguyen 2011 Not specified 
Stringer 2006 (a,b)  Many patients were taking TB treatment for weeks to months prior to cART initiation.  
If newly diagnosed with TB during enrollment, they deferred cART until the acute 
phase of TB treatment was complete, unless CD4 count <50 when cART was started 
immediately. 
Westreich 2012 (a,b)  254 (21.2%) were on TB treatment for >120 days prior to cART initiation. 
320 (26.7%) were on TB treatment for 61-120 days prior to cART initiation. 
289 (24.1%) were on TB treatment for 31-60 days prior to cART initiation. 
334 (27.9%) were on TB treatment for ≤30 days prior to cART initiation. 
Zachariah 2006 Not specified 
Zachariah 2009 Not specified 
Abbreviations: cART, combination antiretroviral therapy; IQR, interquartile range; TB, 
tuberculosis 
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Table 13. Median (IQR) baseline CD4 cell count by TB treatment status, if available 
Study TB treatment No TB treatment 
Bassett 2012 
TB sputum culture positive at 
enrollment:  
80 (41-125) 
On TB treatment at enrollment:  
65 (29-112) 
104 (49-160) 
Bera 2009 NA NA 
Bhowmik 2012 NA NA 
Boulle 2008 (a) 80 (42-137) 116 (58-167) 
Boulle 2008 (b)  61 (27-117) 93 (37-155) 
Boulle 2010 (a,b)  NA NA 
Chu 2011 NA NA 
Dao 2011 NA NA 
DeSilva 2009 NA NA 
Dronda 2011 80 (32-186) 226 (126-310) 
Greig 2012 NA NA 
Gupta 2013 NA NA 
Lartey 2011 46 88 
Liechty 2007 NA NA 
Makombe 2007 (a,b) NA NA 
Manosuthi 2010 37 (17-77) 29 (8-112) 
Mugusi 2012 (a,b) 94.5 (123) 90 (118) 
Mutevedzi 2011 (a,b,c,d) NA NA 
Nguyen 2011 NA NA 
Stringer 2006 (a,b) NA NA 
Westreich 2012 (a,b)  58 (22-116) 94 (34-165) 
Zachariah 2006 NA NA 
Zachariah 2009 NA NA 
Abbreviations: IQR, interquartile range; NA, not available; TB, tuberculosis 
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Table 14. Meta-regression results for the effect of TB treatment on mortality 
Length of 
follow-up time Study or Population Characteristic Category 
Number of 
Studies 
Homogeneity  
p-value RRRE (95% CI) 
Ratio of RRs  
(95% CI) 
1-3 months  Study design Prospective cohort 5 0.13 1.11 (0.80, 1.54) 1.02 (0.49, 2.13) 
  Retrospective cohort 3 0.10 1.08 (0.68, 1.71) Reference 
 Median baseline CD4 count <100 cells/µL 2 0.08 1.97 (0.44, 8.84) 1.67 (0.40, 6.98) 
  ≥100 cells/µL 5 0.23 1.12 (0.89, 1.40) Reference 
 Ratio measure Hazard ratio 4 0.42 1.19 (0.98, 1.44) 1.34 (0.71, 2.54) 
  Risk ratio or odds ratio 4 0.07 1.02 (0.56, 1.86) Reference 
 Adjustment* Adjusted 6 0.08 1.17 (0.89, 1.55) 1.41 (0.62, 3.22) 
  Unadjusted 2 0.80 0.82 (0.52, 1.31) Reference 
 Adjustment for age and sex† Yes 5 0.23 1.12 (0.89, 1.40) 1.04 (0.43, 2.49) 
  No 3 0.05 1.32 (0.51, 3.40) Reference 
 Adjustment for hemoglobin Yes 3 0.13 1.56 (0.99, 2.44) 1.55 (0.96, 2.49) 
  No 5 0.64 0.96 (0.78, 1.18) Reference 
6-12 months Study design Prospective cohort 7 0.10 1.22 (0.86, 1.74) 1.06 (0.63, 1.79) 
  Retrospective cohort 4 0.11 1.10 (0.85, 1.43) Reference 
 Length of follow-up 6-9 months 4 0.14 0.93 (0.68, 1.28) 0.70 (0.51, 0.96) 
  11-12 months 7 0.61 1.29 (1.06, 1.56) Reference 
 Clinical setting HIV care 7 0.10 1.19 (0.95, 1.49) 1.21 (0.68, 2.16) 
  Primary care 4 0.11 1.13 (0.63, 2.03) Reference 
 cART regimen EFV-based 3 0.62 0.86 (0.60, 1.23) 0.74 (0.40, 1.37) 
  NVP-based or a mixture 8 0.03 1.23 (0.96, 1.58) Reference 
 TB is main exposure Yes 6 0.25 0.99 (0.80, 1.23) 0.72 (0.44, 1.16) 
  No 5 0.13 1.46 (1.00, 2.12) Reference 
 Gender Women only 2 0.18 2.57 (0.83, 7.98) 2.08 (0.81, 5.33) 
  Both genders included 9 0.16 1.08 (0.90, 1.29) Reference 
 Mean patient age ≤33 years 4 0.06 1.21 (0.68, 2.16) 0.80 (0.43, 1.48) 
  >33 years 5 0.42 1.26 (1.03, 1.54) Reference 
 Median baseline CD4 count <100 cells/µL 4 0.17 1.12 (0.75, 1.67) 0.84 (0.46, 1.52) 
  ≥100 cells/µL 6 0.15 1.33 (0.97, 1.83) Reference 
 Ratio measure Hazard ratio 6 0.56 1.02 (0.84, 1.24) 0.79 (0.47, 1.33) 
  Risk ratio 5 0.01 1.44 (0.91, 2.27) Reference 
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 Adjustment‡ Adjusted 6 0.73 1.00 (0.82, 1.22) 0.75 (0.45, 1.26) 
  Unadjusted 5 0.01 1.47 (0.95, 2.28) Reference 
 Adjustment for age and sex§ Yes 5 0.66 0.99 (0.81, 1.21) 0.73 (0.44, 1.22) 
  No 6 0.01 1.46 (0.97, 2.20) Reference 
 Adjustment for BMI/weight Yes 2 1.00 1.05 (0.80, 1.38) 0.87 (0.46, 1.68) 
  No 9 0.03 1.21 (0.93, 1.59) Reference 
 Adjustment for hemoglobin Yes 2 0.66 1.28 (0.74, 2.22) 1.11 (0.49, 2.53) 
  No 9 0.03 1.15 (0.91, 1.45) Reference 
18-98 months Study design Prospective cohort 7 0.01 1.14 (0.91, 1.42) 0.54 (0.26, 1.13) 
  Retrospective cohort 3 <0.01 2.21 (0.89, 5.49) Reference 
 Length of follow-up 18-36 months 3 <0.01 1.58 (0.81, 3.10) 1.24 (0.56, 2.76) 
  47-98 months 7 <0.01 1.23 (0.94, 1.62) Reference 
 Geographic location Africa 5 <0.01 1.24 (0.84, 1.82) 0.80 (0.37, 1.73) 
  Asia or Europe 5 0.49 1.50 (1.25, 1.81) Reference 
 Clinical setting HIV care 8 <0.01 1.54 (1.12, 2.10) 1.70 (0.77, 3.76) 
  Primary care 2 0.02 0.91 (0.57, 1.47) Reference 
 All patients ART-naïve Yes 8 <0.01 1.46 (0.99, 2.15) 1.30 (0.54, 3.14) 
  No 2 0.75 1.12 (0.97, 1.28) Reference 
 TB is main exposure Yes 5 0.20 1.30 (1.08, 1.58) 0.92 (0.42, 2.01) 
  No 5 <0.01 1.44 (0.85, 2.44) Reference 
 Used national death registry Yes 2 0.03 0.90 (0.58, 1.38) 0.57 (0.26, 1.24) 
  No 8 <0.01 1.55 (1.14, 2.10) Reference 
 Mean patient age ≤33 years 2 0.01 1.33 (0.33, 5.31) 0.84 (0.28, 2.54) 
  >33 years 7 <0.01 1.41 (1.03, 1.93) Reference 
 Median baseline CD4 count <100 cells/µL 3 0.07 1.32 (0.92, 1.88) 1.05 (0.38, 2.94) 
  ≥100 cells/µL 5 <0.01 1.26 (0.76, 2.08) Reference 
 Ratio measure Hazard ratio or IRR 8 <0.01 1.35 (0.99, 1.85) 1.02 (0.36, 2.90) 
  Risk ratio 2 0.88 1.38 (1.07, 1.77) Reference 
 Adjustment** Adjusted 8 <0.01 1.29 (0.99, 1.70) 0.63 (0.19, 2.12) 
  Unadjusted 2 0.30 2.13 (0.96, 4.72) Reference 
 Adjustment for age Yes 7 <0.01 1.28 (0.93, 1.76) 0.77 (0.31, 1.92) 
  No 3 0.32 1.51 (1.06, 2.14) Reference 
 Adjustment for baseline hemoglobin Yes 2 0.67 1.07 (0.90, 1.27) 0.71 (0.30, 1.70) 
  No 8 <0.01 1.47 (1.04, 2.09) Reference 
  
128
 Adjustment for BMI/weight Yes 4 0.11 1.01 (0.84, 1.21) 0.53 (0.31, 0.90) 
  No 6 <0.01 1.85 (1.25, 2.73) Reference 
 Adjustment for baseline CD4 count Yes 7 <0.01 1.32 (0.95, 1.85) 0.88 (0.35, 2.22) 
  No 3 0.16 1.44 (0.82, 2.54) Reference 
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; cART, combination antiretroviral therapy; CI, confidence interval; 
EFV, efavirenz; HIV, human immunodeficiency virus; IRR, incidence rate ratio; NVP, nevirapine; RR, relative risk; RRRE, random 
effects relative risk; TB, tuberculosis 
* All of the adjusted estimates adjusted for baseline CD4 count and BMI or weight 
† The 5 estimates that adjusted for age also adjusted for sex 
‡ All of the adjusted estimates adjusted for baseline CD4 count 
§ The 5 estimates that adjusted for age also adjusted for sex 
** All of the adjusted estimates adjusted for sex 
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Figure 8. Funnel plots of mortality relative risks and inverse-variance weights 
Funnel plots of mortality relative risks and inverse-variance weights at (a) 1-3 months, (b) 6-12 
months, and (c) 18-98 months after combination antiretroviral therapy initiation. Black circles 
are reported results; white circles are imputed results from the trim-and-fill method. The solid 
line is the null value of 1. The dashed line represents the random effects summary relative risk. 
The dotted line represents the random effects summary relative risk with the imputed studies. 
  
a) 
b) 
c) 
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Sensitivity analysis of asymmetrical confidence intervals 
 
We conducted a three-part sensitivity analysis, in each part of which one of the three values 
would be replaced by a value imputed from the other two, assuming interval symmetry.  With 
lnRR as the natural log of the point estimate, lnLO as the natural log of the lower limit and lnUP 
as the natural log of the upper limit: 
  
a.  imputed lnRR = 0.5(lnUP + lnLO) 
b.  imputed lnLO = lnRR – (lnUP – lnRR) = 2(lnRR) – lnUP 
c.  imputed lnUP = lnRR + (lnRR – lnLO) = 2(lnRR) – lnLO 
 
We then re-ran the analysis with each calculated estimate and 95% CI to examine if and how the 
summarized random effects estimate and 95% CI change, for the appropriate time period. 
 
Table 15. Sensitivity analysis of asymmetrical confidence intervals 
Iteration 
Calculated estimate 
(95% CI) 
Resulting summary 
effect estimate 
(95% CI) 
Mutevedzi 2011a – 3-month estimate   
Asymmetrical interval:  1.59 (0.84, 1.97) 1.10 (0.87, 1.40) 
a. imputed lnRR = 0.5[ln(1.97) + ln(0.84)] = 0.25 1.29 (0.84, 1.97) 1.07 (0.87, 1.32) 
b. imputed lnLO = 2ln(1.59) – ln(1.97) = 0.25 1.59 (1.28, 1.97) 1.13 (0.87, 1.47) 
c. imputed lnUP = 2ln(1.59) – ln(0.84) = 1.10 1.59 (0.84, 3.01) 1.07 (0.85, 1.36) 
Boulle 2008b – 6-month estimate   
Asymmetrical interval:  0.8 (0.5, 1.1) 1.15 (0.94, 1.41) 
a. imputed lnRR = 0.5[ln(1.1) + ln(0.5)] = -0.30 0.7 (0.5, 1.1) 1.14 (0.92, 1.42) 
b. imputed lnLO = 2ln(0.8) – ln(1.1) = -0.54  0.8 (0.6, 1.1) 1.14 (0.93, 1.40) 
c. imputed lnUP = 2ln(0.8) – ln(0.5) = 0.25 0.8 (0.5, 1.3) 1.16 (0.94, 1.42) 
Nguyen 2011 – 60-month estimate   
Asymmetrical interval:  2.9 (1.6, 10.5) 1.33 (1.02, 1.75) 
a. imputed lnRR = 0.5[ln(10.5) + ln(1.6)] = 1.41 4.1 (1.6, 10.5) 1.37 (1.05, 1.79) 
b. imputed lnLO = 2ln(2.9) – ln(10.5) = -0.22 2.9 (0.8, 10.5) 1.33 (1.02, 1.72) 
c. imputed lnUP = 2ln(2.9) – ln(1.6) = 1.66 2.9 (1.6, 5.3) 1.38 (1.06, 1.80) 
Abbreviations: CI, confidence interval; lnLO, natural log of the lower limit; lnRR, natural log of 
the point estimate; lnUP, natural log of the upper limit.  
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Supplemental Material: Aim 2 
 
Table 16. cART regimens utilized in each study 
Study cART regimen(s) 
Almeida 2011 56/89 (65%) NVP-based regimen  
31/89 (35%) EFV-based regimen 
Auld 2011 88% NVP/EFV + d4T + 3TC 
11% NVP/EFV + ZDV+ 3TC 
<1% d4T/ZDV + 3TC + abacavir 
<1% other 
Bassett 2012 “standard ART regimens as per contemporaneous South African guidelines” 
Bastard 2012 83.7% NVP + d4T + 3TC 
11.9% EFV + d4T + 3TC 
4.4% other 
Boulle 2008 (a) NVP + 2 NRTIs 
Boulle 2008 (b)  EFV + 2 NRTIs 
Boulle 2010  8.4% NVP + ZDV + 3TC 
38.5% NVP + d4T + 3TC 
8.8% EFV + ZDV + 3TC 
43.6% EFV + d4T + 3TC 
0.8% other 
Breen 2006 8% triple NRTI 
62% 2 NRTIs + NNRTI 
10% 2 NRTIs + PI 
12% 2 NRTIs + boosted PI 
5% 2 NRTIs + PI + NNRTI 
4% not recorded 
Dronda 2011 Not specified 
Hardwick 2012 EFV-based cART 
Hermans 2011 On TB treatment:  309 (54%) NVP + d4T + 3TC, 242 (43%) EFV + ZDV + 3TC, 19 
(3%) other 
Not on TB treatment:  2025 (63%) NVP + d4T + 3TC, 894 (28%) EFV + ZDV + 3TC, 
308 (9%) other 
Hung 2003 Prior to PI introduction: 2 NRTIs 
After PI introduction: cART “according to CDC guidelines” 
Julg 2012 360 (81%) EFV + d4T + 3TC 
82 (19%) other 
Lartey 2011 600 mg EFV + 400/300mg didanosine + 300 mg 3TC once daily 
Manosuthi 2006  NVP + d4T + 3TC 
d4T switched to tenofovir or ZDV if d4T-related adverse events developed 
Manosuthi 2008 NVP + d4T + 3TC 
d4T switched to tenofovir or ZDV if d4T-related adverse events developed 
Manosuthi 2010 NVP + d4T + 3TC 
d4T switched to tenofovir or ZDV if d4T-related adverse events developed 
Mugusi 2012 On TB treatment:  50.7% EFV + d4T + 3TC, 49.3% EFV + ZDV + 3TC 
Not on TB treatment:  16.9% EFV + d4T + 3TC, 83.1% EFV + ZDV + 3TC 
Mussini 2008 66% PI-based cART, 25% NNRTI-based cART, 10% NRTIs or a combination of 3 drug 
classes 
85% on 3TC, 57% on ZDV, 37% on d4T, 28% on indinavir, 23% on ritonavir, 20% on 
EFV, 18% on nelfinavir, 13% on lopinavir 
Odo 2012 Not specified 
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Patel 2004  225 (88%) EFV + d4T + 3TC 
30 (12%) EFV + ZDV + 3TC 
Schomaker 2013  Not specified 
Shipton 2009 On TB treatment:  55 (35%) NVP + 2 NRTIs, 100 (65%) EFV + 2 NRTIs 
Not on TB treatment:  75 (48%) NVP + 2 NRTIs, 80 (52%) EFV + 2 NRTIs 
Sumantri 2008 56.2% NVP + ZDV + 3TC 
10.8% NVP + d4T + 3TC 
13.1% EFV + ZDV + 3TC 
11.5% EFV + d4T + 3TC 
Tan 2010 Not specified 
Wanchu 2010 (a,b) On TB treatment:  EFV-based 3 drug cART 
Not on TB treatment:  NVP-based cART 
Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; cART, combination antiretroviral 
therapy; d4T, stavudine; EFV, efavirenz; NNRTI, non-nucleoside reverse-transcriptase inhibitor; 
NRTI, nucleos(t)ide reverse-transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; TB, 
tuberculosis; ZDV, zidovudine 
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Table 17. Timing of TB treatment in relation to cART initiation, by study 
Study Timing of TB treatment in relation to cART initiation 
Almeida 2011 Not specified 
Auld 2011 Not specified 
Bassett 2012 144 newly diagnosed by sputum culture at cART enrollment 
199 previously diagnosed and on TB treatment at cART enrollment 
Bastard 2012 Not specified 
Boulle 2008 (a) Patients only included in the TB treatment-exposed group in the analysis if they 
continued TB treatment past 14 days post cART initiation.  
Duration of TB treatment at cART initiation [median (IQR)]: 87 (60-135) days 
Boulle 2008 (b)  Patients only included in the TB treatment-exposed group in the analysis if they 
continued TB treatment past 14 days post cART initiation.  
Duration of TB treatment at cART initiation [median (IQR)]: 73 (44-115) days 
Boulle 2010 Not specified 
Breen 2006 Duration of TB treatment at cART initiation [median (range)]: 2 (0-8) months 
All patients were still on TB treatment at cART initiation. 
Dronda 2011 Duration of TB treatment at cART initiation [median (IQR)]: 53 (25.75-83.25) days 
Hardwick 2012 cART was initiated on the fourth week of TB treatment. 
Hermans 2011 Not specified 
Hung 2003 Not clear 
Julg 2012 Not specified 
Lartey 2011 Duration of TB treatment at cART initiation ranged from 4 to 90 days (median: 33) 
Manosuthi 2006  On rifampin-containing TB treatment for ≥1 month prior to study enrollment 
Manosuthi 2008 Median (IQR) duration of concurrent administration of nevirapine and rifampin: 5.4 
(4.6-6.1) months 
Manosuthi 2010 Median (IQR) duration of concurrent administration of nevirapine and rifampin: 5.4 
(4.6-6.1) months 
Mugusi 2012 All patients diagnosed with TB started cART after 4 weeks of TB treatment. 
Mussini 2008 TB was part of an AIDS diagnosis at the time of HIV diagnosis.  
cART was started a median of 31 (95% CI 30-34) days after HIV diagnosis. 
Odo 2012 Not clear 
Patel 2004  TB treatment started at the same time as cART and continued for 9 months. 
Schomaker 2013  Not specified 
Shipton 2009 Duration of TB treatment at cART initiation [median]: 81 days 
21% had <2 months of overlapping TB treatment and cART 
33% had 2-4 months of overlapping TB treatment and cART 
46% had >4 months of overlapping TB treatment and cART 
Sumantri 2008 All patients simultaneously diagnosed with TB and HIV started cART after 2 weeks of 
TB treatment. 
Tan 2010 Not specified 
Wanchu 2010 (a,b) All patients diagnosed with TB started cART after 1 month of TB treatment. 
Abbreviations: cART, combination antiretroviral therapy; IQR, interquartile range; TB, 
tuberculosis 
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Table 18. Methods for handling loss-to-follow-up and mortality utilized by each study 
Study Methods to handle loss-to-follow-up and mortality 
Almeida 2011 The analysis was limited to a subset of patients with complete baseline, 4-month, and 
10-month HIV RNA and CD4 count measures (n=89). Patients who died or were LTFU 
were excluded. Additionally, patients who did not suppress HIV RNA at either 4 or 10 
months (n=9) were excluded from the odds ratio comparing early vs. late virologic 
controllers. 
Auld 2011 Patients who transferred to other facilities were censored from time-to-event analyses at 
the date of transfer. Multiple imputation was used for missing outcome and covariate 
data in the immunologic treatment failure model. 
Bassett 2012 Patients who missed appointments for >3 months and did not return to the clinic after 
multiple phone attempts were considered LTFU and were censored at the date of last 
clinic visit. Only patients alive and in care at 12 months were included in HIV RNA and 
CD4 count analyses. To assess 12-month virologic suppression, if a patients was alive 
and in care but did not have a 12-month value, they used the 6-month HIV RNA to 
approximate the 12-month data. 
Bastard 2012 The analysis was limited to patients receiving cART for ≥6 months. Methods for 
handling LTFU and mortality were not described. 
Boulle 2008 (a,b) Patients were classified as LTFU after 6 months without a visit. Patients were excluded 
from later analyses if they died, transferred out, were LTFU, stopped or changed drugs, 
or had insufficient follow-up data. Additional censoring at each duration of follow-up 
was due to the patients not being in care for long enough at the close of the study. 
Boulle 2010  No assumption was made on laboratory outcomes in those who missed a scheduled test 
or who were LTFU. Only those with available test results were included in analyses. 
Patients who were LTFU were censored at last visit date. Patients who transferred to 
other services were censored at date of transfer. 
Breen 2006 It does not appear that any of the 82 patients on TB treatment or the 82 controls died or 
were LTFU by 6 months. 
Dronda 2011 Patients who were LTFU were censored at last clinic visit date. Those who died during 
follow-up or did not have an available laboratory test at the time of evaluation were 
included in the analysis, but were considered as non-responders. Sensitivity analyses 
excluded those who lacked a laboratory test and/or died prior to evaluation date, and 
results did not differ from primary analyses. 
Hardwick 2012 Methods for handling LTFU and mortality were not described. 
Hermans 2011 Analysis was limited to patients with ≥96 weeks of follow-up after cART initiation. 
Hung 2003 Patients were censored at death or LTFU. The authors also performed an “on-treatment” 
sensitivity analysis, limited to those who continued cART. 
Julg 2012 Patients were censored if they became LTFU, died, had no HIV RNA testing for >1 
year, or switched cART regimen with detectable HIV RNA levels. 
Lartey 2011 Patients were censored if they discontinued the study (due to TB-IRIS, pregnancy, poor 
adherence, or withdrawal of consent), died, or were LTFU. 
Manosuthi 2006  No deaths or LTFU are reported during the first 24 weeks of cART. However, an “on-
treatment” sensitivity analysis found similar results. 
Manosuthi 2008 Patients who were LTFU, developed HIV drug resistance, experienced adverse events, 
died, or transferred care were included in the “intent-to-treat” primary analysis and 
considered treatment failures. An “on-treatment” sensitivity analysis excluded these 
patients. 
Manosuthi 2010 Patients who discontinued cART for any reason were considered to be treatment 
failures. A “modified intent-to-treat” analysis included all patients in the analysis, but 
those who switched from stavudine were not considered to be treatment failures. 
Missing HIV RNA levels were assumed to be >50 copies/mL. Patients who had been on 
a drug holiday of longer than 4 weeks were considered LTFU and censored at date of 
first missing visit. 
Mugusi 2012 Patients missing follow-up laboratory results were excluded from analysis (n=13). 
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Patients who died were censored. 
Mussini 2008 Methods for handling LTFU and mortality were not described. 
Odo 2012 Patients included in analysis were required to be on cART for ≥1 year and have ≥3 
follow-up CD4 counts. 
Patel 2004  No patients were LTFU or died by 9 months of cART. 
Schomaker 2013  Patients with <6 months of follow-up were excluded. Methods for handling LTFU and 
mortality beyond 6 months were not described. 
Shipton 2009 The analysis was limited to patients with ≥1 HIV RNA and CD4 count after cART 
initiation. Patients who died or were LTFU were censored. 
Sumantri 2008 Patients with incomplete or lost medical records were excluded. Methods for handling 
LTFU and mortality were not described. 
Tan 2010 Methods for handling LTFU and mortality were not described. 
Wanchu 2010 (a,b) Methods for handling LTFU and mortality were not described. 
Abbreviations: LTFU, lost-to-follow-up; IRIS, immune reconstitution inflammatory syndrome. 
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Table 19. Quantification of virologic response to cART, stratified by TB treatment status, as reported by 17 studies 
  VIROLOGIC SUPPRESSION VIROLOGIC FAILURE OTHER 
Study 
TB 
treatment 
Follow-
up 
(months) 
Lower 
limit of 
detection 
Suppressed, 
% 
Suppressed
, n/N 
RR for 
suppression 
(95% CI) 
Follow-
up 
(months) 
Definition of virologic 
failure 
Virologic 
failure, % 
Virologic 
failure, 
n/N 
RR for virologic 
failure 
(95% CI) 
Other measures of 
virologic response 
Almeida Yes 4 400 82a 22/27 1.33 (1.02, 1.74)a NR NR NR NR NR OR for early 
virologic control 
(<400 at 4 months) 
vs. late virologic 
control (>400 at 4 
months and <400 
by 10 months):  
11.0 (1.38, 87.9) 
 No   61a 38/62    NR NR  
Bassett Yes 12 50 83a 285/343a 0.98 (0.92, 1.04)a NR NR NR NR NR  
 No   85 517/608a    NR NR   
Bastard Yes 48 400 NR NR 1.09 (0.73, 1.63) 48 >5000 NR NR 0.94 (0.56, 1.98)  
 No   NR NR    NR NR   
Boulle (a)b Yes 6 400 84a 118/141a 0.5 (0.3, 0.8)a 18 Failure to suppress 
<400 over 18 months 
NR NR 2.0 (1.8, 2.4)a  
 No   92a 1033/1126a    NR NR   
 Yes 12 400 80a 92/115a 0.6 (0.4, 1.0)a 24 Time to first value 
≥400 
NR NR 1.4 (1.0, 1.9)  
 No   88a 688/784a    NR NR   
 Yes 18 400 80a 64/80a 0.7 (0.4, 1.4)a 24 Time to 2 consecutive 
values ≥5000 
NR NR 2.2 (1.3, 3.7)  
 No   86a 447/520a    NR NR   
Boulle (b)b Yes 6 400 94a 663/708a 0.9 (0.6, 1.4)a 18 Failure to suppress 
<400 over 18 months 
NR NR 1.1 (0.8, 1.6)  
 No   94a 574/609a    NR NR   
 Yes 12 400 92a 392/426a 1.1 (0.7, 1.7)a 24 Time to first value 
≥400 
NR NR 0.9 (0.7, 1.1)  
 No   92a 399/434a    NR NR   
 Yes 18 400 89a 193/218a 0.8 (0.5, 1.7)a 24 Time to 2 consecutive 
values ≥5000 
NR NR 1.1 (0.6, 2.0)  
 No   90a 206/230a    NR NR   
Boulle (a)b Yes NR NR NR NR NR 60 Time to 2 consecutive 
values ≥5000 
NR NR 1.3 (0.9, 1.9)  
 No   NR NR    NR NR   
Boulle (b)b Yes NR NR NR NR NR 60 Time to 2 consecutive 
values ≥5000 
NR NR 1.7 (1.1, 2.5)a,c  
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 No   NR NR    NR NR   
Breen Yes 6 400 87 71/82 0.95 (0.85, 1.05)a NR NR NR NR NR  
 No   91 75/82    NR NR   
Dronda Yes 6 50 59 44/75 0.91 (0.75, 1.11)a NR NR NR NR NR  
 No   64 899/1396    NR NR   
 Yes 12 50 60 34/57 0.90 (0.72, 1.12)a NR NR NR NR NR  
 No   66 761/1147    NR NR   
Hung Yes 1 400 43 20/46  0.93 (0.65, 1.34) 17 >400 after 
undetectable, or never 
undetectable after 4 
months 
38 13/34 1.49 (0.92, 2.41)  
 No   47 107/230    26 57/222   
Lartey Yes 6 400 91 21/23 0.97 (0.83, 1.13)a NR NR NR NR NR  
 No   94 31/33    NR NR   
 Yes 11 400 80 16/20 0.83 (0.66, 1.04)a 11 Failure to get <400 by 
week 24, or rebound 
to >400 at week 48 
after suppressing at 
week 24 
NR NR 2.04 (0.50, 8.37)  
 No   96 27/28    NR NR   
Manosuthi Yes 6 50 73 51/70 1.11 (0.89, 1.38)a NR NR NR NR NR  
 No   66 46/70    NR NR   
Manosuthi Yes 33 50 61 43/70 1.19 (0.61, 2.35) 33 Rebound >1000 at 144 
weeks after previously 
<50, or lack of 
achieving <50 by 24 
weeks 
10 7/70 1.17 (0.41, 3.30)a  
 No   57 40/70    9 6/70   
Manosuthi Yes 48 50 53 37/70 1.12 (0.58, 2.18) NR NR NR NR NR  
 No   50 35/70    NR NR   
Mussini Yes NR NR NR NR NR 106 Among those who 
initially suppressed, 
time until first value 
>500 
NR NR 1.73 (1.24, 2.42)  
 No   NR NR    NR NR   
Schomaker Yes 12 400 81 851/1052a 1.02 (0.99, 1.06)a NR NR NR NR NR  
 No   79 11544/ 
14594a 
   NR NR   
Shipton Yes 3 400 90a 111/123a 0.98 (0.91, 1.05)a NR NR NR NR NR  
  
138
 No   92a 121/131a    NR NR   
 Yes 6 400 86a 44/51a 0.92 (0.80, 1.05)a NR NR NR NR NR  
 No   94a 33/35a    NR NR   
 Yes 9 400 91a 61/67a 1.00 (0.90, 1.12)a NR NR NR NR NR  
 No   91a 59/65a    NR NR   
 Yes 12 400 90a 47/52a 1.08 (0.94, 1.25)a NR NR NR NR NR  
 No   83a 50/60a    NR NR   
Sumantri Yes 6 400 62a 31/50a 0.71 (0.54, 0.92)a NR NR NR NR NR  
 No   88a 21/24a    NR NR   
Tan Yes 11 50 100 15/15 1.00 (1.00, 1.00)a NR NR NR NR NR Median HIV RNA 
at 3 months: 233 
copies/mL 
 No   100 27/27    NR NR  <50 copies/mL 
Abbreviations: CI, confidence interval; NR, not reported; OR, odds ratio; RR, relative risk; TB, tuberculosis. 
a
 Calculated or estimated from reported data, but not directly reported by the study 
b
 (a) Nevirapine-based cART; (b) Efavirenz-based cART 
a
 CI estimated from reported data, using incidence rate ratios to approximate the adjusted hazard ratios 
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Table 20. Meta-regression results for the effect of TB treatment on virologic suppression after cART initiation 
Category Number of 
estimates Tau-squared 
Homogeneity  
p-value 
RRRE 
(95% CI) 
Ratio of RRs  
(95% CI) 
All 13 0.003 0.060 0.97 (0.92, 1.03)  
Lower limit of detection of 400 
copies/mL 
10 0.006 0.027 0.97 (0.89, 1.05) Reference 
Lower limit of detection of 50 
copies/mL 
3 0.000 0.656 0.98 (0.92, 1.03) 1.00 (0.85, 1.17) 
Mixed cART regimens 9 0.003 0.037 0.97 (0.92, 1.03) Reference 
EFV-based cART regimens 2 0.000 0.605 0.99 (0.85, 1.14) 1.01 (0.80, 1.28) 
NVP-based cART regimens 2 0.118 0.130 0.83 (0.44, 1.55) 0.80 (0.46, 1.42) 
Abbreviations: cART, combination antiretroviral therapy; CI, confidence interval; EFV, efavirenz; NVP, nevirapine; RR, relative risk; 
RRRE, random-effects summary relative risk; TB, tuberculosis 
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Figure 9. Forest plot of cART regimen-specific relative risks of virologic suppression 
cART regimen-specific relative risks of virologic suppression in those receiving vs. not receiving tuberculosis treatment at cART 
initiation, as reported by or calculated from 6 studies. Estimates were abstracted according to the precision and stratification used by 
the original authors. Estimates calculated using available data are reported to 2 decimal places. Abbreviations: cART, combination 
antiretroviral therapy; CI, confidence interval; EFV, efavirenz; NVP, nevirapine; RR, relative risk. 
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Figure 10. Funnel plot of overall relative risk of virologic suppression 
Funnel plot of virologic suppression relative risks and inverse-variance weights included in the 
1-48 month summary estimate. Black circles are reported results; the white circle is the imputed 
estimate from the trim-and-fill method. The solid line is the null value of 1. The dashed line 
represents the random effects summary relative risk. The dotted line represents the random 
effects summary relative risk with the imputed study. 
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Table 21. Quantification of CD4 count response to cART, stratified by TB treatment status, as reported by 21 studies 
 
 
 
CHANGE IN CD4 COUNT 
IMMUNOLOGIC SUCCESS 
OTHER IMMUNOLOGIC RESPONSE 
MEASURES 
Study 
Follow-
up 
(months) 
TB 
treatment 
Baseline 
CD4 
counta 
Change 
in CD4 
counta 
Absolute 
CD4 
counta 
Definition of 
immunologic 
success 
Success, 
% 
Success,  
n/N 
RR for success (95% 
CI) Measure 1 Measure 2 
Auld 36 Yes NR NR NR NR NR NR NR aHR for immunologic 
failure [CD4 count decline 
from baseline, CD4 <100, or 
50% decline from peak CD4 
count after ≥6 months of 
cART]: 
1.0 (0.7, 1.3) 
Rate of immunologic 
failure:  
13.9/100PY 
 
  No NR NR NR  NR NR   14.0/100PY 
Bassett 12 Yes 71b 123.5b NR NR NR NR NR   
  No 104 109 NR  NR NR    
Boulle (a)c 18 Yes 80 NR NR NR NR NR NR Increase in CD4 count from 
baseline: 29 more cells than 
those not on TB treatment 
 
  No 116 NR NR  NR NR    
Boulle (b)c 18 Yes 61 NR NR NR NR NR NR Increase in CD4 count from 
baseline: 29 more cells than 
those not on TB treatment 
 
  No 93 NR NR  NR NR    
Boulle 6 Yes NR NR NR NR NR NR NR Increase in CD4 count from 
baselined: 4.7 more cells 
than those not on TB 
treatment 
 
  No NR NR NR  NR NR    
Breen 6 Yes NR 97 NR NR NR NR NR   
  No NR 89 NR  NR NR    
Dronda 6 Yes 80 NR NR Increase of ≥50 60 47/78 0.87 (0.72, 1.04)b   
  No 226 NR NR  69 1000/1442    
 12 Yes 80 188 NR Increase of 
≥100 
56 33/59 0.91 (0.72, 1.14)b   
  No 226 182 NR  62 728/1181    
Hardwick (a)e 3 Yes 83 109b 192b NR NR NR NR   
  No 106 81b 187b  NR NR    
 6 Yes 83 118b 201b NR NR NR NR   
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  No 106 91b 197b  NR NR    
 9 Yes 83 122b 205b NR NR NR NR   
  No 106 116b 222b  NR NR    
 11 Yes 83 128b 211b NR NR NR NR   
  No 106 104b 210b  NR NR    
Hardwick (b)e 3 Yes 95 112b 207b NR NR NR NR   
  No 100 115b 215b  NR NR    
 9 Yes 95 181b 276b NR NR NR NR   
  No 100 154b 254b  NR NR    
 11 Yes 95 155b 250b NR NR NR NR   
  No 100 165b 265b  NR NR    
Hermans 22 Yes 54 NR NR NR NR NR NR Increase in CD4 count from 
baseline: 3.8 more cells than 
those not on TB treatment 
 
  No 111 NR NR  NR NR    
Hung 1 Yes 38 71 NR NR NR NR NR   
  No 80 64 NR  NR NR    
Julg 12 Yes NR NR NR Absolute CD4 
count >200d 
64 116/182 1.05 (0.90, 1.21)b   
  No NR NR NR  61 145/238    
 30 Yes NR NR NR Absolute CD4 
count >500 
20 37/183 1.33 (0.87, 2.01)b OR for absolute CD4 count 
<500: 0.58 (0.33, 1.03) 
Increase from 
baseline:  
9.55 cells/month 
  No NR NR NR  15 36/236   8.66 cells/month 
Lartey 6 Yes 76 172 NR NR NR NR NR   
  No 88 112 NR  NR NR    
 11 Yes 76 234 NR NR NR NR NR   
  No 88 205 NR  NR NR    
Manosuthi 3 Yes 37 NR 200b NR NR NR NR   
  No 29 NR 151b  NR NR    
 6 Yes 37 NR 227b NR NR NR NR   
  No 29 NR 205b  NR NR    
 9 Yes 37 NR 265b NR NR NR NR   
  No 29 NR 243b  NR NR    
 11 Yes 37 NR 296b NR NR NR NR   
  No 29 NR 261b  NR NR    
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 14 Yes 37 NR 308b NR NR NR NR   
  No 29 NR 300b  NR NR    
 17 Yes 37 NR 346b NR NR NR NR   
  No 29 NR 341b  NR NR    
 19 Yes 37 NR 355b NR NR NR NR   
  No 29 NR 356b  NR NR    
 22 Yes 37 NR 404b NR NR NR NR   
  No 29 NR 370b  NR NR    
 28 Yes 37 NR 411b NR NR NR NR   
  No 29 NR 418b  NR NR    
 33 Yes 37 NR 430b NR NR NR NR   
  No 29 NR 441b  NR NR    
Manosuthi 48 Yes 37 NR 352 NR NR NR NR   
  No 29 NR 425  NR NR    
Mugusi 3 Yes 94.5 109 NR NR NR NR NR   
  No 90 113 NR  NR NR    
Odo 53 Yes 126 NR NR NR NR NR NR Median on treatment peak 
CD4: 517 cells/µL 
Median change 
between baseline and 
on treatment peak 
CD4: 381 cells/µL 
 
  No 161 NR NR  NR NR  531 363 
Patel 3 Yes 84 141 225 NR NR NR NR   
  No 118 126 244  NR NR    
 6 Yes 84 167 251 NR NR NR NR   
  No 118 177 294  NR NR    
 9 Yes 84 190 275 NR NR NR NR   
  No 118 176 295  NR NR    
Schomaker 6 Yes 45 NR NR NR NR NR NR CD4 recovery slope: 
-3.25 more cells/6 months 
than those not on TB 
treatment 
 
  No 102 NR NR  NR NR    
 48 Yes 45 NR NR NR NR NR NR CD4 recovery slope: 
4.94 more cells/6 months 
than those not on TB 
treatment 
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  No 102 NR NR  NR NR    
Shipton 3 Yes 72 NR 210b NR NR NR NR   
  No 85 NR 220b  NR NR    
 6 Yes 72 NR 230b NR NR NR NR   
  No 85 NR 270b  NR NR    
 9 Yes 72 NR 253b NR NR NR NR   
  No 85 NR 271b  NR NR    
 12 Yes 72 NR 275b NR NR NR NR   
  No 85 NR 270b  NR NR    
Sumantri 6 Yes 126 129 257 NR NR NR NR   
  No 241 138 394  NR NR    
Tan 3 Yes 22 NR 173 NR NR NR NR   
  No 34 NR 141  NR NR    
 11 Yes 22 NR 204 NR NR NR NR   
  No 34 NR 218  NR NR    
Wanchu (a)f 6 Yes 150 195b 345 NR NR NR NR   
  No 159 158b 317  NR NR    
Wanchu (b)f 6 Yes 49 200b 249 NR NR NR NR   
  No 50 155b 205  NR NR    
Abbreviations: aHR, adjusted hazard ratio; cART, combination antiretroviral therapy; CI, confidence interval; NR, not reported; OR, 
odds ratio; RR, relative risk; TB, tuberculosis. 
a
 CD4 count was measured in cells/µL. If the median was not available, the mean is reported. 
b
 Calculated or estimated from reported data, but not directly reported by the study 
c
 (a) Nevirapine-based cART; (b) Efavirenz-based cART 
d
 CD4 count analysis limited to virologically-suppressed patients 
e
 (a) a cohort from Ethiopia; (b) a cohort from Tanzania 
f
 (a) patients with baseline CD4 counts of 100-200 cells/µL; (b) patients with baseline CD4 counts <100 cells/µL 
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Supplemental Material: Aim 3 
 
Table 22. Baseline characteristics of all 246 children who initiated cART 
Characteristic All patients 
Children included 
in the analysis 
Children not 
included  
in the analysis Pa 
No. of patients (%) 246 (100) 199 (80.9) 47 (19.1)  
On TB treatment at cART 
initiation 
110 (44.7) 92 (46.2) 18 (38.3) 0.32 
Median age, years (IQR) 2.1 (0.8 – 4.7) 2.1 (0.9 – 4.6) 2.6 (0.5 – 5.0) 0.87 
   <1 71 (28.9) 54 (27.1) 17 (36.2) 0.15 
   1-2 71 (28.9) 64 (32.2) 7 (14.9)  
   3-4 48 (19.5) 36 (18.1) 12 (25.5)  
   5-6 39 (15.9) 31 (15.6) 8 (17.0)  
   7-8 17 (6.9) 14 (7.0) 3 (6.4)  
Male sex, no. (%) 131 (53.3) 103 (51.8) 28 (59.6) 0.33 
Weight-for-age z-score, 
median (IQR)b 
-1.51 (-2.49 – -0.66) -1.52 (-2.51 – -0.67) -1.44 (-2.29 – -0.38) 0.55 
   <-2, underweight for age 91 (37.3) 72 (36.2) 19 (42.2) 0.45 
   <-3, very low weight for age 30 (12.3) 24 (12.1) 6 (13.3) 0.82 
Median hemoglobin, g/dl 
(IQR)c 
10.0 (9.1 – 11.0) 10.0 (9.1 – 11.0) 10.0 (9.2 – 11.2) 0.91 
   Mild anemia, no. (%)d 53 (24.4) 45 (24.9) 8 (22.2) 0.84 
   Moderate anemia, no. (%)e 110 (50.7) 91 (50.3) 19 (52.8)  
   Severe anemia, no. (%)f 4 (1.8) 4 (2.2) 0 (0.0)  
Median HIV RNA, log10 
copies/mL (IQR)g 
5.6 (5.0 – 6.1) 5.6 (4.9 – 6.0) 5.7 (5.2 – 6.4) 0.04 
Median CD4 count, cells/µL 
(IQR)h 
676 (366 – 1069) 665 (340 – 1069) 751 (410– 1079) 0.57 
Median CD4 cell percentage 
(IQR)h 
18.0 (11.7 – 24.8) 17.1 (11.6 – 23.3) 22.1 (11.8 – 29.0) 0.02 
WHO age-specific severity of 
immunodeficiency, no. (%) 
       
   Not significant 41 (17.6) 28 (14.7) 13 (31.0) 0.07 
   Mild 28 (12.0) 22 (11.5) 6 (14.3)  
   Advanced 40 (17.2) 33 (17.3) 7 (16.7)  
   Severe 124 (53.2) 108 (56.5) 16 (38.1)  
First-line cART regimen, no. 
(%)i 
       
   Efavirenz-basedj 98 (42.4) 79 (39.7) 19 (59.4) 0.04 
   LPV/r-basedk 133 (57.6) 120 (60.3) 13 (40.6)  
Timing of cART initiation, no. 
(%) 
       
   According to pre-2010 
guidelines 
81 (32.9) 67 (33.7) 14 (29.8) 0.61 
   According to 2010 
guidelines 
165 (67.1) 132 (66.3) 33 (70.2)  
Abbreviations: cART, combination antiretroviral therapy; IQR, interquartile range; LPV/r, 
lopinavir/ritonavir; TB, tuberculosis; WHO, World Health Organization. 
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a
 Wilcoxon rank-sum testing was used to compare continuous variables; Pearson’s X2 test was 
used for categorical variables. Exact methods were used when necessary. Statistical significance 
defined as P <0.05 for all tests. 
b Baseline weight-for-age z-scores were not available for 2 patients 
c Baseline hemoglobin values were not available for 29 patients 
d Mild anemia was defined as hemoglobin 10.0-10.9 g/dl in children <5 years or 11.0-11.4 g/dl in 
children ≥5 years. 
e Moderate anemia was defined as hemoglobin 7.0-9.9 g/dl in children <5 years or 8.0-10.9 g/dl 
in children ≥5 years. 
f Severe anemia was defined as hemoglobin <7.0 g/dl in children <5 years or <8.0 g/dl in 
children ≥5 years. 
g
 Baseline HIV RNA values were not available for 30 patients 
h Baseline CD4 cell percentages and CD4 counts were not available for 13 patients 
i cART regimens were not available for 15 patients 
j Efavirenz-based cART was generally used for children ≥3 years and ≥10 kilograms. 
k Protease inhibitor-based cART was generally used for children <3 years or <10 kilograms. 
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Table 23. Baseline characteristics of children of initiated efavirenz- vs. lopinavir/ritonavir-based 
cART 
Characteristic All patients 
Children included 
in the analysis 
Children not 
included  
in the analysis Pa 
No. of patients (%) 199 (80.9) 79 (39.7) 120 (60.3)  
On TB treatment at cART 
initiation 
92 (46.2) 39 (49.4) 53 (44.2) 0.47 
Median age, years (IQR) 2.1 (0.9 – 4.6) 5.6 (4.2 – 6.8) 1.1 (0.5 – 1.9) <0.01 
   <1 54 (27.1) 0 (0.0) 54 (45.0) <0.01 
   1-2 64 (32.2) 2 (2.5) 62 (51.7)  
   3-4 36 (18.1) 33 (41.8) 3 (2.5)  
   5-6 31 (15.6) 30 (38.0) 1 (0.8)  
   7-8 14 (7.0) 14 (17.7) 0 (0.0)  
Male sex, no. (%) 103 (51.8) 38 (48.1) 65 (54.2) 0.40 
Weight-for-age z-score, 
median (IQR) 
-1.52 (-2.51 – -0.67) -1.49 (-2.12 – -0.69) -1.56 (-2.70 – -0.67) 0.23 
   <-2, underweight for age 72 (36.2) 25 (31.6) 47 (39.2) 0.28 
   <-3, very low weight for age 24 (12.1) 3 (3.8) 21 (17.5) <0.01 
Median hemoglobin, g/dl 
(IQR)b 
10.0 (9.1 – 11.0) 10.3 (9.5 – 11.4) 9.7 (8.8 – 10.8) <0.01 
   Mild anemia, no. (%)c 45 (24.9) 17 (25.4) 28 (24.6) 0.79 
   Moderate anemia, no. (%)d 91 (50.3) 31 (46.3) 60 (52.6)  
   Severe anemia, no. (%)e 4 (2.2) 2 (3.0) 2 (1.8)  
Median HIV RNA, log10 
copies/mL (IQR)f 
5.6 (4.9 – 6.0) 5.2 (4.5 – 5.6) 5.8 (5.3 – 6.2) <0.01 
Median CD4 count, cells/µL 
(IQR)g 
665 (340 – 1069) 438 (250 – 669) 929 (523 – 1464) <0.01 
Median CD4 cell percentage 
(IQR)g 
17.1 (11.6 – 23.3) 15.8 (9.6 – 20.7) 18.5 (13.0 – 25.1) 0.02 
WHO age-specific severity of 
immunodeficiency, no. (%)g 
       
   Not significant 28 (14.7) 19 (25.7) 9 (7.7) <0.01 
   Mild 22 (11.5) 10 (13.5) 12 (10.3)  
   Advanced 33 (17.3) 12 (16.2) 21 (17.9)  
   Severe 108 (56.5) 33 (44.6) 75 (64.1)  
Timing of cART initiation, no. 
(%) 
       
   According to pre-2010 
guidelines 
67 (33.7) 26 (32.9) 41 (34.2) 0.85 
   According to 2010 
guidelines 
132 (66.3) 53 (67.1) 79 (65.8)  
Abbreviations: cART, combination antiretroviral therapy; IQR, interquartile range; LPV/r, 
lopinavir/ritonavir; TB, tuberculosis; WHO, World Health Organization. 
a
 Wilcoxon rank-sum testing was used to compare continuous variables; Pearson’s X2 test was 
used for categorical variables. Statistical significance defined as P <0.05 for all tests. 
b Baseline hemoglobin values were not available for 18 patients. 
c Mild anemia was defined as hemoglobin 10.0-10.9 g/dl in children <5 years or 11.0-11.4 g/dl in 
children ≥5 years. 
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d Moderate anemia was defined as hemoglobin 7.0-9.9 g/dl in children <5 years or 8.0-10.9 g/dl 
in children ≥5 years. 
e Severe anemia was defined as hemoglobin <7.0 g/dl in children <5 years or <8.0 g/dl in 
children ≥5 years. 
f
 Baseline HIV RNA values were not available for 22 patients. 
g Baseline CD4 cell percentages and CD4 counts were not available for 8 patients. 
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Table 24. Virologic response outcomes, stratified by TB treatment status, with a virologic 
suppression cut point of HIV RNA <400 copies/mL 
Outcome All patients 
Children 
receiving  
TB treatment 
Children not 
receiving TB 
treatment P 
Virologic suppression        
Time to suppression, 
median months (IQR) 
5.7 (3.3 – 7.7) 5.6 (3.4 – 8.0) 6.0 (3.1 – 7.7) 0.99 
HR (95% CI)        
   6 months (crude)   1.09 (0.67, 1.77) 1.0  0.73 
   6 months (adjusted)a   1.20 (0.69, 2.08) 1.0  0.53 
   12 months (crude)   1.04 (0.72, 1.49) 1.0  0.85 
   12 months (adjusted)a   1.23 (0.82, 1.84) 1.0  0.32 
   24 months (crude)   0.94 (0.69, 1.28) 1.0  0.70 
   24 months (adjusted)a   1.36 (0.94, 1.96) 1.0  0.10 
        
Virologic reboundb        
HIV RNA >1000 
copies/mL, no. (%) 
46/177 (26.0) 19/81 (23.5) 27/96 (28.1) 0.48 
Time to rebound, median 
months (IQR) 
17.5 (11.7 – 21.0) 17.7 (11.9 – 21.0) 15.1 (11.6 – 23.5) 0.99 
Crude HR (95% CI)c   1.13 (0.60, 2.15) 1.0  0.70 
Adjusted HR (95% CI)a,c   1.66 (0.77, 3.58) 1.0  0.20 
Abbreviations: cART, combination antiretroviral therapy; CD4%, CD4 cell percentage; CI, 
confidence interval; HR, hazard ratio; IQR, interquartile range; TB, tuberculosis. 
a
 Multivariable models adjusted for timing of cART initiation relative to the 2010 change in 
guidelines, age at cART initiation, sex, cART regimen, and baseline HIV RNA, CD4 cell 
percentage, hemoglobin, and weight-for-age z-score. Adjusted models include individuals who 
had complete covariate data: n=164 for the suppression model and n=147 for the rebound model. 
b
 Virologic rebound was assessed among the 177 individuals who suppressed <400 copies/mL at 
any point following cART initiation. 
c
 Hazard ratios account for 24 months of follow-up after cART initiation. 
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Table 25. The effect of TB treatment on virologic response outcomes, stratified by cART regimen, with a virologic suppression cut 
point of HIV RNA <400 copies/mL 
Outcome Efavirenz-based 
cART (n=79) 
LPV/r-based 
cART (n=120) 
Efavirenz-based cART (n=79) LPV/r-based cART (n=120) 
Children 
receiving  
TB treatment 
(n=39) 
Children not 
receiving TB 
treatment (n=40) 
Children 
receiving  
TB treatment 
(n=52) 
Children not 
receiving TB 
treatment (n=69) 
Virologic suppression             
Time to suppression, 
median months (IQR) 
4.5 (3.0 – 6.2)a 6.1 (3.5 – 9.7) 4.5 (3.1 – 6.3) 4.8 (3.0 – 6.2) 6.1 (4.8 – 10.5) 6.2 (3.5 – 9.1) 
Crude HR (95% CI)c 1.78 (1.30, 2.44)a 1.0  1.06 (0.66, 1.69) 1.0  0.83 (0.55, 1.26) 1.0  
Adjusted HR (95% CI)c 1.26 (0.63, 2.51)d 1.0  1.66 (0.88, 3.16)e,f 1.0  1.04 (0.64, 1.69)e,g 1.0  
 
            
Virologic reboundh             
HIV RNA >1000 
copies/mL, no. (%) 
19/76 (25.0) 27/101 (26.7) 6/37 (16.2) 13/39 (33.3) 13/44 (29.5) 14/57 (24.6) 
Time to rebound, 
median months (IQR) 
17.8 (11.6 – 21.0) 15.0 (11.7 – 21.1) 19.2 (17.4 – 21.0) 15.1 (11.6 – 19.4) 15.0 (11.9 – 20.9) 15.4 (11.7 – 23.5) 
Crude HR (95% CI)c 1.09 (0.57, 2.07) 1.0  0.65 (0.24, 1.77) 1.0  1.74 (0.73, 4.14) 1.0  
Adjusted HR (95% CI)c 0.59 (0.14, 2.47)d 1.0  1.07 (0.27, 4.20)e,f 1.0  2.36 (0.82, 6.83)e,g 1.0  
Abbreviations: cART, combination antiretroviral therapy; CD4%, CD4 cell percentage; CI, confidence interval; HR, hazard ratio; 
IQR, interquartile range; LPV/r, lopinavir/ritonavir; TB, tuberculosis. 
a
 The efavirenz-based vs. LPV/r-based cART comparison was statistically significant (P <0.05). 
b
 The TB treatment vs. no TB treatment comparison was statistically significant (P <0.05). 
c
 Hazard ratios account for 24 months of follow-up after cART initiation. 
d
 Multivariable models included TB treatment at cART initiation, timing of cART initiation relative to the 2010 change in guidelines, 
age at cART initiation, sex, cART regimen, and baseline HIV RNA, CD4 cell percentage, hemoglobin, and weight-for-age z-score. 
Adjusted models include individuals who had complete covariate data: n=164 for the suppression model and n=147 for the rebound 
model. 
e Multivariable models included TB treatment at cART initiation, timing of cART initiation relative to the 2010 change in guidelines, 
age at cART initiation, sex, and baseline HIV RNA, CD4 cell percentage, hemoglobin, and weight-for-age z-score. 
f Adjusted models include individuals who had complete covariate data: n=61 for the suppression model and n=59 for the rebound 
model. 
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g Adjusted models include individuals who had complete covariate data: n=103 for the suppression model and n=88 for the rebound 
model. 
h Virologic rebound was assessed among the 177 individuals who suppressed <400 copies/mL at any point following cART initiation. 
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Table 26. The effect of TB treatment on virologic response outcomes, stratified by timing of cART initiation, with a virologic 
suppression cut point of HIV RNA <400 copies/mL 
Outcome 
According to 
pre-2010 
guidelines 
(n=67) 
According to the 
2010 guidelines 
(n=132) 
According to pre-2010 guidelines 
(n=67) 
According to the 2010 guidelines 
(n=132) 
Children 
receiving  
TB treatment 
(n=34) 
Children not 
receiving TB 
treatment (n=33) 
Children 
receiving  
TB treatment 
(n=57) 
Children not 
receiving TB 
treatment (n=74) 
Virologic suppression             
Time to suppression, 
median months (IQR) 
4.1 (3.1 – 6.5) 6.0 (3.5 – 7.7) 4.6 (3.3 – 8.0) 3.5 (3.0 – 6.2) 5.9 (3.6 – 8.3) 6.0 (3.4 – 7.7) 
Crude HR (95% CI)c 1.59 (1.16, 2.20)a 1.0  0.87 (0.52, 1.45) 1.0  0.92 (0.62, 1.36) 1.0  
Adjusted HR (95% CI)c 1.94 (1.35, 2.80)a,d 1.0  1.04 (0.59, 1.85)e,f 1.0  1.45 (0.90, 2.35)e,g 1.0  
 
            
Virologic rebounde             
HIV RNA >1000 
copies/mL, no. (%) 
18/59 (30.5) 28/118 (23.7) 12/30 (40.0) 6/29 (20.7) 7/51 (13.7)b 21/67 (31.3) 
Time to rebound, 
median months (IQR) 
18.3 (14.5 – 21.3) 14.0 (10.9 – 19.7) 17.8 (12.1 – 21.0) 21.0 (17.8 – 24.8) 17.7 (11.7 – 20.0) 12.9 (9.4 – 19.4) 
Crude HR (95% CI)c 1.08 (0.57, 2.07) 1.0  3.29 (1.15, 9.41)b 1.0  0.44 (0.17, 1.13) 1.0  
Adjusted HR (95% CI)c,d 1.22 (0.59, 2.56)d 1.0  3.00 (0.94, 9.60)e,f 1.0  0.85 (0.26, 2.83)e,g 1.0  
Abbreviations: cART, combination antiretroviral therapy; CD4%, CD4 cell percentage; CI, confidence interval; HR, hazard ratio; 
IQR, interquartile range; TB, tuberculosis. 
a
 The old guidelines vs. new guidelines comparison was statistically significant (P <0.05). 
b
 The TB treatment vs. no TB treatment comparison was statistically significant (P <0.05). 
c
 Hazard ratios account for 24 months of follow-up after cART initiation. 
d
 Multivariable models included TB treatment at cART initiation, timing of cART initiation relative to the 2010 change in guidelines, 
age at cART initiation, sex, cART regimen, and baseline HIV RNA, CD4 cell percentage, hemoglobin, and weight-for-age z-score. 
Adjusted models include individuals who had complete covariate data: n=164 for the suppression model and n=147 for the rebound 
model. 
e Multivariable models included TB treatment at cART initiation, age at cART initiation, sex, cART regimen, and baseline HIV RNA, 
CD4 cell percentage, hemoglobin, and weight-for-age z-score. 
f Adjusted models include individuals who had complete covariate data: n=60 for the suppression model and n=53 for the rebound 
model. 
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g Adjusted models include individuals who had complete covariate data: n=104 for the suppression model and n=94 for the rebound 
model. 
h Virologic rebound was assessed among the 177 individuals who suppressed <400 copies/mL at any point following cART initiation. 
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Figure 11. Kaplan-Meier graph of virologic suppression, stratified by cART regimen and TB 
treatment status at cART initiation 
 
Abbreviations: cART, combination antiretroviral therapy; EFV/TB+, receiving efavirenz-based 
cART and TB treatment; EFV/TB-, receiving efavirenz-based cART and no TB treatment; 
LPV/TB+, receiving lopinavir/ritonavir-based cART and TB treatment; LPV/TB-, receiving 
lopinavir/ritonavir-based cART and no TB treatment; TB, tuberculosis. 
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